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ABSTRACT 
 
There is potential for haemorrhaging injuries to become contaminated with toxic 
chemicals e.g. sulphur mustard (SM) in certain scenarios. There are currently no 
specific medical countermeasures for such injuries. It is proposed that haemostats could 
simultaneously stop bleeding and decontaminate wounds. Products must be able to clot 
SM-contaminated blood and reduce SM percutaneous absorption to be considered 
suitable. Blood clot viscosity was assessed ex vivo using thrombelastography (TEG). 
Sulphur mustard did not significantly affect coagulation following application in vitro 
or in vivo. Overall, SM did not affect the pro-coagulatory function of haemostats. 
Although, three of the seven haemostats tested were ineffective at increasing the rate of 
coagulation. Additionally, clot strength in WoundStat™ treated blood was adversely 
affected by SM in vitro.  
Porcine skin provides a suitable model for human skin and allows direct 
comparison between in vitro and in vivo percutaneous absorption studies. Static 
diffusion cells are an established system for the measurement of percutaneous 
absorption in vitro and allow the screening of candidate products for decontaminant 
efficacy. Both liquid and polysaccharide-based haemostats significantly increased the 
rate and amount of SM penetrating through undamaged skin and were excluded from 
further study. Removal of the barrier layer of the skin (stratum corneum and epidermis) 
significantly increased the percutaneous absorption of SM (rate and amount) which was 
mitigated by the timely application of WoundStat™. This haemostat was comparable in 
performance to standard military topical decontaminants.  
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Sulphur mustard percutaneous absorption data showed good agreement between in vivo 
and in vitro data with a significant reduction in the reported latent period between SM 
exposure and presentation of dermal toxicity in a damaged skin porcine model. 
Moreover, the altered toxicodynamics imply that the latent period associated with SM 
pathology is due, in part, to rate of absorption and not solely caused by biochemical 
pathways. Microarray analysis has identified that SM exposure via damaged skin causes 
previously unidentified changes in gene expression which may warrant further 
investigation as potential therapeutic targets. Furthermore, WoundStat™ was shown to 
reduce SM percutaneous absorption and subsequent pathology in vivo and warrants 
further investigation as haemostatic decontaminant. 
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INTRODUCTION 
Sulphur mustard (SM) has been recognised as a significant chemical hazard to military 
personnel since its first reported use against allied troops in Ypres, Belgium during the 
First World War (Marshall. 1919). However, it may also pose a threat to civilian 
populations (Wattana and Bey. 2009).  Over the last 25 years, the reported exposure of 
civilians to SM during the Iran-Iraq conflict (late 1980s), the sarin attacks on the Tokyo 
underground (1995) and the more recent 9/11 and 7/7 terrorist attacks in New York and 
London have heightened the perceived threat to civilian populations from “dirty bomb” 
scenarios, in which penetrating injuries or abraded skin could become contaminated 
with highly toxic chemicals such as SM. 
Current regimes for decontamination of said injuries involve the use of dilute 
(0.5%) hypochlorite solutions and aggressive irrigation and lavage of the wound. 
However, use of hypochlorite solutions in wounds is contraindicated, particularly for 
use in abdominal cavity wounds which can result in peritoneal fibrosis and adhesions 
(Levine and Saltzman. 1996). Standard military topical skin decontaminants (fuller’s 
earth, Reactive Skin Decontamination Lotion
®
; RSDL
®
 and M291) are also 
contraindicated for use in wounds.  The fine granular nature of fuller’s earth and M291 
hinders complete removal from wounds and residual particulate matter could potentially 
illicit an immune response, ultimately resulting in fibrosis and granulomatous reactions 
in the surrounding tissue (Gibbs and Pooley. 1994, Sakula. 1961). Reactive Skin 
Decontamination Lotion
® 
has been shown to adversely affect wound healing processes 
resulting in decreased collagen content and reduced wound strength in an animal model 
(Walters, et al. 2007). Therefore, there is a considerable need for the development of a 
decontaminant which is safe for use on abraded skin and in open wounds. In addition to 
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the capacity to decontaminate wounds, a product which could simultaneously stop 
bleeding would be advantageous. 
The aim of this Thesis was to investigate if commercially available haemostats 
could be suitable to fulfil this dual decontamination/haemostasis requirement. 
Haemostats promote the coagulation of blood by either adsorbing plasma to locally 
concentrate clotting factors, activating extrinsic and intrinsic coagulation pathways or a 
combination of both.  
 
SKIN AND PERCUTANEOUS ABSORPTION 
Skin 
The skin is a key interface between the internal biological milieu and the environment, 
preventing loss of water and nutrients, ingress of microorganisms and limiting 
absorption of UV radiation and hazardous compounds (Poet and McDougal. 2002). 
Human skin consists of three layers: the stratified, avascular epidermis, the dermis 
consisting of blood vessels, nerve endings and connective tissue and the hypodermis 
which is primarily comprised of subcutaneous fat providing a thermal barrier, 
mechanical cushion and energy store (Barry. 1991).  
 
Epidermis 
The epidermis is the outermost layer of the skin and is connected to the dermis by the 
basement membrane (Figure 1.1). The epidermis is predominately comprised of 
keratinocytes (90 – 95%) which can be further subdivided into distinct stratified layers 
(Haake, et al. 2001). Other cell types present within the epidermis include melanocytes,  
 
4 
 
 
 
Figure 1.1: Diagrammatic cross-section of a typical section of human skin 
The dermis is connected to the epidermis via the basement membrane or basale lamina. 
A sub-layer of the epidermis (stratum corneum) provides the main barrier function of 
the skin. The epidermis is avascular whilst the dermis is well perfused and contains 
lymphatic vessels and nerve ending (not shown). Appendages to the skin (hair follicle, 
sebaceous and sweat glands) are also shown and these may provide additional routes 
of penetration through the stratum corneum into the viable layers of the skin.     
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Langerhans cells and Merkel cells which are involved in pigment formation, 
immunological function and sensory perception, respectively (Forslind and Lindberg. 
2003). There is an increasing calcium concentration from the lower layers of the 
epidermis (the stratum basale and stratum spinosum) to the upper layers (the stratum 
granulosum and the stratum corneum; SC) which correspond to increasing levels of 
differentiation in the epidermis (Kanitakis. 2002, Akiyama. 2011). In addition to these 
layers, hairless skin which has a thick epidermis (e.g. skin on the soles of the feet) has a 
stratum lucidum layer below the SC (McGrath, et al. 2010).  
The stratum basale is a single layer of viable keratinocytes, approximately 10% 
of which are stem cells, that occupies the basement membrane. The stratum basale is 
attached to the basement membrane via hemidesmosomes (McGrath, et al. 2010). 
Adjoining keratinocytes are attached via desmosomes which are maintained upon 
differentiation to form a continuous layer (Forslind and Lindberg. 2003). The cells 
undergo apical migration from the basement membrane to form the remaining layers of 
the epidermis (McGrath, et al. 2010). 
The stratum spinosum comprises several cell layers, adjoined by desmosomes 
and tight junctions which give the layer its characteristic spiny appearance when viewed 
microscopically (McGrath, et al. 2010). These cells also contain a greater number of 
keratin filaments compared to the cells in the stratum basale (Hwa, et al. 2011).  
The stratum granulosum is characterised by the presence of keratohyalin 
granules, increased number of lamellar bodies and the flattening of the epidermal cells 
compared to the lower layers of the epidermis (Jennemann, et al. 2007). The stratum 
granulosum has an abundance of lamellar bodies, which are a major component in the 
synthesis of epidermal lamellar lipids such as ceramides, fatty acids and cholesterol 
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which contribute to the hydrophobicity of the upper epidermal layers. The keratohyalin 
granules contain profilaggrin, loricrin, cysteine-rich proteins and keratins 1 and 10 
(Dale, et al. 1983, Baroni, et al. 2012). These proteins are important in maintaining skin 
barrier properties (Akiyama. 2011).    
The outermost layer of the epidermis is the stratum corneum (SC) which is 
considered to be the primary barrier of the skin (Figure 1.1) (Blank. 1965). The three 
components which contribute to the barrier properties of the SC include: cornified cell 
envelope (corneocytes), intercellular lipid bilayer and keratin-filaggrin degradation 
products (McGrath and Uitto. 2008). Keratinocytes undergo terminal differentiation and 
cornification to form non-viable corneocytes. In the proposed “brick and mortar” model 
of the SC, the corneocytes (bricks) are surrounded by intercellular lipids (ceramides, 
fatty acids and cholesterol) and proteins secreted from the lamellar bodies (mortar) 
(Michaels, et al. 1975). However, other models have suggested the SC may not be so 
structured with cisternae of fluid interspersed throughout the SC (Warner, et al. 2003). 
Filaggrin is a 37 kDa protein proteolytically cleaved product of profilaggrin which is 
involved in corneocyte formation (Gan, et al. 1990). Filaggrin binds to keratin fibres 
causing them to bundle into insoluble macrofibrils (Markova, et al. 1993). Aggregation 
of keratin and subsequent collapse of the cytoskeleton results in the formation of 
corneocytes. The SC is maintained at a constant thickness through the process of 
desquamation whereby corneocytes are “sloughed off” as cells from the lower layers 
move up. In the upper layers of the SC, filaggrin is proteolysed into a mixture of 
hygroscopic amino acids known as skin natural moisturising factor (NMF) which helps 
modulate SC hydration (Markova, et al. 1993).  
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Dermis 
The dermis is connected to the epidermis via the basement membrane (Figure 1.1) and 
is comprised of two layers; the upper (papillary) layer and lower (reticular) layer. The 
papillary dermis projects into the epidermis, increasing the interface between the two 
integument layers. These projections are termed dermal papillae whilst the 
corresponding epidermal projections are described as rete ridges (Figure 1.1). The 
major cell types of the dermis, fibroblasts, mast cells and macrophages, are surrounded 
by extracellular matrix comprised of collagen, elastin and proteoglycans (McGrath, et 
al. 2010). The dermis is highly vascularised; networks of blood vessels, lymphatic 
vessels as well as nerve fibres, provide nutrients to the avascular epidermis. There is not 
a distinct boundary between the papillary and reticular layers but the reticular layer 
contains a more mature elastin fibre network within the collagen matrix (Haake, et al. 
2001). 
 
Appendages  
Additional structures present within the dermis including hair follicles, sweat glands 
and sebaceous glands are termed appendages or adnexa. The presence and density of 
these structures varies widely between species and anatomical regions (Monteiro-
Riviere. 2005). The appendageal structures pass from the dermis through the epidermis 
and SC to form openings or “pores” on the surface of the skin (Figure 1.1). There is 
particular interest in these structures as an alternative route of absorption into the skin 
(Figure 1.2), especially for chemicals whose molecular weight is too high to penetrate 
the SC under normal conditions (Monteiro-Riviere. 2005).  
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Biotransformations in Skin 
The skin has been shown to perform both Phase I and Phase II detoxification reactions 
and is capable of xenobiotic metabolism (Rettie, et al. 1986, Roper, et al. 1997, 
Steinsträsser and Merkle. 1995, Yourick and Bronaugh. 2000).  These activities may 
influence both toxicity and percutaneous absorption in the skin. Metabolism of 
xenobiotics is a multistep process whereby a chemical has functional groups added 
(Phase I) before conjugation (Phase II) and elimination. There are a number of Phase I 
and Phase II enzymes present within the skin including; cytochrome P450 superfamily, 
esterases, dehydrogenases and transferases. Immuno-localisation studies have identified 
the basal cells and viable keratinocytes of the epidermis, sebaceous glands and hair 
follicle cells as the primary sites of enzyme activity (Steinsträsser and Merkle. 1995, 
Cheung, et al. 1999).  
 
Phase I enzymes 
Cytochrome P450  
The cytochrome P450 (CYP) superfamily is considered a key group of Phase I 
enzymes, particularly regarding their ability to activate chemicals to toxic 
intermediates. Cytochromes P450 are haem-containing, mixed function oxidases which 
catalyse the insertion of a single oxygen atom (from molecular oxygen) into the 
xenobiotic. Generally, the amount of CYP is much lower in the skin compared to the 
liver (Pham, et al. 1990, Zhu, et al. 2002), although the expression of some isoforms 
e.g. CYP2S1 is considerably higher in the skin (Smith, et al. 2003).  
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It is generally accepted that CYP activity does not affect percutaneous absorption due to 
the location of these enzymes (lower epidermis). However, increased toxicity of 
xenobiotics (due to activation by CYP) has been well documented (Rogan, et al. 1993, 
Bronaugh, et al. 1994). Sulphur mustard has previously been shown to inhibit CYP 
activity in vitro (Brimfield, et al. 2009, Brimfield, et al. 2012) and upregulate CYP 
expression in lung epithelium following an aerosol challenge (Pons, et al. 2001). 
Currently, the effect of SM on CYP activity within the skin in vivo is unknown.  
 
Esterases  
Esterases are ubiquitously expressed in mammalian tissues including the skin (Satoh 
and Hosokawa 1998). The most significant group present in the skin (in terms of 
xenobiotic metabolism) are the carboxylesterases, which catalyse the hydrolysis of 
carboxylic acid esters to a carboxylic acid and an alcohol group (Steinsträsser and 
Merkle. 1995). Carboxylesterase activity is localised to the basal keratinocytes, 
sebaceous glands and hair follicles (Jewell, et al. 2007a, Jewell, et al. 2007b, Meyer and 
Neurand. 1976) although non-specific esterase activity has also been identified in the 
stratum corneum (Beisson, et al. 2001). 
Esterases are known to be robust enough to withstand freezing and esterase 
activity has been identified in previously frozen skin (Hewitt, et al. 2000). It is widely 
accepted that hydrolysis resulting from esterase activity will reduce the systemic 
absorption of the parent compound (Williams, et al. 1990). Whilst this may reduce 
systemic toxicity attributed to the parent compound, the resulting carboxylic acid and 
alcohol groups could be further metabolised to more reactive metabolites. Esterase 
activity may also promote percutaneous absorption once the compound has entered the 
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SC by increasing the water solubility (and hence increasing the ability to diffuse 
through the more aqueous layers of the epidermis) (Liederer and Borchardt. 2006). 
 
Alcohol and Aldehyde Dehydrogenases 
Alcohol dehydrogenase (ADH) oxidises alcohol groups to aldehyde groups via the 
removal of two hydrogen atoms, using NAD+ as a co-substrate. Aldehyde 
dehydrogenase (ALDH) also uses NAD+ as a co-substrate to oxidise aldehyde groups 
to carboxylic acid groups. Both enzymes appear to have a potential role in the 
mechanism of skin sensitisation (Cheung, et al. 2003). Aldehydes formed by ADH may 
subsequently react with (and covalently bind) proteins within the epidermis resulting in 
haptenisation (Lockley, et al. 2004, Lockley, et al. 2002).  
 
Phase II enzymes 
Transferases  
There are a number of transferase enzymes located within the dermal tissues that are 
able to conjugate both the parent compound and the functionalised compounds 
generated from Phase I metabolism. These reactions generally result in the 
pharmacological inactivation or detoxification of chemicals and help facilitation 
elimination from the body (McCarver and Hines. 2002).  The higher relative activity of 
Phase II enzymes (compared to Phase I) within the skin highlights the important 
detoxification capacity of the cutaneous tissues (Götz, et al. 2012). Phase II enzymes 
are thought to be important in terms of detoxifying reactive oxygen species (ROS) 
originating from ultra violet (UV) exposure (Götz, et al. 2012). Generally, they are not 
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thought to modulate percutaneous absorption due to their localisation in the stratum 
basale and dermal appendages.  
Transferases identified within the skin include glucuronyl transferases, N-
acetyltranferases, sulphotransferases and glutathione transferases. Glutathione 
transferases catalyse the conjugation of reduced glutathione (a cysteine-containing 
tripeptide) with electrophilic chemicals including SM (Gross, et al. 1993). Glutathione 
(GSH) plays a central role in the detoxification of ROS within the skin and depletion of 
GSH may contribute to SM-induced cell death (Kumar, et al. 2001, Rappeneau, et al. 
2000).  
 
Percutaneous absorption and penetration 
The penetration of xenobiotics through the skin is largely considered to be a passive 
diffusion process (Hadgraft. 2001). There is active intraepidermal transport of large 
organic cations via an organic anion transporting polypeptide (Schiffer, et al. 2003) but 
this is unlikely to impact upon percutaneous absorption.  
 
The function of skin as a barrier to absorption 
The primary barrier to dermal absorption is the SC (Blank. 1965). Whilst the SC is not 
impermeable to chemicals it does function to limit the penetration and absorption of the 
vast majority of compounds (Schaefer, et al. 2011). Corneocytes and intercellular 
lamellar lipids are two of the main components of the SC and it is thought that the 
intercellular lamellar lipids provide a route through which chemicals can be absorbed in 
the skin (Wertz. 2004). 
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Routes of dermal absorption 
There are several routes by which molecules can pass through the SC and into the 
viable epidermis/dermis (and hence potentially reach the systemic circulation); these are 
termed intercellular, transcellular and appendageal routes (Figure 1.2). In the 
intercellular route, chemicals pass between the corneocytes in the SC via the lipid 
matrix. This is widely considered to be the principal route of percutaneous absorption 
(Kitson and Thewalt. 2000). The transcellular route of absorption occurs when a 
substance passes through both the corneocytes and the lipid matrix within the SC. 
However, the physiological significance of this route is questionable due to the 
unfavourable thermodynamics of chemicals passing through multiple layers of 
corneocytes and intercellular lipids (Flynn. 1990). The appendageal route of absorption 
involves chemicals by-passing the SC to enter the lower epidermal or dermal layers. 
This can be achieved by passage of chemicals through appendage structures including 
hair follicles and sweat glands (Maibach et al. 1971). However, the density of the 
appendages varies greatly between different anatomical locations and species 
(Scheuplein. 1967).  
It is thought this route of percutaneous absorption may be most important 
immediately after application of a penetrant or if the penetrant is large or very polar 
(Scheuplein. 1967).  It is likely to have higher significance as a route of absorption in 
animals with high follicle densities (Illel, et al. 1991). The significance of the 
appendageal route can be measured using the skin sandwich model (Essa, et al. 2002) to 
determine the follicular versus bulk transport (penetration through SC) ratio.  
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Figure 1.2: Routes of percutaneous penetration through the stratum corneum. 
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Kinetics of dermal absorption 
Skin absorption occurs when a chemical, such as SM, undergoes passive diffusion 
through the SC into the viable layers of the skin. Diffusion can be defined as the 
process by which matter moves from one part of a system to another as a result of 
random molecular motion and can be characterised by Fick’s laws (Brisson. 1974). The 
four main factors influence the rate of skin absorption (J; Equation 1.1) based on Fick’s 
laws of diffusion include: partitioning (partition coefficient; Km), diffusivity (diffusivity 
coefficient; D), distance (h) and concentration (C). Fick’s first law of diffusion applies 
to “steady state” or “infinite dose” conditions where the amount of chemical available 
for diffusion does not significantly decrease. Fick’s second law of diffusion applies to 
“finite dose” conditions where the amount of chemical available for diffusion is 
significantly reduced over time (due to rapid percutaneous absorption or evaporation).  
   Equation 1.1  
Equation 1.1: Calculation of the overall rate (or flux) of diffusion (J) across the skin (g 
cm
-2
 h
-1
). Where D is diffusivity coefficient, C is concentration, h is the thickness of the 
SC, and Km is the partition coefficient.  
Diffusivity (or diffusivity coefficient) (D) is a temperature-dependent parameter related 
to the mobility of a penetrating molecule within the SC and is expressed as cm
2
 h
-1
. 
This parameter is affected by a number of factors including: potential for interactions 
between the molecule and SC (hydrogen bonding or electrostatic interactions) and the 
size of molecule (steric hindrance). The extent to which a chemical moves into the SC 
from the skin surface is expressed as the partition coefficient (Km) and is primarily 
determined by the relative solubility of the chemical in water or octanol (log P value). 
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The distance parameter (h; cm) refers to the mean diffusional path length through the 
SC as this is the main rate-limiting membrane which a chemical must transverse. 
Finally, the concentration (C; g cm
-1
) of a chemical is assumed to be equal to its liquid 
density at a given temperature.  
Fick’s first law makes the assumption that diffusion is driven by concentration 
gradients. However, thermodynamic activity (based on Fick’s second law) is the driving 
force for diffusion of chemicals across the skin (Barry, et al. 1985) and diffusion is not 
solely reliant on concentration gradients due to physiological processes such as 
sweating. Sweating results in the formation of an aqueous layer over the skin surface. If 
a hydrophobic chemical were applied to the skin the presence of an aqueous layer like 
sweat would decrease the concentration of the chemical. However, the presence of a 
hydrophobe in an aqueous solution results in disruption of the hydrogen bonding 
network between water molecules in the solution (less thermodynamically favourable) 
and increase fugacity. Fugacity can be defined as the tendency of a molecule to move 
from one environment to another dependent on its physiochemical properties (Pugh and 
Chilcott. 2008). In the case of lipophilic chemicals this results in increased diffusion 
from the aqueous phase (less favourable) to the more lipid-rich SC (more favourable).  
The maximum rate of absorption of a chemical can be determined 
experimentally from the gradient of the slope from the linear phase (steady-state flux) 
of cumulative amount absorbed (g cm
-1
) over time (h; Figure 1.3). True steady-state can 
only be measured under infinite dose conditions. However, a pseudo steady-state can be 
measured under finite dose conditions from the linear portion of the graph (Figure 1.3). 
The lag time, which is defined as the time intercept of the linear portion of the 
cumulative absorption time curve, can be calculated using Equation 1.2.  
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Figure 1.3: Example of cumulative penetration profile for a chemical under finite dose 
conditions. 
Maximum absorption rate is determined from the gradient of the slope from the linear 
phase of the graph.  
  
0 3 6 9 12 15 18
0.000
0.005
0.010
0.015
Gradient of slope =
Maximum Absorption
Rate (Jmax)
Time (h)
C
u
m
u
la
ti
v
e
 P
e
n
e
tr
a
ti
o
n
 (
m
g
 c
m
-2
)
 
17 
 
 
  Equation 1.2 
 
Equation 1.2: Calculation of lag time where, TL is the lag time, L is the effective 
thickness of the skin, C is the concentration of the chemical applied to the skin surface 
(assumed to be constant in steady-state), D is the diffusion coefficient of the skin and kd 
is the diffusion parameter (defined as kd = D/L
2
) (Twizell and Kubota. 1994).  
 
Physicochemical factors affecting dermal absorption 
The main physicochemical factors that can influence percutaneous absorption include: 
the lipophilicity of the penetrant, the size of the penetrant (molecular weight), if the 
penetrant is applied to the skin in a vehicle and the volume of the dose applied.  
 
Molecular weight of a penetrant 
Smaller molecules (low molecular weight) will pass through the skin much more 
rapidly than those with a higher molecular weight.  The importance of different routes 
of absorption may also depend on the molecular weight of a molecule; for instance, the 
appendageal route is more important for the absorption of larger molecules than for 
smaller molecules (Scheuplein. 1967). However, as a general guide it is considered that 
chemicals with a molecular weight greater than 500 Da do not penetrate the skin under 
‘normal’ circumstances (Bos and Meinardi. 2000).  
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Hydrophobicity of a penetrant 
Hydrophobicity, expressed as Log P (the logarithm to base ten of the partition 
coefficient between octanol and water), is a major factor in determining the dermal 
penetration of a chemical. The higher the Log P value, the more lipophilic the chemical 
is. Compounds with a Log P above 3 are considered highly lipophilic. The relative 
hydrophilicity and lipophilicity affects dermal absorption because, as previously 
described, in terms of entropy and free energy within a system it is more 
thermodynamically favourable for lipophilic chemicals to partition into the SC. 
Conversely it is likely to be less favourable for these chemicals to partition into the 
more aqueous viable epidermis and dermis and pass into systemic circulation 
(Bronaugh. 2004). Thus potentially forming a reservoir within the skin. 
 
Solvent vehicle for application of a penetrant 
Applying a chemical to the skin surface in a solvent vehicle can affect the percutaneous 
absorption of the chemical. The absorption of a chemical into the skin may be impeded 
if it is more soluble in the vehicle it is applied in than the SC (Jacobi, et al. 2006). 
Contrary to this, if a chemical is more soluble in the SC than its application vehicle, 
then the chemical is more likely to penetrate into the SC. The rate of percutaneous 
absorption for a chemical is highest when it is at saturated concentration in its 
application vehicle (because thermodynamic activity is maximal). Hence, the same 
concentration of a lipophilic chemical will be absorbed more rapidly if it is dissolved in 
an aqueous vehicle compared with a more lipophilic vehicle. Furthermore, some solvent 
vehicles are able to act as penetration enhancers (Ma, et al. 2010, Williams and Barry. 
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2004, Duracher, et al. 2009), either by perturbing the arrangement of SC lipids, or by 
entering the SC and creating a reservoir for dissolution of the chemical penetrant. 
Therefore, it is important to take into consideration these effects if a chemical is applied 
in a solvent vehicle. Additionally, this is an important consideration for decontaminants 
which aim to prevent the absorption of chemicals into the skin and therefore the 
chemical (to be decontaminated) should have a higher solubility in the decontaminant 
than the SC. 
 
Dose of a penetrant 
Whether the dose of a chemical is applied to the skin as a finite or infinite dose can 
have a significant influence on dermal absorption. Infinite doses require the application 
of a sufficient volume of penetrant to the skin that will not significantly deplete (due to 
absorption or evaporation) over time. This allows the maximum rate of absorption and 
permeability coefficient of the penetrant to be measured under steady-state conditions. 
However, these conditions are not generally reflective of a typical exposure scenario. 
Application of a finite dose of penetrant to the skin surface (which is depleted over time 
by evaporation or absorption) is more relevant to exposure scenarios. However, 
absorption may not reach steady-state as the dose applied becomes depleted over time 
due to absorption and evaporation dependent on the physicochemical properties of the 
penetrant (Franz. 1978).     
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Biological factors affecting dermal absorption 
Biological factors relate to the variability seen in the structure or chemical structure of 
the skin. Differences in the influence of biological factors can be seen intra or inter-
individually, as well as between different species. The main biological factors that 
influence dermal absorption include the anatomical location of the skin, gender, age, 
skin damage/disease and also species. 
 
Anatomical location of the skin 
The anatomical location is an important consideration when investigating dermal 
absorption due to differing skin permeability depending on location of the site on the 
body (Maibach, et al. 1971). Where the SC is thickest, such as the palms of the hands 
and soles of the feet the skin is less permeable to chemicals than areas of the body 
where the SC much thinner, such as the scrotum or eyelids (Scheuplein and Blank. 
1971). Differences between anatomical locations are not limited to skin thickness there 
is also variation in the corneocyte arrangement and the lipid composition of the SC 
between sites on the same individual and intra-individually (Lampe, et al. 1983). 
However, no correlation between specific SC lipids and barrier function has been 
observed (Norlen, et al. 1999).  
Conversely, intra-individual variations in filaggrin, which is a major structural 
protein in the SC, have been shown to impact barrier function in a mouse model 
(Kawasaki et al. 2012). Filaggrin contributes to the mechanical strength and integrity of 
the SC (Dale, et al. 1985) and is also further processed to hygroscopic amino acids 
which are important in SC hydration (Rawlings and Harding. 2004). Therefore, 
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decreased levels of this protein may result in SC barrier disruption and increase 
percutaneous absorption of some chemicals.    
 
Gender and Age  
Gender-specific differences in the structure, permeability and protein composition of 
the SC have been observed (Jacobi, et al. 2005). However, it is unclear whether these 
anatomical differences correlate with significant differences in percutaneous penetration 
between the sexes. Age-related changes in the skin structure between older (>65 years) 
and younger (<40 years) volunteers that may potentially increase skin permeability 
have been reported (Roskos, et al. 1989). These included decreased SC hydration status, 
reduced skin surface lipids and flattening of the dermal-epidermal junction (loss of rete 
ridges and corresponding dermal papillae) (Roskos, et al. 1989). Conversely, age-
related decreases in cutaneous perfusion may act to decrease rates of penetration 
(Monteiro-Riviere. 2004).  
 
Skin damage 
The effect of skin damage on the penetration of chemicals has been previously 
investigated using a variety of methods.  These have included; chemical disruption to 
skin barrier e.g. sodium lauryl sulphate (Borrás-Blasco, et al. 1997, Jakasa, et al. 2006) 
and physical damage to skin e.g. removal of SC via tape stripping or abrasion (Bashir, 
et al. 2001, Akomeah, et al. 2008). As the SC is the main barrier to dermal absorption it 
is reasonable to assume that its removal would increase the rate and amount of a 
chemical absorbed through the skin. However, in vitro damaged skin studies which 
 
22 
 
have completely removed the epidermis have shown that enhanced absorption favours 
hydrophilic molecules more than hydrophobic ones (Gattu and Maibach. 2011).  
Presumably this is due to the aqueous nature of the epidermis/dermis being less 
thermodynamically favourable for diffusion of hydrophobic molecules compared to 
hydrophilic ones.   
 
Species differences 
Key factors which appear to influence the suitability of different animal skin to model 
human skin include the thickness of the SC and hair follicle density. Ideally the skin 
used for percutaneous absorption studies would be human.  This would reduce the 
problem of trying to account for species differences when extrapolating to in vivo 
predictions (Bronaugh and Franz. 1986). However, it is unethical to use human 
volunteers for percutaneous absorption studies using toxic or potentially toxic 
penetrants and obtaining sufficient quantities of suitable human skin for in vitro studies 
is difficult. Therefore, animal models are needed but the SC thickness differs greatly 
between commonly studied mammalian species (Bartek, et al. 1972, Monteiro-Riviere, 
et al. 1990). Rodent species have a thinner epidermis compared to human skin resulting 
in overestimate absorption of chemicals (Dalton, et al. 2006). Pig skin has a similar 
thickness to human skin (Monteiro-Riviere, et al. 1990) and is widely accepted as the 
most suitable animal model for human skin absorption (Barbero and Frasch. 2009, 
Simon and Maibach. 2000). Hair follicle density also varies greatly between species. 
The dorsal skin of the rat and mouse has 289 and 658 follicles per cm
2
, respectively. In 
contrast, human dorsal skin has 11 follicles per cm
2
 (Bronaugh, et al. 1982). As 
previously described the higher follicle density means the appendageal route of 
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absorption is likely to represent a more significant route of penetration in rodent skin 
compared to human skin (Illel, et al. 1991). 
 
Measurement of percutaneous absorption - in vitro techniques 
Highly toxic chemicals such as SM cannot be administered to human volunteers in vivo.  
Thus, in vitro assessment of dermal absorption provides an ethical alternative to in vivo 
studies. Measurement of dermal absorption using skin mounted in diffusion cells is a 
well established method (Chilcott, et al. 2005, Hattersley, et al. 2008, Miller and 
Kasting. 2010, Franz. 1975). Generally, absorption data obtained from in vitro studies 
correlate with in vivo absorption data (Williams. 2006). Penetration of chemicals in vivo 
may be influenced by blood flow, or inflammation in response to the chemical applied 
at the skin surface (Williams. 2006). These events cannot be replicated using excised 
skin in the diffusion cell system. Therefore, penetration of a chemical in vitro may not 
accurately predict in vivo penetration (Williams. 2006). This may be particularly 
relevant to SM which has been shown to reduce dermal perfusion (Brown, et al. 1998, 
Reid, et al. 2007) and increase expression of pro-inflammatory cytokines (Price, et al. 
2009, Ricketts, et al. 2001, Sabourin, et al. 2000).  Therefore, SM may induce blood 
flow or inflammatory response changes which may influence the dermal or systemic 
absorption of SM.  
 
Diffusion Cells 
Two main types of diffusion cell are used to measure in vitro percutaneous absorption; 
static and the flow-through. The principle behind both systems is the same: chemicals 
 
24 
 
are applied to the skin surface and the amount of chemical penetrating through the skin 
into the receptor fluid below can be measured.  In the flow-through diffusion cell 
(Bronaugh and Stewart. 1985) receptor fluid is constantly removed from the receptor 
fluid chamber and replenished with fresh receptor. The flow-through system was not 
used in this Thesis and so will not be discussed further.  
As the name suggests, in static diffusion cell systems the receptor fluid is static 
and allows the penetrant to accumulate (Franz. 1975). The diffusion cells used in this 
Thesis were of the water-jacketed variety allowing control over receptor fluid and skin 
surface temperature via a heated-water circulator (Figure 1.4). Skin is mounted between 
a donor and receptor chamber and clamped in placed. Serial samples of the receptor 
fluid can be taken via the sampling port and the cumulative penetration of a chemical 
over time can be measured (Figure 1.3). The amount of chemical remaining on the skin 
surface, within the skin layers or within the receptor fluid at the end of the study can 
also can be measured. 
 
Receptor fluid 
Common used receptors included physiological saline (0.9%) with and without bovine 
serum albumin (BSA) and culture medium containing nutrients (Rubio, et al. 2011, 
Kasting, et al. 1997). The partitioning of a chemical into the receptor fluid is limited by 
the chemical’s solubility and affinity for the receptor fluid phase. Underestimation of 
skin permeability may result if the thermodynamic activity of the penetrant in the 
receptor fluid exceeds 10% of that in the donor chamber due to loss of infinite sink 
conditions (Cooper and Berner. 1985). Therefore, it is important that the volume and 
composition of the receptor fluid are appropriate for the test compound to ensure 
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efficient removal of the penetrant from the skin/receptor fluid interface and 
maintenance of effective “sink” conditions (Guy, et al. 1985). The absorption of more 
lipophilic chemicals can be facilitated by the addition of BSA (Bronaugh. 2004). Given 
the low solubility of SM (less that 0.1% at 22°C) 50% aqueous ethanol is used as a 
receptor fluid as it facilitates the partitioning of SM into the receptor phase (Hattersley, 
et al. 2008, Ramsey, et al. 1994, Scott and Ramsey. 1987). Moreover, SM is rapidly 
hydrolysed in 50% aqueous ethanol (T½ ~ 30 seconds) maintaining the concentration 
gradient and infinite sink conditions (Chilcott 2000). This reduces the problem of 
underestimating the amount or rate of absorption, which is particular concern for toxic 
chemicals such as SM.  
 
Skin Preparation 
In vitro dermal absorption studies have be conducted using various skin preparations 
including full thickness skin (Vallet, et al. 2007, Chilcott, et al. 2000, Van de Sandt, et 
al. 2004), split thickness skin (dermatomed) (Dalton, et al. 2006, Van de Sandt, et al. 
2004, Schmook, et al. 2001) or epidermal membranes (Hattersley, et al. 2008, Chilcott, 
et al. 2000). However, use of full-thickness skin may affect the penetration of lipophilic 
chemicals due to the lack of functioning circulation in vitro (Wilkinson, et al. 2006, 
Hawkins and Reifenrath. 1986). Epidermal membranes are separated from the 
underlying dermis and would not be suitable for generating a superficial wound in vitro 
model. Therefore, split-thickness (or dermatomed) skin is widely regarded as a suitable 
in vitro model for measuring percutaneous absorption and has shows better agreement 
with in vivo data than full-thickness skin (Hawkins and Reifenrath. 1986).  
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Figure 1.4: A Schematic diagram of static diffusion cell. 
Skin is mounted between an upper (donor) and lower (receptor/acceptor) chamber and 
clamped in place. The lower chamber is filled with an appropriate fluid which is 
maintained at a constant temperature via an external source of heated water. A stirring 
mechanism is used to ensure mixing of the receptor chamber fluid.  
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Split-thickness skin is obtained by removing a layer of skin using a dermatome, 
allowing the SC and the epidermis to be removed from the majority of the dermis.  
 
Measurement of dermal barrier integrity 
Measuring the physical integrity (SC integrity) prior to a dermal penetration study is a 
requirement of the Organisation for Economic Co-operation and Development (OECD) 
guidelines (OECD. 2004) and is used to check that skin barrier function has not become 
unintentionally compromised (which could affect the penetration of the chemical 
through the skin). There are several methods used to measure barrier integrity 
including: transepidermal water loss (TEWL) (Elkeeb, et al. 2010), penetration of 
tritiated water (
3
H) (Lawrence. 1997) and electrical resistance across the skin (Davies, 
et al. 2004, Chilcott, et al. 1996). However, there is disagreement over the effectiveness 
of TEWL as a measure of barrier function in vitro (Chilcott, et al. 2002). Briefly, the 
electrical resistance of the skin, when physiological saline is applied to the donor and 
receptor chamber, is measured using an alternating current (AC) impedance meter. If 
the skin were damaged then the passage of an electrical current through the skin would 
be easier (lower resistance). Skin is generally considered undamaged if the resistance is 
greater than 1.5 kΩ cm-2 (Davies, et al. 2004).     
 
Measurement of percutaneous absorption - in vivo techniques 
Determining percutaneous absorption in vivo could involve the use of relevant 
laboratory species or human volunteers. However, use of human volunteers is unethical 
for measuring the absorption of toxic chemicals such as SM. For the reasons mentioned 
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earlier, the use of rodents (in measuring SM absorption) may not accurately predict 
human dermal absorption due to higher hair follicle density and thinner SC and 
epidermis. However, the pig is a well established model for measuring percutaneous 
absorption and SM lesion development (Reid, et al. 2007, Brown and Rice. 1997, 
Chilcott, et al. 2007, Graham, et al. 2001). The in vivo system has a number of 
advantages over the in vitro system including: the presence of relevant physiological 
processes (inflammation and xenobiotic metabolism) and the presence of cutaneous 
blood flow (Monteiro-Riviere, et al. 1990).  
The dermal absorption of chemicals in vivo can be measured in similar ways to 
in vitro including the use of radiolabelled (typically 
14
C) chemicals (Chilcott, et al. 
2005, Van de Sandt, et al. 2000) or quantification and speciation of parent or metabolite 
compounds using liquid or gas chromatography combined mass spectrometry (Black, et 
al. 1992, Fairhall, et al. 2008, Lawrence, et al. 2008).  
Another method of determining percutaneous absorption in vivo is to quantify 
the biological response to the chemicals (Wester and Maibach. 2001). One major 
advantage of this technique is that it is non invasive but inter-individual variation may 
limit the accuracy of this method (Levin and Maibach. 2005). The use of biophysical 
measurements is limited to chemicals which elicit a visible or measurable effect upon 
the skin. Sulphur mustard is known to elicit a number of skin effects which can be 
quantified using a range of techniques including transepidermal water loss (skin barrier 
function), laser Doppler imaging (dermal blood flow), skin reflectance spectroscopy 
(skin colour) and infrared thermography (skin surface temperature) (Chilcott. 2000, 
Braue, et al. 2007, Graham, et al. 2002). 
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Transepidermal water loss is the outward diffusion of water through the dermal layers 
(Oestmann, et al. 1993). Transepidermal water loss measurements can provide an 
indication of the structural integrity of the skin barrier (Kalia, et al. 1996) by measuring 
the water vapour-pressure gradient of the air adjacent to the skin surface (Nilsson. 
1977). A correlation between increased TEWL and increased in vivo percutaneous 
absorption has been observed for both lipophilic and hydrophilic compounds for human 
(Oestmann, et al. 1993, Lotte, et al. 1987) and murine (Kanikkannan, et al. 2002) skin. 
Increases in TEWL following SM vapour exposure have been observed in intact 
porcine skin in vivo (Chilcott. 2000). As the lipids of the SC are thought to provide the 
primary barrier to loss of water (Golden, et al. 1987), it is reasonable to postulate that 
removal or damage to the SC may increase TEWL.  
Laser Doppler imaging (LDI) is based on the principle that the movement of the 
reflecting body (i.e. erythrocytes within the superficial cutaneous vasculature) will 
cause a frequency shift (Doppler shift) in the reflected light detected (Forrester, et al. 
2002, Droog, et al. 2001). By scanning the laser beam over the tissue, an image of 
cutaneous blood flow can be produced. Laser Doppler imaging is an established non-
invasive technique for the assessment of burn severity, wound healing and 
inflammation (Graham, et al. 2002, Droog, et al. 2001) and has shown good correlation 
with histopathological findings (Brown, et al. 1998, Braue, et al. 2007).  
Infrared thermography (IRT) allows the visualisation of changes in anatomical 
heat distribution in response to various stimuli (Ring. 1990). Factors which can affect 
skin surface temperature (other than environmental factors) include: inflammation and 
changes in dermal blood flow (Lahiri, et al. 2012, Cole, et al. 1990, Bharara, et al. 
2006, Ruminski, et al. 2007). Sulphur mustard has previously been shown to affect 
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dermal perfusion (Brown, et al. 1998) and IRT has been used to assess the efficacy of 
debridement for as a treatment for SM-induced skin lesions (Dalton, et al. 2006).  
Skin reflectance spectrophotometry (SRS) allows a quantitative assessment of 
skin colour changes including; erythema (Lahti, et al. 1993) and blanching (Waring, et 
al. 1993, Pershing, et al. 1992). The reflectance spectrophotometer measurements were 
recorded in the Commission International d’Eclairage L*a*b* (CIELAB) colour space 
values (Weatherall and Coombs. 1992) where changes in; lightness (L*), chroma (a*; 
redness) and hue (b*; blueness) can be attributed to eschar formation, 
erythema/blanching and cyanosis, respectively. Skin reflectance spectrophotometry has 
been previously described for the quantification of skin colour changes following SM 
exposure (Chilcott. 2000). 
 
COAGULATION AND HAEMOSTASIS 
Coagulation is a tightly controlled biochemical system, which must balance the rapid 
production of a fibrin clot against the maintenance of blood flow through the 
vasculature. Chronic effects of SM on coagulation include thrombocytopenia and 
anaemia (Balali-Mood, et al. 2005, Mahmoudi, et al. 2005, Krumbhaar and Krumbhaar. 
1919). Very little is known about the acute effects of SM on coagulation but, given its 
ability to alkylate biological macromolecules, there is potential for SM to alkylate 
components of the coagulation system.  
The cell-based model of coagulation proposes three overlapping coagulation 
phases; initiation, amplification and propagation (Hoffman. 2003).  The activation of 
the initial clotting factors occurs on tissue factor (TF) bearing cells (Figure 1.5).  
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This multi-domain cell surface receptor acts as both a binding site and cofactor for 
factor VII and is constitutively expressed on a wide range of extravascular cells 
(Hoffman. 2003). It is only when injury is sustained to the vascular wall that the TF 
expressing cells are exposed to circulating blood and are able to bind factor VIIa, which 
circulates in small amounts in normal plasma. During the initiation phase, the bound 
factor VIIa is able to activate factor VII, which binds to TF to form the factor VIIa-TF 
complex.  This complex is then able to activate factor IX and X in the presence of Ca
2+
 
which activate prothrombin (II) to thrombin (Monroe, et al. 2002).  
During the amplification phase, blood components (including platelets and von 
Willebrand factor; vWF) come into contact with TF-bearing cells (Figure 1.5). The 
small amounts of activated thrombin activate platelets and clotting factors including V 
(released from activated platelets), VIII (cleavage product of vWF) and XI. The 
activated platelets adhere to the injury site and aggregate to form an initial plug. Pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF-α have been shown to 
demonstrate pro-coagulatory activity and increase the rate of clotting and platelet 
numbers (Collombet, et al. 2005, Watts, et al. 1996). Sulphur mustard has been shown 
to increase expression of these cytokines in vivo (Arroyo, et al. 2004a, Yaraee, et al. 
2009) and so, SM exposure could potentially increase the rate of coagulation. 
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Figure 1.5: The cell-based model of coagulation showing the three overlapping 
phases; initiation, amplification and propagation. 
Activation of clotting factors on tissue factor (TF) bearing cells produces nominal 
levels of activated thrombin (II). During the amplification phase, blood components 
(including platelets and von Willebrand factor; vWF) come into contact with TF-
bearing cells. Thrombin activates platelets and clotting factors which results in large 
amount of thrombin being activated (propagation phase).  Thrombin cleaves fibrinogen 
to produce fibrin monomers.  These form a fibril network incorporating the platelet 
plug and are covalently linked by factor XIIIa to produce a stable fibrin clot. The small 
a denotes activated form (adapted from Hoffman, 2003). 
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During the propagation phase, factor Xa is able to complex with factor Va, Ca
2+
 and 
platelet factor 3 to form the prothrombinase complex (Figure 1.5). This complex 
converts prothrombin to its active form, thrombin, which stimulates a number of 
positive and negative feedback loops in addition to catalysing the cleavage of 
fibrinogen to fibrin peptides A and B and fibrinogen monomers (Tuthill, et al. 2001).  
The fibrin monomers arrange into fibrils and eventually form a network of fibres. 
Thrombin uses Ca
2+
 as a co-factor to activate factor XIII which transaminates the non-
covalent bonds between the monomer fibres (Nielsen, et al. 2004). This covalently 
cross-links the fibrin monomer fibrils to form a stable fibrin clot that is resistant to 
proteolytic degradation by plasmin (Sierra. 1993). Sulphur mustard alkylates a number 
of amino acid residues including; histidine, glutamic acid, aspartic acid and valine 
(Black, et al. 1997, Noort, et al. 1996). Histidine and aspartic acid are critical amino 
acids in the active site of thrombin (Ye, et al. 1991) and thus alkylation could result in 
conformational or functional changes to thrombin leading to a reduction in clotting. 
Thrombin regulates its own production by activating physiological pathways to localise 
its formation at the injury site and prevent the clot from extending to uninjured 
endothelial surfaces (Mahdy and Webster. 2004, Roberts, et al. 2004). Regulatory 
pathways and the fibrinolytic pathway are crucial for overall haemostasis within the 
body and to prevent thrombosis. The thrombin regulatory pathways inhibit thrombin 
activity (antithrombin III) as well as clotting factors upstream of thrombin to prevent 
further production of thrombin (protein C pathway, antithrombin III and tissue factor 
pathway inhibitor). 
The function of the fibrinolytic pathway is the dissolution of cross-linked fibrin 
clots (Castellino. 1981). Conversion of the zymogen (plasminogen) to activated plasmin 
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is achieved by specific plasminogen activators (Castellino. 1984). Once activated, 
plasmin degrades clots via cleaving fibrin, disrupting platelet function, collagenases 
activation and inactivation of factors Va and VIIIa.  Plasminogen activators include 
tissue type plasminogen activator (t-PA) and urinary type plasminogen activator or 
urokinase (uPA) (Francis and Marder. 1987). Both t-PA and uPA are inhibited by type 
1 plasminogen activator inhibitor (PAI-1) and plasmin is also directly inhibited by α2-
antiplasmin (Kunamneni, et al. 2008). Sulphur mustard has been shown to increase uPA 
activity in vitro by 20 – fold within 24 h of exposure (Detheux, et al. 1997) which could 
result in increased fibrinolysis. Thus overall, there are three potential mechanisms 
through which SM may exert an anti-coagulatory effect. 
 
In vitro measurement of coagulation – Thrombelastography  
Thrombelastography (TEG) measures the viscoelastic properties of whole blood during 
clotting and was first described by Hartert (Hartert. 1948). Unlike classical coagulation 
tests (prothrombin time, partial thromboplastin time and activated prothrombin time), 
TEG measures the clotting ability of a whole blood sample (Mallett and Cox. 1992). 
Thrombelastography measures the physical properties of clot formation using an 
oscillating cup and pin. A plastic cup or cuvette containing the blood sample is 
maintained at 37˚C and is rotated in each direction through 4˚45’ at a frequency of 0.1 
Hz (Figure 1.6A) (Khurana, et al. 1997). The plastic pin is coaxially suspended into the 
cup and becomes coupled to the motion of the cup once the fibrin clot forms. The pin is 
attached to a torsion wire which acts as torque transducer. The resistance of the clot to 
deformation is plotted as a function of time and provides a quantitative assessment of 
the rigidity of the clot (Figure 1.6B) (Khurana, et al. 1997).  
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Six clotting parameters are measured using TEG: R Time, K Time, α angle maximum 
amplitude, shear elastic modulus strength (SEMS) and coagulation index (CI) (Figure 
1.6B). These parameters provide details of the clotting dynamics and clot strength and 
relate to the phases of coagulation in the cell-based model (Figure 1.5) (Hoffman. 
2003). R Time is the latent interval from the start of the recording to the formation of a 
three-dimensional fibrin gel network with a defined rigidity of 2 mm.  
The R time is a measure of the enzymatic function (clotting factors) and 
corresponds to the initiation phase (Johansson, et al. 2009). K Time is the interval from 
the R time to a fixed amplitude point (20 mm). This reflects the amplification phase of 
coagulation pathway (Kawasaki, et al. 2004). The α-angle is the angle of the slope of 
the TEG trace from R time to K time. The alpha angle is indicative of the thrombin 
“burst” stage of the amplification phase (Johansson, et al. 2008).  K time combined 
with α angle reflects the overall clotting kinetics. The maximum amplitude is the 
greatest amplitude achieved on the TEG trace and is representative of total clot strength 
(Johansson, et al. 2009).  Shear elastic modulus strength (SEMS) is a function of the 
maximum amplitude and is a measure of the clot elasticity to shearing forces (Khurana, 
et al. 1997). Two components contribute to the overall strength of the clot, the fibrin 
clot matrix and platelet aggregation. The coagulation index (CI) is derived from a linear 
equation and assigning a coagulation score based on R Time, K Time, α-angle and 
maximum amplitude. 
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Figure 1.6: Schematic diagram of Haemoscope Thrombelastograph
®
 pin and cup 
setup (A) and example TEG trace with the four key parameters labelled (R Time, K 
time, α-angle and maximum amplitude) (B). 
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Haemostatic products 
The haemostatic products tested in this Thesis are intended for application to wounds in 
order to arrest haemorrhage and have demonstrated efficacy in vivo (Kheirabadi, et al. 
2009, Ahuja, et al. 2006, Alam, et al. 2004, Alam, et al. 2003). A variety of 
formulations were tested including dressings, granular and liquid products.  
Three products (WoundStat™, QuikClot Advanced Clotting Sponge plus®; 
QuikClot ACS+
® 
and ProQR
®
) are categorised as inorganic particles or granules. 
Overall, these products are thought to arrest bleeding via adsorption of water from 
plasma into the lattice structure of the product, resulting in localisation and subsequent 
activation of clotting factors (Kheirabadi, et al. 2009). 
Additionally, QuikClot ACS+
®
 (a non mineral zeolite bead) is also thought to 
facilitate the coagulation phenomenon known as the “glass effect”, whereby its negative 
surface charge promotes coagulation via the activation of factor XII (and subsequent 
activation of factor IX; Figure 1.5) in the same manner as the negative surface charge of 
glass (Cochrane, et al. 1973). WoundStat™ is an aluminium silicate member of the 
smectite clay family (Carraway, et al. 2008). The haemostatic activity of WoundStat™ 
is largely attributed to the tetrahedral sheet-like organisation of the clay which can 
absorb large amounts of water resulting in localised concentration of clotting factors 
(Bowman, et al. 2011). Additionally, aluminium silicate clays have zones of negative 
and positive charges which are able to activate the coagulation process via factors XII 
and XI (Figure 1.5). Similarly to QuikClot ACS+
®
 it has been proposed that negative 
surface charges on the promote coagulation via the activation of factor XII. ProQR
®
 is a 
granular non-zeolite mineral haemostat comprised of a mixture of a hydrophilic 
polymer and potassium iron oxyacid salt (Ho and Hruza. 2007). In addition to plasma 
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adsorption the potassium salt in combination with hydrophilic polymer, provides a 
scaffold for red blood cells and platelets to bind, resulting in the formation of an 
artificial eschar (Ho and Hruza. 2007). 
Two chitosan-based products (HemCon
®
 and Celox™) achieve haemorrhage 
control by forming a seal at the site of vessel injury via mucoadhesive properties 
(Brown, et al. 2007, Pusateri, et al. 2003a, Pusateri, et al. 2003b).  Electrostatic 
interactions with blood cells (resulting in erythrocyte and platelet aggregation) have 
also been suggested as contributory mechanisms (Brown, et al. 2007, Kozen, et al. 
2008, Kozen, et al. 2007). 
Finally, two liquid haemostats (FastAct
®
 and VitaGel™) were also chosen for 
testing. The intention of this Thesis was to combine these liquid products with a novel 
decontaminant (described in Chapter 2) to produce a reactive decontaminant/haemostat 
mixture. Both products contain activated clotting factors such as thrombin and factors 
VII, IX and X, which can trigger the amplification and propagation phases of 
coagulation (Figure 1.5) (Alam, et al. 2004, Prior, et al. 2000). 
 
SULPHUR MUSTARD 
Sulphur mustard (bis (2-chloroethyl) sulphide) is a vesicant or blistering agent, which is 
able to alkylate a range of biological macromolecules (Figure 1.7) (Papirmeister, et al. 
1985). The relatively high percutaneous LD50 (100 mg kg
-1
; rabbit) for SM means that it 
is generally considered a non-lethal weapon but instead causes considerable 
incapacitation (Graham, et al. 2005). Sulphur mustard is poorly soluble in water (0.07% 
at 10°C), and has a relatively low volatility and high freezing point (14°C) and so is 
 
39 
 
able to persist in the environment for long periods especially in damp, cooler climates 
(Balali-Mood and Hefazi. 2005). 
 
 
Figure 1.7: Chemical structure of sulphur mustard. 
 
Characteristics of sulphur mustard-induced injuries 
The three main target organs for SM are the skin, eyes and lungs. High exposures to SM 
can also results in systemic toxicity, characterised by fever, gastrointestinal tract effects 
(diarrhoea), and bone marrow suppression (leukocytopenia and thrombocytopenia) 
(Kehe and Szinicz. 2005, Dacre and Goldman. 1996). The focus of this Thesis was on 
the cutaneous route of exposure and subsequent pathology and so further details on 
respiratory or ocular toxicity have not been included.  
Due to its lipophilic nature (Log P 1.37), SM can easily penetrate through 
epithelial tissue and thus skin plays a very important role as a route of entry for SM 
(Renshaw. 1946). The typical skin pathology induced by SM can be divided into three 
overlapping phases; initial erythema followed by blistering and finally ulceration (Kehe 
and Szinicz. 2005). There is a well documented latent period between the time of 
exposure and the onset of clinical symptoms, with an inverse correlation between the 
exposure dose and the latency period (Papirmeister et al. 1991). Following a latency 
period of 4 – 8 h erythema is observed at threshold doses (10 – 20 µg cm-2) whilst 
blistering is seen at higher doses (40 – 100 µg cm-2) (Papirmeister et al. 1991). 
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Toxicokinetics 
There is good correlation between SM penetration rates using human skin in vitro and 
human volunteers, with rates of 71 – 294 µg cm-2 hr-1 and 60 – 240 µg cm-2 hr-1 for in 
vitro and human volunteer studies, respectively (Chilcott, et al. 2000, Kehe and Szinicz. 
2005, Nagy, et al. 1946). The amount of SM needed to produce blisters has been found 
to be 20 µg cm
-2
 of liquid SM (Papirmeister, et al. 1984). However, only 4 µg cm
-2
 of 
saturated SM vapour is needed to produce the same result (Nagy, et al. 1946). This 
discrepancy is due to the fact that of the applied liquid dose, 80% will evaporate with 
20% of the dose penetrating (Renshaw 1946). Therefore, occluded conditions will 
increase the skin penetration and severity of SM–induced skin lesion (Chilcott, et al. 
2000). There is some disagreement in the literature over what percentage of SM 
remains in the skin, how much is absorbed systemically and whether or not there is a 
reservoir within the skin of unreacted SM (Hattersley, et al. 2008, Renshaw. 1946, 
Chilcott, et al. 2001).  The reported amount retained within the skin varies from 10 – 
20% up to 60% of the applied dose, with variability in the amount absorbed 
systemically also seen (ranging from 40% to 80 – 90% of the applied dose) (Hattersley, 
et al. 2008, Renshaw. 1946). Once SM has entered the systemic circulation, it is quickly 
cleared and mostly excreted in the urine, with 60% of the absorbed dose found to be 
excreted within 24 hours. Metabolites of SM found in the urine result from either 
hydrolysis or direct oxidation at the sulphur atom or from reactions with glutathione 
(Black, et al. 1992, Black and Read. 1995). Two separate studies using rats have found 
that conjugation with glutathione is more important than hydrolysis in terms of SM 
breakdown products (Davison, et al. 1961, Roberts and Warwick. 1963). Whole body 
autoradiography studies with mice using 
35
S–SM found that there was increased 
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radioactivity localised to the kidney, liver, intestines and nasal regions following both 
intravenous and percutaneous administration (Clemedson, et al. 1963).  
 
Gross skin pathology 
Sulphur mustard skin lesion pathology is characterised by the appearance of erythema 
followed by the formation of small vesicles which coalesce to form gross blisters or 
large bullae (Papirmeister, et al. 1984). The blisters, which initially appear as small 
vesicles, display positive Nikolsky signs and occur within the area of erythema 
approximately 18 h post – exposure (Papirmeister, et al. 1984). Blistering is a result of 
separation of the epidermal–dermal layer with the upper portion of the lamina lucida 
(Kehe, et al. 2009, Sayer, et al. 2010). Sulphur mustard–induced micro–blisters 
coalesce to form large blisters, which are thin-walled and filled with a clear yellow-
amber coloured fluid which does not contain active SM (Kehe, et al. 2009). 
Macroblistering, resulting from the coalescence of micro-blisters, is almost exclusive to 
humans (Maynard. 2007). At 48 hours post-exposure, blistering becomes more marked 
and large blisters usually break leading to erosions, full thickness skin loss and 
ulceration (Sidell, et al. 1997). Necrosis may occur at these sites followed by formation 
of an eschar at 72 hours post exposure (Maynard. 2007). The eschar usually begins to 
slough by 4 – 6 days leaving a scar which may be characterised by hypo- or hyper-
pigmentation (Balali-Mood and Hefazi. 2005). The severity of SM-induced injury is 
also dependent on anatomical location with skin at warm, moist body areas, including: 
the axilla and scrotum, being more susceptible to SM injuries (Sidell, et al. 1997). 
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Microscopic effects 
Following SM exposure there is both marked keratinocyte cell death as well as terminal 
differentiation of keratinocytes within the basal layer of the skin, with the build up of 
necrotic and apoptotic cells and signs of a substantial inflammatory response (Sayer, et 
al. 2010, Smith. 1999, Simbulan-Rosenthal, et al. 2006). Histopathology has revealed 
that SM-exposed skin shows vasodilation and neutrophil infiltration, indicative of 
vasoactive and chemo attractant mediator production within the exposed area (Brown 
and Rice. 1997). Vasodilation would present clinically as erythema (Smith, et al. 1997). 
Basal cells of the epidermis appear to be the most sensitive to SM toxicity, possibly as 
these cells are actively dividing and so are more susceptible to the alkylating properties 
of SM (Papirmeister et al. 1991). SM is able to alkylate a variety of cellular 
components, including DNA and proteins (Papirmeister, et al. 1985).  The primary site 
of DNA alkylation is the N7 position of deoxyguanosine residues (Wheeler. 1962). The 
main targets for SM alkylation of proteins include carboxyl, sulphydryl and α-amino 
groups as well as the imidazole ring of histidine (Balali-Mood and Hefazi. 2005). 
 
Proposed mechanisms of sulphur mustard toxicity 
Although SM was first used over 90 years ago and despite many decades of research, 
there is currently no conclusive mechanism of action for SM. However, most recently 
proposed mechanisms focus on the ability of SM to alkylate cellular components, 
including DNA and proteins and induced cellular oxidative stress. There is also no 
defined mechanism to explain why SM causes epidermal-dermal separation or 
preferentially targets the basal cells of the epidermis. Similarities between SM-induced 
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blisters and clinical blistering diseases such as epidermolysis bullosa have been 
observed (Monteiro-Riviere and Inman. 2000, Monteiro-Riviere, et al. 1999). Protease 
involvement in vesication has been proposed following the observation that a 
transmembrane protein (BP180) was present on both the roof and the floor of a SM 
blister (Greenberg, et al. 2006). The most upregulated matrix metalloprotease (MMP) in 
the skin following SM exposure in vivo has been identified as MMP-9 (Ruff and 
Dillman III. 2007, Shakarjian, et al. 2006, Vallet, et al. 2012, Dachir, et al. 2010). 
However, SM-induced vesication is unlikely to be due to MMP involvement alone.   
Sulphur mustard selectively targets the basal cells of the epidermis and induces 
cell death in a dose dependent manner (Sun, et al. 1999, Dabrowska, et al. 1996, Kehe, 
et al. 2000). At higher concentrations (≥500 µM endothelial cells, 1000 µM HeLa 
cells), cell death is by necrosis, whilst at lower concentrations (≤200 µM endothelial 
cells, 100 µM HeLa cells) cell death is due to apoptosis (Sun, et al. 1999, Dabrowska, 
et al. 1996). This concentration-dependent variability in mechanism is particularly 
important for dermal exposure to liquid SM due to the effects of surface spreading 
(Szinicz, et al. 2007). Work by Chilcott et al. (2000) observed rapid spreading of 
radiolabelled-SM on skin surface following application of a 20 µL droplet, even though 
the droplet bead was still visible.  Therefore, there will be a higher concentration of SM 
at the contact point, subsequently decreasing as it spreads (Chilcott, et al. 2000). This 
may present a considerable challenge when trying to identify targets for therapeutics as 
there is likely to be different modes of cell death occurring.  
The aim of this section is to give an outline on how SM specifically induces 
apoptosis and does not aim to give an in-depth account of apoptosis. Both apoptosis and 
necrosis are defined and well orchestrated processes (Rosenthal, et al. 1998, Rosenthal, 
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et al. 2001, Festjens, et al. 2006). However, intracellular levels of adenosine 
triphosphate (ATP) influence the mode of cell death because the process of apoptotic 
cell death requires sufficient amounts of ATP to allow full completion whilst necrosis 
does not (Eguchi, et al. 1997). Due to the delay between SM exposure and appearance 
of visible cutaneous injury it has been suggested that apoptosis predominates as the 
mode of cell death (Kehe, et al. 2009). 
Key processes involved in apoptosis which have been shown to be influenced by 
SM are summarised in Figure 1.8. Sulphur mustard has been shown to initiate both the 
intrinsic and extrinsic apoptotic pathways culminating in activation of effector caspase-
3 and apoptotic cell death (Rosenthal, et al. 1998, Ray, et al. 2005, Steinritz, et al. 
2007, Kehe, et al. 2008). The activated Fas receptors cluster to form Fas-associated 
death domain (FADD) upon activation. An initiator procaspase (such as caspase-8) is 
recruited to form a death inducing signalling complex (DISC). 
Expression of the pro-apoptotic ligands Fas and tumour necrosis factor alpha (TNF-α) 
and the Fas receptor, which can form a death inducing signalling complex with caspase-
8, have been shown to be up-regulated in keratinocytes by SM (Arroyo, et al. 2004a, 
Rosenthal, et al. 2003). However, whilst cell expressing negative Fas-associated death 
domain (activated Fas receptors which have clustered together) show reduced apoptosis 
in response to SM exposure it is not obliterated, suggesting the involvement of 
additional pathways (Arroyo, et al. 2004a). Sulphur mustard has also been shown to 
shift the balance between pro and anti-apoptotic members of the Bcl-2 family in favour 
of apoptosis. This pro-apoptosis shift can result in the opening of the mitochondrial 
outer membrane pore (MOMP). Sulphur mustard has been found to induce MOMP, 
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cytochrome c release and caspase-9 activation in bronchial cells (Sourdeval, et al. 
2006).  
Sulphur mustard has been shown to promote the dephosphorylation of Bad (a 
Bcl-2 family member), promoting apoptotic death via the calmodulin pathway 
(Shakarjian, et al. 2010). Basal cells exposed to SM exhibit morphological 
characteristics of apoptosis including: membrane blebbing, perinuclear budding and 
pyknosis (Petrali, et al. 1991, Petrali, et al. 1994). 
DNA Damage 
Sulphur mustard is able to react and alkylate many cellular components including DNA, 
forming mono and bifunctional adducts (Wheeler. 1962). Each 2-chloroethyl side chain 
of the SM molecule is able to undergo first order (SN1) intramolecular cyclisation with 
the release of the chloride ion. The ethylene sulfonium cation intermediate forms the 
highly reactive carbonium ion which reacts with nucleophiles such as DNA, RNA and 
proteins (Figure 1.9) (Papirmeister, et al. 1985). Adenine and guanine residues are more 
favourable for adduct formation, with N7 position of guanine nucleotides being the 
most common accounting for an approximately 61% of total alkylations (Kehe and 
Szinicz. 2005). Inter or intrastrand cross links resulting from bifunctional adducts 
account for nearly 17% of all SM alkylations (Brookes and Lawley. 1961, Brookes and 
Lawley. 1960, Lawley and Brookes. 1968). However, the DNA lesion postulated to be 
most critical for cell damage is O6-(2-ethylthioethyl) guanine, despite the low 
frequency of occurrence (~0.1% of all DNA lesions), due to a lack of repair mechanism 
in humans (Ludlum, et al. 1984, Ludlum, et al. 1986).  
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Figure 1.8: Schematic of major apoptotic pathways affected by SM. 
Sulphur mustard triggers apoptosis directly by destabilising p53 and indirectly via 
DNA damage, activating pro-apoptotic members of the Bcl-2 family, resulting in 
increased expression of death receptors and ligands. Death receptors activate adaptor 
proteins e.g. procaspase-8 to form a death inducing signalling complex (DISC). The 
caspase cascade is activated via caspase-3. Mitochondrial outer membrane pore 
(MOMP) opening in response to SM results in Smac protein and cytochrome c release. 
Cytochrome c activates caspase-9 via the apoptosome which subsequently activates the 
caspase cascade via caspase-3. Smac proteins inhibit inhibitors of apoptotic proteins 
(IAPs) activity. Nuclear factor κB (NF-κB) promotes IAP and anti-apoptotic Bcl-2 
protein activity. Red asterisks indicate proteins are known to be effected by SM 
exposure.        
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Double DNA strand breaks results in two outcomes that contribute to cell death.  
Firstly, strand breaks arrest the cell cycle at either G1 or G2 stage checkpoints in a SM 
dose-dependent manner (Rosenthal, et al. 1998, Ismail, et al. 2005). Secondly, DNA 
strand breaks can activate protein kinases (ataxia-teleangiectasa mutated protein and 
ataxia-teleangiectasa and Rad3-related kinase) which are able to phosphorylate pro-
apoptotic downstream targets including; p53, Chk 1 and Chk2 (Jowsey, et al. 2012, 
Jowsey, et al. 2009, Banin, et al. 1998, Enders. 2008). Deoxyribose nucleic acid repair 
may prompt terminal differentiation or programmed cell death via apoptosis (Kehe, et 
al. 2009, Rosenthal, et al. 1998).    
The DNA repair process triggered in response to SM-induced damage may also 
contribute to cell death. Several groups have proposed a role for poly (adenosine 
diphosphate) polymerase (PARP) in contributing to SM-induced cell death and 
subsequent blister formation (Papirmeister et al. 1991, Kehe, et al. 2008, Debiak, et al. 
2009, Bhat, et al. 2001). The isoform of particular interest is PARP-1 which is activated 
by DNA strand breaks such as those seen with SM exposure (Bhat, et al. 2001). Studies 
by Rosenthal et al. (1998) observed significant increases in activity within one hour of 
SM exposure in human keratinocytes. Overactivation of PARP, due to increased 
genomic stress, can result necrotic cell death due to depletion of intracellular 
nicotinamide adenine dinucleotide (NAD
+
) and ATP in a SM concentration-dependent 
manner (Kan, et al. 2003). However, the cytotoxic action of SM cannot be solely 
attributed to PARP as the inhibition of PARP only provides limited cytoprotection in 
the first few hours following SM exposure (Martens and Smith. 2008). There also 
appears to be cell-specific response to SM as PARP over-activation determines the 
mode of cell death in fibroblasts but not keratinocytes (Rosenthal, et al. 2001).   
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Figure 1.9: Sulphur mustard breakdown products and DNA adduct formation. 
During SM hydrolysis from SM to thiodiglycol (TDG), a sulphonium ion intermediate is 
formed. This can generate a highly reactive carbonium ion which reacts with and 
alkylates DNA (or RNA) residues e.g. N7-guanine.   
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Ca
2+
 signalling and calmodulin 
A number of studies have reported a SM-induced irreversible rise in intracellular levels 
of Ca
2+ 
although the exact mechanism for this remains unclear (Hua, et al. 1993, Mol 
and Smith. 1996, Hamilton, et al. 1998, Sawyer and Hamilton. 2000). There is a 
reported cell type-dependent response in the lag time between SM exposure and 
intracellular Ca
2+
 response for fibroblasts (5 – 10 min) and primary keratinocytes (3 – 
24 h) (Mol and Smith. 1996, Sawyer and Hamilton. 2000). Responses for secondary 
cultures of confluent human keratinocytes (≤ 2 min) are similar to fibroblast responses 
(Hamilton, et al. 1998). The physiological relevance of such observations is unclear as 
the reported rises in intracellular Ca
2+
 were only moderate (less than two fold) (Kehe, et 
al. 2009, Ruff and Dillman III. 2007) but would be sufficient to induce terminal 
differentiation, which is a form of Ca
2+ 
dependent cell death in keratinocytes (Lippens, 
et al. 2005). Low Ca
2+
 concentrations allow for proliferation in the basal layers but as 
the Ca
2+
 concentration progressively increases in the upper epidermal layers, 
cornification is triggered by converting cells into corneocytes (Simbulan-Rosenthal, et 
al. 2006, Whitfield, et al. 1995). The markers of terminal differentiation include the 
suppression of fibronectin, induction of keratin 1 and 10 and cross linking of involucrin 
(Rosenthal, et al. 1998). 
Sulphur mustard has also been shown to alter gene expression of the calcium 
binding proteins, calmodulin (CaM) and calcineurin (Simbulan-Rosenthal, et al. 2006). 
The Ca
2+
-CaM-calcineurin pathway may have a role in SM-induced apoptosis, possibly 
via dephosphorylation of the pro-apoptotic Bcl-2 family member, Bad (Kehe, et al. 
2009, Simbulan-Rosenthal, et al. 2006). Once activated Bad is able to interact with Bcl-
2 and Bcl-xl and induce MOMP opening and subsequently induce apoptosis (Figure 
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1.8) (Simbulan-Rosenthal, et al. 2006). Sulphur mustard activated Ca
2+
-CaM 
complexes can also directly regulate apoptosis. The CaM-Ca
2+
 complex is able to 
directly bind Fas receptor as well as activate caspases and endonucleases resulting in 
DNA cleavage and apoptotic DNA ladders (Kehe, et al. 2009, Simbulan-Rosenthal, et 
al. 2006, Ankarcrona, et al. 1996). Increased Ca
2+
 and calmodulin levels can also have 
downstream effects on other pathways including nitric oxide production and oxidative 
stress (Bloch, et al. 2007, Gao, et al. 2007). 
  
Nitric oxide, reactive oxygen species and oxidative stress  
Cell death resulting from SM exposure has also been linked to nitric oxide production 
and oxidative stress (Paromov, et al. 2008). Under normal physiological conditions, 
reactive oxygen species (ROS) are constantly produced within the cell and the free 
radicals are removed by the antioxidant defence system. Three key enzymes are 
involved in this pathway; superoxide dismutase (SOD), glutathione peroxidases (GPx) 
and catalase (CAT) (Sies. 1997, Sies. 1993). Superoxide dismutase converts free radical 
superoxide to hydrogen peroxide which is subsequently catalysed to water by GPx and 
CAT (Figure 1.10). Oxidative stress results as a consequence of the normal cellular 
defence system becoming overwhelmed (e.g. through glutathione depletion) and may 
contribute to SM induced cell death (Kumar, et al. 2001, Rappeneau, et al. 2000, 
Giuliani, et al. 1997, Gross, et al. 1993).  
Expression of inducible nitric oxide synthase (iNOS) has been shown to 
increase following SM exposure (Gao, et al. 2008). Nitric oxide (NO) is a physiological 
messenger involved in blood vessel homeostasis (Champion, et al. 2003), immune and 
inflammatory response (Kanwar, et al. 2009) and wound healing (Luo and Chen. 2005). 
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Nitric oxide is also able to react with superoxide (O2
-
) to form peroxynitrite (ONOO
-
) 
(Figure 1.10) which can subsequently form other reactive nitrogen species (RNS) 
(Squadrito and Pryor. 1998). Peroxynitrite and RNS are able to induce cytotoxicity in a 
similar fashion to ROS through oxidation and covalent modification of membrane 
lipids, proteins and DNA (Sawyer, et al. 1996, Korkmaz, et al. 2006). Both 
peroxynitrite and superoxide both trigger DNA single strand breaks which will 
subsequently increase PARP activation and so highlights how SM exposure can result 
in cumulative cytotoxic effects.  
 
Inflammation 
Sulphur mustard exposure results in increased expression of pro-inflammatory 
cytokines including; IL 1α/β, 6 and 8 and TNFα (Ruff and Dillman III. 2007, Arroyo, et 
al. 2001b, Smith, et al. 1998, Arroyo, et al. 2001a). Nuclear factor–κB (NF-κB) 
pathway and mitogen-activated protein kinases (MAPKs) have been shown to be 
involved in the regulation of genes for inflammatory cytokines following SM injury 
(Minsavage and Dillman III. 2007, Rebholz, et al. 2008).  
Sulphur mustard activates NF-κB pathway resulting in translocation of NF-κB 
to the nucleus, where it can mediate cellular stress, apoptosis and inflammatory 
responses (Figure 1.8) (Minsavage and Dillman III. 2007, Karin and Ben-Neriah. 2000, 
Hayden and Ghosh. 2008, Karin and Greten. 2005). Sulphur mustard has also been 
shown to activate the p38 MAPK pathway which is involved in cell apoptosis and 
terminal differentiation through the phosphorylation of p38 in a dose dependent manner 
(Rebholz, et al. 2008). Inhibition of p38 has been found to reduce SM-induced 
inflammatory cytokine production (Dillman III, et al. 2004).   
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Figure 1.10: Summary of mechanisms for SM-induced cytotoxicity. 
SM can induce oxidative stress resulting in DNA damage or cause DNA damage 
directly. Poly (ADP-ribose) polymerase (PARP) becomes activated. If the DNA damage 
cannot be repaired apoptosis results.  If the damage is sufficiently severe, PARP 
becomes overactivated leading to ATP and NAD
+
 depletion and necrotic cell death. SM 
has also been found to increase intracellular Ca
2+
, which can activate pro-apoptotic 
members of the Bcl-2 family. SM has also been found to activate pro-apoptotic proteins 
and stabilise p53, resulting in cell death. SM also triggers increased production of 
nitric oxide (NO; possibly via iNOS) and superoxide (O2
-
) culminating in increased 
production of peroxynitrite. Excessive peroxynitrite, hydrogen peroxide and superoxide 
can overwhelm the normal antioxidant processes resulting in oxidative stress and 
subsequent lipid peroxidation, protein oxidation and DNA damage.   
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HYPOTHESIS AND AIMS 
The majority of haemostats increase the rate of coagulation by passively adsorbing 
plasma which subsequently results in increased local concentration of clotting factors 
resulting in activation of the coagulation process (Figure 1.5). Passive adsorption is also 
the mechanism of action for in-service military decontaminants including fuller’s earth 
(Taysse, et al. 2007, Taysse, et al. 2011). Therefore, haemostatic products appear to 
have the potential function as both decontaminants and clotting agents. This may help 
resolve the issue of how to simultaneously treat and decontaminate haemorrhaging 
wounds which are contaminated with toxic chemicals such as SM.  
 
To evaluate the suitability of haemostats to function as decontaminants the following 
hypotheses were investigated: 
 The efficacy of haemostats to increase the rate of coagulation in vitro is not 
affected by the presence of SM in the blood. 
 The rate and extent of SM absorption is significantly increased in vitro and in 
vivo when applied via superficially damaged skin. 
 Haemostats are effective in significantly reducing the rate and extent of SM 
absorption in vitro and in vivo.  
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GENERAL METHODS 
Chemicals 
Sulphur mustard (SM; bis (2-chloroethyl) sulphide) used for thrombelastography 
studies was purchased from the Defence Science and Technology Laboratory (Dstl) and 
was reported to be >98 % pure by NMR. Sulphur mustard for all other studies and its 
radiolabelled (
14
C) analogue were custom synthesised by TNO Defense. The purity of 
the agents was determined to be 99.2% and >97% for SM (NMR analysis) and 
14
C-SM 
(GC-MS and HPLC analysis), respectively. The 
14
C-SM solution was diluted with 
unlabelled SM to give a working solution (nominal activities 0.635 mCi g
-1
; static 
diffusion studies, 11 mCi g
-1
; in vivo studies) which was stored for up to three months at 
4°C. The storage and use of chemical warfare (CW) agents was in full compliance with 
the Chemical Weapons Convention (1993).   
Supplier details are summarised in Table 2.1. All reagents were purchased from 
Sigma-Aldrich unless otherwise stated. All general consumables were purchased from 
Fisher Scientific UK Ltd. 
 
Animals 
Specific pathogen-free, out-bred domestic pigs (Sus scrofa domestica; Large White 
strain, female) were purchased from a reputable supplier (weight range 15 – 25 kg) and 
were individually housed in approved pens under a 12 h/12 h light/dark cycle.   
  
 
56 
 
Reagents, consumables or 
equipment  
Supplier Name Supplier Address 
Microarray supplies 
Agilent Technologies UK 
Ltd. 
Wokingham, UK 
RNA storage & isolation  Ambion, Applied Biosystems Warrington, UK 
AC resistance meter AVO multimeter Dover, UK 
In vivo consumables  BD Franklin Lakes, USA 
Precellys
®
 Bertin Technologies 
Montigny-le-
Bretonneux, France 
AquaFlux evaporimeter Biox Systems London, UK 
Surgical consumables 
Burtons Medical Equipment 
Ltd. 
Marden, UK 
Camera Canon Uxbridge, UK 
SM (non-radiolabelled) 
Defence Science and 
Technology Laboratory (Dstl) 
Porton Down, UK 
Custom pig sling Ellegaard Dalmose, Denmark 
Dermatome Eurosurgical Ltd. Guildford, UK 
Histology supplies Fisher Scientific UK Ltd. Loughborough, UK 
Infrared camera FLIR Systems West Malling, UK 
Pipettes Gilson Scientific Ltd. Luton, UK 
Statistical analysis software GraphPad Software San Diego, USA 
Surgical equipment Harvard Apparatus Ltd. Edenbridge, UK 
Homogeniser IKA
®
-Werke GmbH & Co. Staufen, Germany 
Reflectance spectrometer Konica Minolta Warrington, UK 
Thrombelastography supplies MediCell Ltd. London, UK 
Laser Doppler line scanner Moor Instruments Axminster, UK 
Liquid scintillation counter 
supplies and tissue solubliser   
PerkinElmer Beaconsfield, UK 
Static diffusion cells PermeGear Chicago, USA 
RNA isolation kit QIAGEN Crawley, UK 
Hyponoval
®
 sedative Roche Products Ltd. 
Welwyn Garden City, 
UK 
Histology supplier Sakura Finetek UK Ltd Thatcham, UK 
Chemicals Sigma-Aldrich Gillingham, UK 
Scintillation vials Simport Scientific Beloeil, Canada 
Anti-coagulant blood tubes Teklab Ltd Sacriston, UK 
Nanodrop spectrometer  Thermo-Fisher Scientific Waltham, USA 
14
C-SM TNO Defense 
Rijswijk, The 
Netherlands 
Monitoring equipment Welch Allyn (UK) Ltd. Aston Abbotts, UK 
Alfaxan
®
 anaesthetic and 
Dolethal
®
 
Vétoquinol UK Ltd. Buckingham, UK 
Table 2-1: Supplier's details for materials and equipment used in Thesis.  
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Daily husbandry was carried out by staff in the experimental animal house (EAH) at 
Dstl. Animals had access to water and food ad libitum. All animals were frequently 
inspected by a qualified veterinary surgeon. Animal weights were recorded on a regular 
basis to provide an objective measure of each animal’s general health status. All in vivo 
experiments (Chapters 5 and 6) were conducted under terminal anaesthesia. Animal 
studies were performed under a specific project licence granted by the UK Home Office 
(reference PPL 30/2662).  All staff involved with animal work were fully trained and 
held appropriate (Home Office) personal licences.  The use of animals was conducted in 
accordance with the Animals (Scientific Procedures) Act (1986).  
 
Haemostatic Products and Decontaminants 
Haemostatic products (Table 2.2) were stored in accordance with manufacturers’ 
instructions and fresh packets were used on the day of each experiment.  Three skin 
decontaminants used by the military (fuller’s earth, Reactive Skin Decontaminant 
Liquid
®
; RSDL
®
 and M291) were used to provide a benchmark of decontamination 
efficacy (Table 2.3). A novel decontaminant comprised of tetraglyme, oxime and poly 
(ethyleneimine) (TOP) was also tested. The TOP formulation was prepared fresh on the 
day of each experiment to produce a working solution comprising tetraglyme (30% 
w/v), 2-pyridine aldoxime mesylate (2-PAM; 50mM) and poly(ethyleneimine) solution 
(50% w/v) in phosphate buffered saline (pH 8.0 ± 0.1).  
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Haemostatic Product Manufacturer Description 
Celox
®
 
Medtrade Products Ltd., 
Crewe, UK 
Granules made from 
chitosan 
FastAct
®
 
Wortham Laboratories Inc, 
Chattanooga, USA 
Bovine-derived activated 
clotting factors 
HemCon
®
 
HemCon Medical 
Technologies, Inc., Tigard, 
USA 
Chitosan-based dressing 
ProQR
®
 Biolife, Sarasota, USA 
Hydrophilic polymer and 
potassium-ferrite 
oxyacid salt 
QuikClot Advanced 
Clotting Sponge plus
®
 
Z-Medica, Wallingford, 
USA 
Synthetic zeolite beads 
WoundStat™ 
TraumaCure, Inc., 
Bethesda, USA 
Granules made from 
smectite clay 
Vitagel™ 
Orthovita, Inc., Malvern, 
USA 
Collagen and thrombin 
in calcium chloride 
solution 
Table 2-2: Summary of haemostatic products 
 
Decontaminant Manufacturer Description 
M291 containing 
Ambergard XE-555 resin  
Kindly supplied by Dr 
Edward Clarkson (United 
States Army Medical 
Research Institute of 
Chemical Defense, 
Aberdeen Proving Ground, 
MD, USA) 
Activated charcoal 
absorbent, polystyrene 
polymeric and ion 
exchange resin 
RSDL
®
 
Reactive liquid 
decontaminant 
Fuller’s earth 
Sigma-Aldrich, 
Gillingham, UK 
Montmorillonite powder 
Tetraglyme, oxime and 
poly(ethyleneimine) 
(TOP) 
Kindly provided by Dr 
Richard Gordon for 
evaluation (WRAIR, 
Silverspring, MD, USA) 
Reactive liquid 
decontaminant 
Table 2-3: Summary of decontaminants  
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Thrombelastography 
Experimental Apparatus 
Parameters relating to blood-clotting were measured using an eight-channel 
thrombelastograph system (TEG 5000
®
; MediCell Ltd.).  All TEG-related consumables 
were purchased from MediCell Ltd.  Daily calibrations of the electromagnetic detector 
and torsion wire were performed as per manufacturer’s instructions, as were weekly 
quality control standards (Biological QC Level I and Level II).   
 
Experimental Procedures 
Daily samples of blood (8 ml) were acquired from each of the animals (n=6) following 
sedation with midazolam (Hyponoval
®
; 6 ml intramuscular administration, Roche 
Products Ltd.) and light anaesthesia (3 – 5% isofluorane in 8 L min-1 O2). Blood 
samples were drawn from the cephalic vein or cranial vena cava into dried polystyrene 
tubes containing 3.2 % sodium citrate (Teklab Ltd.) and were equilibrated on a tube 
roller (ambient temperature; 30 min) prior to use. The actual anatomical location via 
which venous samples were obtained was altered on a regular basis to ensure minimum 
discomfort to the animals.   
Each TEG channel was set to 37°C and allowed to equilibrate (10 min) prior to 
use to minimise effect of temperature-driven coagulation.  Treatment groups are shown 
in Table 2.4. Haemostatic products (9 mg of granular or dressings or 9 µl of liquids) 
were placed into 5 ml polyethylene vials and mixed with citrated whole blood (2 ml). In 
the case of SM treatment groups, 1 µl SM was added to blood (with or without 
haemostat) to give a 4 mM SM concentration.  
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Treatment Group Haemostat? Sulphur Mustard? 
Control No No 
Haemostat Yes No 
SM No Yes 
Haemostat + SM Yes Yes 
Table 2-4: Treatment groups for thrombelastography study 
 
 
 
 Machine 1 Machine 2 Machine 3 Machine 4 
Channel 1 2 3 4 5 6 7 8 
Sample ID 
Haemostat plus SM or SM only 
treatment groups (duplicates) 
Haemostat only or control 
(untreated) treatment groups 
(duplicates) 
Table 2-5: Channel setup for the four thrombelastography (TEG) machines. 
Channels 5 – 8 were solely used with uncontaminated (not SM treated) blood, with all 
SM contaminated blood analysis performed using channels 1 – 4. 
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The vials were capped and gently mixed for 30 s.  Following mixing, aliquots (340 µl) 
were transferred to TEG cups pre-treated with calcium chloride (20 µl; 0.2 M). Calcium 
chloride was present to overcome anticoagulant effect of sodium citrate and reactivate 
endogenous haemostatic pathways. An untreated blood sample served as a control. 
Samples were tested in duplicate and TEG traces were recorded until acquisition of 
maximum clot amplitude.  
Due to Health and Safety requirements, two loan machines could not be used 
with SM-contaminated blood. Therefore, all SM treatment groups (Table 2.4) were 
analysed using Health Protection Agency owned TEG machines (termed “Channels 1 – 
4”, Table 2.5). The loan machines (termed “machine 3 and 4”, Channels 5 – 8) were 
only used with blood which had not been treated with SM. To quantify whether there 
was bias between the machines, all channels were calibrated simultaneously (using QC 
standards I & II) before use. 
 
Data Analysis 
The coagulation parameters investigated by TEG were R time (min), K time (min), 
alpha angle (degrees) and maximum amplitude (mm). From these data, two further 
parameters were calculated: shear elastic modulus strength (SEMS or G; dynes cm
-2
; 
Equation 2.1) and Coagulation Index (CI; (Equation 2.2). 
 
    
–
  Equation 2.1 
 
Equation 2.1: Calculation of SEMS (G; dynes cm
-2
) where MA is maximum amplitude 
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- - -   Equation 2.2  
 
Equation 2.2: Calculation of coagulation index (CI) where R is R time, K is K time, MA 
is maximum amplitude and α is alpha angle. 
 
In Vitro Dermal Absorption Studies 
Experimental Apparatus 
In vitro dermal absorption was measured using Franz-type glass diffusion cells 
purchased from PermeGear (Figure 1.4). Split-thickness skin was clamped between the 
upper (donor) and lower (receptor) chambers with an area of 1.76 cm
2
 available for 
diffusion. Each receptor chamber was filled with an appropriate receptor fluid. 
Magnetic stirrer-bars (polytetrafluoroethylene; 12 x 4.5 mm, cylindrical, Fisher 
Scientific UK Ltd.) which provided adequate and rapid mixing of the receptor fluid but 
did not produce a vortex (Ng, et al. 2010) were placed in the receptor chamber. 
Assembled diffusion cells were placed into holding blocks above a magnetic stirrer 
(V9-CB Stirrer, PermeGear). Warm (36°C) water was continuously circulated around 
each cell’s water jacket using a recirculating water heater to give a skin surface 
temperature of ~32°C (confirmed by infrared thermography; FLIR P620, FLIR 
Systems). 
A liquid scintillation counter (Model 2810 Tri-Carb, PerkinElmer) was used for 
the quantification of radioactivity in all samples. The instrument was calibrated before 
use using the self-normalization and calibration (SNC) standards for 
14
C, 
3
H and 
background. 
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Experimental Procedures 
Skin Preparation and Storage 
Undamaged skin studies (study 1 – 3) were performed using abdominal skin. Dorsal 
skin was used for the damaged skin investigation (study 4) due to problems associated 
with the dermatoming of abdominal skin. Undamaged dorsal skin was also used as a 
control in study 4, as a validation step to allow comparison between the undamaged 
skin and damaged skin experiments.     
 
Intact Skin Preparation 
Abdominal skin was obtained post mortem from female pigs (weight range 20 – 25 kg).  
The skin was stored flat between aluminium foil sheets at -25°C and thawed at 5°C for 
18 h prior to the commencement of each study. The excised skin was carefully close-
clipped and sectioned to a nominal depth of 500 µm using an electric dermatome 
(Humeca D42, Eurosurgical Ltd.). The actual skin section thickness was ~ 570 µm 
when measured using a micrometer. The skin was visually inspected to identify areas of 
damage.  Sections were cut to size (approximately 2.5 cm
2
) using a scalpel.  
 
Damaged Skin Preparation 
Pig dorsum skin was obtained and stored using the same method as above. Uniform 
damage to the skin surface was achieved using an electric dermatome (Humeca D42, 
Eurosurgical Ltd.) through the removal of a nominal 100 µm layer from the skin surface 
(corresponding to the removal of the SC and the majority of the epidermis).  Further 
skin sections were taken at a nominal thickness of 500 µm.  
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Assessment of skin integrity and receptor fluid composition  
The structural integrity of the membrane was assessed by measuring electrical 
resistance across the membrane (Chilcott, et al. 1996) skin sections were clamped 
between the receptor and donor chamber with the SC side upward. The donor and 
receptor chamber were filled with 0.9% saline solution (~ 13 ml and 500 µl for receptor 
chamber and donor chamber, respectively) and allowed to equilibrate for 1 h.  
Membrane resistance was measured using an AC resistance meter (M3004 AVO 
multimeter) and membranes with a resistance below 1.5 kΩ were rejected. The saline 
solution was removed and receptor chamber medium (50% aqueous ethanol) was added 
so that the meniscus in the sampling arm was level with the surface of the skin. The 
surface of the skin was swabbed to remove any residual saline solution. The cells were 
connected to the circulating water jacket and equilibrated for a further 24 h.   
 
Skin absorption and related measurements 
Following equilibration, baseline samples (250 µl) of receptor fluid were taken. A 10 µl 
droplet of 
14
C-SM was subsequently applied to the skin surface and left in situ for the 
study duration (24 h). Thirty seconds post exposure, haemostatic products or standard 
decontaminants (Table 2.2 and 2.3) were applied to the contaminated skin surface (200 
mg or 200 µl for dry and liquid products, respectively). Contaminated skin with no 
decontamination served as controls. All products were left in situ for the duration of the 
study (24 h). Samples of receptor fluid (250 µl) were taken (via the sampling port) at 
regular intervals (3 h) for 24 h post-exposure. Hourly samples were taken for the 
control samples for the initial 6 h. Samples were placed into liquid scintillation counting 
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fluid (5 ml; LSC, Ultima Gold, PerkinElmer) within opaque, plastic scintillation vials 
(6.5 ml; Simport Scientific). After sampling, fresh 50% aqueous ethanol (250 µl) was 
added to each receptor chamber to maintain a constant volume.  
 
Dose distribution 
Twenty-four hours post-exposure, the diffusion cells were removed from the heated 
manifold and dismantled. The receptor fluid media and decontaminant were recovered 
separately into 20 ml glass Wheaton vials. Twenty millilitres of LSC fluid was added to 
each vial containing recovered decontaminant. The skin surface was swabbed using dry 
cotton wool and placed into 10 ml isopropanol. The skin was removed from the 
diffusion cell and placed into a pre-weighed 20 ml glass Wheaton vial.  The skin weight 
was recorded and 10 ml Soluene-350™ (quaternary ammonium hydroxide in toluene, 
PerkinElmer) was added to solubilise the skin. Vials were stored at ambient temperature 
for up to 5 days (with occasional vigorous shaking) to facilitate dissolution into the 
respective solvent.  Aliquots (250 µl) of all dose recovery samples were placed into 5 
ml LSC fluid.   
Reference standards (containing known quantities of 
14
C-SM) were prepared for 
the skin, test products and receptor fluid to obtain the specific activity (disintegrations 
per minute per gram; DPM g
-1
) and to ascertain the quenching effects of the skin or 
products. From the specific activity, the amount of radioactivity within each sample 
could be converted to amount of 
14
C-SM.  
Test product (haemostat or decontaminant) standards were prepared in triplicate 
by the addition of 
14
C-SM (2 µl) to vials containing product (200 mg or 200 µl for dry 
and liquid products, respectively). Separate skin standards were prepared for each 
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experiment. Three representative sections of unexposed dermatomed skin were placed 
into individual glass vials and 
14
C-SM (5 µl) was applied. Soluene-350™ (10 ml) was 
added to solubilise the skin. All vials were stored for 5 days (ambient temperature) with 
occasional vigorous shaking to assist dissolution. Triplicate aliquots (250 µl) from each 
standard were added to 5 ml LSC fluid.   
Receptor fluid standards were made by the addition of 
14
C-SM (10 µl) to 50% 
aqueous ethanol (10 ml). Sub-samples (100, 75, 50 and 25 µl) were taken in triplicate 
and added separately to 5 ml LSC fluid.   
 
Liquid Scintillation Counting 
All samples were allowed to equilibrate in the counter for 1 h prior to measurement. 
Radioactivity (disintegrations per minutes; DPM) was quantified using a 2 minute count 
time calibrated to Ultima-Gold liquid scintillation fluid using a pre-installed 
14
C quench 
curve.  
 
Evaluation of 
14
C-SM desorption from haemostats  
Desorption or vapour loss of 
14
C-SM from the products was measured at ambient 
temperature using a modified static diffusion cell experiment. Diffusion cells were 
assembled as previously described with the dermatomed skin replaced with aluminium 
foil (2.5 cm
2
), which served as an impermeable membrane. The difference in recovery 
of 
14
C-SM between occluded and unoccluded cells was measured. A droplet of neat 
14
C-SM (2 µl) was applied to the foil surface and the haemostats or decontaminants 
(200 mg bolus) were added to the donor chamber. Following the addition of 
14
C-SM 
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cells were occluded (where applicable) using foil applied to the top of the donor 
chamber using silicon-based vacuum grease to form a seal. The haemostats or 
decontaminants remained in situ for 3 h. Diffusion cells which were treated with 
14
C-
SM but not haemostat or decontaminant served as the control group. Three hours post 
exposure, the diffusion cells were dismantled and the foil (occluding and membrane) 
and haemostat were recovered separately in 20 ml glass vials.  Dry cotton swabs were 
used to swab the inside surface of the donor chamber and were retained for analysis.        
 
Quantification of 
14
C-SM  
The activity of 
14
C-radiolabel (DPM) measured in samples of receptor chamber fluid, 
surface swabs, skin and decontaminant was converted to amount of 
14
C-SM by 
calculating the specific activity (DPM g
-1
). The specific activities for the standards used 
were calculated using Equation 2.3. 
 
-
-
 Equation 2.3 
The DPM measured for each unknown sample were converted into amount of 
14
C-SM 
using Equation 2.4. 
 
-
-
  Equation 2.4. 
 
The 
14
C-SM vapour loss from the haemostatic products was approximated using 
Equation 2.5. 
 
 
68 
 
-  Equation 2.5. 
 
The maximum rate of penetration (Jmax) was calculated from the gradient of the slope of 
the straight line for between the 3, 6 and 9 h time points (Equation 2.6).  
 
 Equation 2.6. 
Equation 2.6: Where; m = slope, x = x-intercept at time point, c = y-intercept at 
time point  
 
In Vivo Dermal Absorption Studies 
Experimental Apparatus 
Physiological parameters (pulse oximetry; % oxygen saturation, capnography; exhaled 
CO2, core body temperature, electrocardiogram; ECG, respiratory rate and blood 
pressure) were monitored throughout the study using a Propaq
®
 Encore 204-EL (Welch 
Allyn (UK) Ltd.). Surgical and anaesthesia equipment was provided by Dstl and was 
subject to annual servicing and calibration. Animals were placed in ventral recumbence 
in a custom sling (Ellegaard) and sling frame (kindly provided by EAH staff at Dstl) 
whilst in the fume-hood. Due to the air-flow within the fume-hood, animals were placed 
on a thermal blanket (Harvard Apparatus Ltd.) to maintain core body temperature (37.5 
± 1°C).  
A range of biophysical measurements were taken during the study including; LDI 
(LDLS, Moor Instruments), SRS (CM-2600d, Konica Minolta), IRT (FLIR SC620; 
FLIR Systems), TEWL (AquaFlux AF200; Biox Systems) and standard digital 
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photographs (EOS 40d; Canon). Where appropriate, all equipment was calibrated 
before use in accordance with manufacturer’s guidelines. 
 
Experimental Procedures 
Surgical Procedures  
Following an overnight fast, each animal was sedated with midazolam (up to 6 ml; 2 
mg ml
-1
 Hypnoval
®
, Roche Products Ltd.) prior to induction of anaesthesia using 3.5  –  
5% isoflurane delivered via a facemask. After an equilibration period of 5 to 15 
minutes, an endotracheal tube was introduced via which anaesthesia (1.5 – 2.5% 
isofluorane) was maintained for subsequent surgery.  The carotid artery and the internal 
jugular vein were surgically cannulated using 8 French gauge sterile catheters (2.7 outer 
diameter; Burtons Medical Equipment Ltd.). This provided access for arterial blood 
sampling and subsequent intra-venous administration of anaesthetic (Alfaxan; 
alfaxalone, Vétoquinol UK Ltd.). Alfaxan (10 mg ml
-1
) was administered at a rate of 1.0 
– 1.2 mg kg-1 h-1 for the remainder of the study. The level of consciousness was 
monitored throughout the study with adjustments made to the rate of alfaxan infusion 
when required (range used 12 – 26 ml hr-1).  
 
Experimental measurements 
The left side of the dorsum was close clipped and up to 4 dosing rings attached to 
indicate areas for pre-damage biophysical measurements. Treatment groups were 
randomly assigned to multiple dorsal sites to reduce any effect of anatomical bias 
(Figure 2.1). For sites requiring damaged skin, a small (~ 3 cm
2
) area was dermatomed 
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(Humeca Model D42, Eurosurgical Ltd.) to a nominal depth of 100 µm.  This resulted 
in transient, punctuate bleeding and so the area was subsequently swabbed with cotton 
gauze soaked in saline to remove extraneous material such as dried blood. The study 
design was such that only one site per animal was exposed to 
14
C-SM. 
Once the appropriate sites had been dermatomed, baseline (pre SM-exposure) 
biophysical measurements and blood samples were taken. Following removal of SM 
from the skin surface (1 h post-exposure), biophysical measurements (LDI, SRS, IRT, 
TEWL and standard digital photographs) were taken at 60 min intervals until 6 hours 
post-exposure. All equipment was calibrated according manufacturer’s instructions and 
equipment settings are given in Table 2.6.   
 
Physiological parameters and blood sampling 
Physiological parameters (pulse rate, ECG, arterial blood pressure, breathing rate, core 
temperature, CO2 and SpO2) were monitored and recorded for the study duration. 
Arterial blood samples (4 ml) were acquired during pre-damage and baseline 
measurements and at hourly intervals thereafter. Each sample was placed into 3.2% 
sodium citrate treated vials (Teklab Ltd.) for radiometric (2 ml) and thrombelastography 
(2 ml) analysis.  
Sulphur Mustard Challenge 
Following baseline measurements a multi-vesicating (10 µl) dose of 
14
C-SM was 
applied as a discrete droplet to skin within the dosing area. The agent was left in situ for 
60 minutes before removal with cotton swabs and surgical gauze.  
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Equipment 
Calibration 
Procedures 
Measurement settings 
Export file 
type 
LDI 
Laser turned on 
prior to 
measurements 
(1 h) to stabilise 
Repeat line scanner images taken in 
triplicate (200 ms per line). Raw 
images were converted to the 
maximum resolution and the region of 
interest (ROI; area within dosing ring) 
was selected and exported (LDLS 
V1.1a software; Moor Instruments). 
ASCII file 
Imported in 
Microsoft 
Excel
®
 
SRS 
Zero and white 
calibrations 
procedures 
performed daily 
The observer angle was set to 2° and 
D65 was selected as the primary 
illuminant. Measurements were taken 
in triplicate (specular component 
included and excluded). Absorbance 
values (360 nm – 740 nm) and 
CIELAB parameters, L*a*b* were 
exported from SpectraMagic NX 
(Konica Minolta). 
CSV file 
Imported in 
Microsoft 
Excel
®
 
IRT 
Internal auto 
calibration 
Thermographs of the treatment sites 
were obtained in triplicate. The ROI 
(area within dosing ring) was selected 
and exported (ThermaCAM™ 
Researcher software; FLIR Systems 
Ltd.). 
CSV file 
Imported in 
Microsoft 
Excel
®
 
TEWL 
Calibrated daily 
and allowed to 
equilibrate (1 h) 
prior to 
measurements. 
Flux values recorded in triplicate and 
exported. 
TXT file 
Imported in 
Microsoft 
Excel
®
 
Standard 
photography 
N/A 
Photos were taken with Canon EOS 
40D; 17 – 85 mm lens using the 
following settings; F-Stop; f/5.6, ISO; 
400 and exposure time; 1/60. 
JPG file 
Table 2-6: Measurement and calibration settings for biophysical equipment used. 
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Figure 2.1: Schematic of dosing site setup for in vivo experiments. 
Metal dosing rings were taped to the dorsum. Each animal in the SM group (Chapter 5) 
had 3 treatment sites; control (untreated; striped), damaged unexposed (white) and SM 
exposed damaged (black). Each animal in the WoundStat™ treated group (Chapter 6) 
had 4 treatment sites; control (untreated; striped), damaged unexposed (white), 
damaged WoundStat™ treated (grey) and SM exposed WoundStat™ treated (white & 
black diamonds).   
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Removal of the SM from the treatment site was a Health and Safety requirement to 
limit transfer of 
14
C-SM to the measuring equipment. All sites received this treatment 
and swabs were retained for radiometric analysis. 
 
Application of WoundStat™ 
WoundStat™ (2 g) was applied (30 s post-exposure) to the appropriate exposure site. 
The product was applied so that it covered the area within the dosing ring. 
WoundStat™ was also applied to an unexposed, damaged site to assess whether the 
treatment would cause any adverse reactions in vivo. The product was removed 60 min 
post-exposure and retained for radiometric analysis. To aid recovery of the product, 1 
ml of sterile water was applied to the haemostat immediately before removal so that it 
formed a clay-like mass.  
 
Termination of study and post mortem 
Animals were euthanized (6 h post-exposure) by intravenous administration of a lethal 
dose of Dolethal (pentobarbital; 200 mg ml
-1
, Vétoquinol UK Ltd.). Animals were 
exsanguinated and the skin at each treatment site was excised and weighed.  
Representative samples were taken for histological, genomic and radiometric analysis.  
Post mortem examinations were carried out on animals and the main organs 
(brain, heart, lung, liver, kidney, pancreas and spleen) were removed, weighed and 
representative samples taken for radiometric analysis. Representative sections of small 
intestine were also taken for radiometric analysis.  
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Dose distribution of 
14
C-sulphur mustard 
Skin, swab and WoundStat™ 
Skin exposure sites were placed into vials containing up to 40 ml tissue solubiliser 
(Soluene-350™).  Cotton swabs and surgical gauze were placed into isopropanol (20 
ml). Vials were stored at ambient temperature for at least 14 days (with occasional 
vigorous shaking) to allow dissolution and extraction into the respective solvent.  
Standard solutions were prepared by adding 5 µl 
14
C-SM to vials containing (i) 
20 ml isopropanol, (ii) cotton swab or (iii) skin. Vials containing cotton swabs and skin 
were treated as per experimental samples with the addition of isopropanol (20 ml) or 
Soluene-350™ (up to 40 ml), respectively. Vials were stored at ambient temperature for 
the same period of time as experimental samples. Aliquots (250 µl) of all standard and 
experimental samples (gauze swabs, sponges and dissolved skin) were removed and 
placed into 5 ml LSC fluid and analysed by liquid scintillation counting as previously 
described. 
 
Blood and Organs 
A modification of an existing method was used to prepare blood samples for liquid 
scintillation counting (Moore. 1981).  Triplicate aliquots of blood (0.4 ml) were mixed 
with 1 ml Soluene-350™ and isopropanol solution (1:2 ratio) and incubated (60°C; 2 
h).  After cooling, samples were treated with hydrogen peroxide (0.5 ml; 30 % v/v) and 
incubated (ambient temperature; 30 min). Samples were subsequently heated (60°C; 30 
min) and cooled prior to the addition of liquid scintillation fluid (20 ml).  
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Organ samples (100 mg) were prepared in triplicate by the addition of Soluene-350™ 
(2 ml) followed by incubation (60°C; 4 h). Samples were allowed to cool prior to the 
subsequent addition of 20 ml liquid scintillation fluid. Blood and organ samples for 
reference standards were obtained from non-exposed animals. Samples were treated 
with 
14
C-SM (5 µl) and prepared in triplicate following the methods above.  
The density of the blood and organs were measured to account for difference in 
volume when calculating the amount of 
14
C in the solubilised sample (Table 2.7). 
Samples of each organ (5 g) were homogenised using a stator-rotor homogeniser (T 10 
ULTRA-TURRAX
®
, IKA
®
-Werke GmbH & Co.). Aliquots (1 ml) were sampled and 
weighed in triplicate using a positive displacement pipette (Microman
®
, Gilson 
Scientific Ltd).  
All samples were analysed by LSC with an analysis time of 5 minutes per 
sample. The amounts of radioactivity in each sample were converted to amount of 
14
C-
radiolabelled SM by comparison to the corresponding reference standards (measured 
simultaneously).  
Radiolabel (
14
C) elimination kinetics for the blood were calculated from linear 
regression analysis of a semi-logarithmic plot of blood concentration against time at 
steady state where the decrease in concentration of 
14
C-SM with time was constant 
(Shen. 2008). The kinetic parameters were calculated from equations 2.7 – 2.10 based 
on the standard equation of a straight line (y = mx + c) where y = blood concentration, 
m = gradient of slope and c = y-axis intercept. 
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Table 2-7: Measured organ density for use in radiometric calculations. 
  
Sample Density (g ml
-1
) 
Brain 0.87 
Heart 0.89 
Lungs 0.77 
Liver 0.98 
Spleen 0.96 
Pancreas 0.84 
Kidney 0.91 
Small intestine 0.89 
Blood 1.05 
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-
 Equation 2.7. 
Equation 2.7: Calculation of half life of elimination (T½) where, Co is initial 
blood concentration (equal to the y-axis intercept, ‘c’). 
 
-  Equation 2.8. 
Equation 2.8: Calculation of the elimination constant (Kel) where, m is the 
gradient of the slope. 
 
 Equation 2.9. 
Equation 2.9: Calculation of the apparent volume of distribution (Vd) where, Da 
is the original applied dose. 
 
 Equation 2.10. 
Equation 2.10: Calculation of dose (D) where, Cmax is the maximum 
(experimentally measured) whole blood concentration of 
14
C (derived from 
14
C–SM). 
 
Histology 
Sample collection and preparation  
A section of excised skin from each site was pinned flat to a cork board (21 gauge 
needles; BD) and skin samples were submerged in 10% neutral buffered formalin 
(NBF; 20 times sample weight). Samples remained in the fixative for at least one week 
(up to 6 months).     
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Sample processing 
Samples were removed from the fixative and rinsed with distilled water.  Skin samples 
were trimmed (width 5 mm) and placed in tissue processing cassettes (Tissue-Tek
®
 
Uni-cassettes
®
, Sakura Finetek UK Ltd.). Skin samples were processed using an 
automated vacuum infiltration tissue processor (VIP; Tissue Tek
®
, Sakura Finetek UK 
Ltd.).The VIP processing schedule comprised dehydration of samples through a series 
of ethanol gradients (80, 90 and 3 x 100%; 1 h each) followed by three changes of 
100% chloroform (changes 1 and 2; 1 h, change 3; 2 h) and 15 min in 50% 
xylene/chloroform. The samples were then placed in xylene (100%) for 10 min prior to 
the paraffin wax infiltration (2 changes; 2 h, 1 change; 1 h). Once the infiltration step 
was complete, the samples were embedded using paraffin wax (transverse side down) in 
metal embedding moulds and chilled on a cooling block (-5°C). 
 
Sectioning and Staining procedures 
The paraffin-embedded skin was mounted in a microtome and sections cut to a nominal 
thickness of 5 µm. Consecutive sections were floated on a 30% ethanol bath and 
transferred to a warm water (~40°C) bath to help the sections flatten. Sections were 
lifted onto glass microscope slides (Superfrost Plus; Fisher Scientific UK Ltd.) and 
placed into a drying oven (37°C) overnight. Sections from each sample were 
subsequently stained with Haematoxylin and Eosin.   
Sections were deparaffinised in 3 changes of xylene (1 min each) and rehydrated 
through an ethanol series (100%, 100%, 95%, 95% and 50%; 1 min each).  Slides were 
placed in distilled water (1 min) and stained with Haematoxylin (Mayer’s 
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Haematoxylin; 5 min). Slides were rinsed and differentiated in running tap water (1 
min), 1% acid alcohol (1 min), running tap water (1 min) and alkaline alcohol (1% 
sodium hydroxide; 1 min). Sections were counter-stained in alcoholic Eosin Y (0.25%; 
1 min) and rinsed in distilled water (1 min).  Sections were dehydrated through an 
ethanol series (95%, 100% and 100%; 2 min each) and immersed in 3 changes of 
xylene (1 min each). Slides were cover-slipped using Tissue-Tek
®
 Film Coverslipper™ 
(Sakura Finetek UK Ltd.) and allowed to dry prior to examination. 
 
Histopathological analysis 
Stained skin sections were examined by a qualified histopathologist. Each section was 
subjectively scored for the occurrence and severity of several indicators including; 
keratinocyte necrosis, escharification, sub-epidermal separation or vesication, blood 
vessel dilation and inflammatory cell infiltrate.  
 
Genomic analysis 
Tissue preparation and RNA extraction 
Skin samples from each treatment site (approximately 0.5 cm
3
) were placed into 1.5 ml 
microcentrifuge tubes containing RNAlater
®
 (Ambion, Applied Biosystems; at least 5 
times v/w). Samples were incubated at 4°C overnight to allow full absorption into the 
tissue and stored at -20°C until required (up to 1 year).  
Total ribonucleic acid (RNA) was extracted using RNeasy Fibrous Tissue Mini 
kit (QIAGEN) with minor modifications to the protocol. Briefly, 30 mg skin samples 
were transferred to RLT lysis buffer (300 µl; QIAGEN) containing 1% β-
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mercaptoethanol and homogenised using a Precellys
®
 24 tissue homogeniser (Bertin 
Technologies). Samples were processed at 6300 rpm for 23 s for 4 cycles. Between 
cycles samples were incubated on ice (1 min). The resulting homogenate was mixed in 
a fresh 2 ml microcentrifuge tube with 590 µl nuclease-free water, 10 µl Proteinase K 
and incubated at 55°C for 10 min. Following incubation, tubes were centrifuged at 
10,000 x g at ambient temperature for 3 min. The supernatant (approximately 900 µl) 
was transferred to a fresh 2 ml tube containing 1 ml acid-phenol:chloroform:isoamyl 
alcohol (pH 4.5; 25:24:1, Ambion). Tubes were vortexed (1 min) and incubated on ice 
for 15 min prior to centrifugation (10,000 x g; 20 min, 4°C). The aqueous phase was 
transferred to a fresh 2 ml microcentrifuge tube containing 0.5 volume of ethanol 
(99.9%; molecular biology grade) and incubated at -20°C for 16 h. Samples were 
transferred to an RNeasy mini spin column (QIAGEN) and processed as per the 
manufacturer’s instructions with the optional on-column DNase I digest performed. 
Ribonucleic acid was quantified by spectrophotometry (Nanodrop ND1000 UV-
Vis spectrophotometer; Thermo-Fisher Scientific) and stored at -80°C (Equation 2.11). 
An A260/A280 ratio greater than 1.8 was deemed a suitable indication of RNA purity 
(Appendix 1; Table 1). Samples with a RNA concentration below 60 ng µl
-1 
or an 
A260/A280 ratio below 1.8 underwent further processing (sodium acetate-ethanol 
precipitation step) to concentrate the RNA and remove organic solvent or salt 
contamination. Briefly, the RNA sample was mixed and incubated (-80°C; 1 h or -
20°C; 16 h) with sodium acetate (1/10 volume; 3 M, pH 5.2, Ambion) and ethanol (2 
volumes; ice-cold, molecular biology grade). The sample was centrifuged (16,000 x g; 
30 min, 4°C) and the supernatant discarded. The RNA pellet was resuspended in 
ethanol (70%; ice-cold) and centrifuged (16,000 x g; 15 min, 4°C). The supernatant was 
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removed and the pellet was allowed to air-dry before resuspension in nuclease-free 
water (20 µl).       
The integrity of the RNA was confirmed using RNA 600 Nano chips and 
BioAnalyzer 2100 (Agilent Technologies UK Ltd.). Samples with genomic DNA 
contamination (indicated by large product bands on the gel) were treated with TURBO 
DNA-free™ (Ambion) according to manufacturer’s instructions.  A RNA integrity 
number (RIN) of above 6.0 and clear peaks at 18S and 28S were considered indicators 
of good quality RNA that could be used for microarray analysis (Appendix 1; Table 1). 
If the RNA quality was unsatisfactory the entire process was repeated using stored skin 
tissue.  
Labelling procedure 
All equipment, slides and reagents using for labelling RNA samples and processing 
microarray slides were purchased from Agilent Technologies (Agilent Technologies 
UK Ltd.) unless otherwise stated. The RNA was reverse-transcribed, labelled and 
converted from complement DNA (cDNA) to complement RNA (cRNA) using the 
Agilent One Colour Low Input Quick Amp Labelling kit (Figure 2.2). The labelling 
was carried out according to manufacturer’s instructions with One-Colour RNA Spike 
mix included as a control. Once labelled, the amplified RNA was purified using 
RNeasy mini-spin columns (QIAGEN) to remove uncoupled cyanine-3 (Cy3) dye. 
Briefly, cRNA sample was diluted with nuclease-free water (84 µl) and mixed with 
RLT lysis buffer (350 µl) and ethanol (250 µl; molecular biology grade). The sample 
was transferred to a spin column and centrifuged (10,000 x g; 30 s, 4°C). The sample 
was washed twice with RPE wash buffer (500 µl) and centrifuged (10,000 x g; 30 s, 
4°C) after each wash step.   
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Figure 2.2: Schematic of amplified cRNA synthesis and hybridisation to 
oligonucleotide microarrays. 
Total RNA was reverse-transcribed to cDNA. cRNA was synthesised and amplified from 
this template, incorporating Cy3 fluorescent dye. cRNA was purified, fragmented and 
hybridised to an oligonucleotide microarray. Following hybridisation slides were 
washed and scanned.   
AAA    3’5’Temple total RNA from 
sample
cDNA synthesis
Purified labelled 
cRNA(anti-sense)
cRNA
1st strand cDNA
Oligonucleotide
Microarray
cRNA synthesis & amplification
cRNA purification
Fragmentation & hybridisation 
sample prep
Hybridisation and wash steps
3’
5’
TTT Promoter 5’
AAA Anti-sense promoter
2nd strand cDNA
3’
3’
5’
UUU Promoter 5’
AAA Anti-sense promoter 3’
CC
3’ UUU Promoter 5’CC
Cy3Fragmented cRNA
2nd strand cDNA
Cy3
Cy3
Cy3Cy3
Cy3Cy3
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Flow-through was discarded after each step. The column was transferred to a fresh 1.5 
ml tube and centrifuged (10,000 x g; 1 min, 4°C) to remove any remaining RPE wash 
buffer. The cRNA sample was transferred to a fresh 1.5 ml tube and incubated with 
nuclease-free water (30 µl). The column was centrifuged (10,000 x g; 30 s, 4°C) to 
elute the sample and incubated on ice.  
Labelling efficiency was determined by spectrophotometry (Nanodrop ND1000 
UV-Vis spectrophotometer; Thermo-Fisher Scientific). A yield of ≥1.65 µg cRNA and 
a specific activity (Cy3 dye incorporation) of >6 pmol µg
-1 
cRNA was deemed 
acceptable.       
 
Hybridisation procedure 
Hybridisation samples were prepared by mixing labelled cRNA (1.65 µg) with 10X 
blocking agent (11 µl), 25X fragmentation buffer (2.2 µl) and adjusted to the final 
volume (55 µl) with nuclease-free water. Samples were incubated (60°C; 30 min) to 
fragment the RNA and then immediately cooled on ice (1 min). Fragmented samples 
were mixed with an equal volume of 2X GEx Hybridisation buffer (HI-RPM) and 
centrifuged (10,000 x g; 1 min, ambient temperature). Samples were stored on ice prior 
to loading onto a gasket slide. The 4x44K gasket slide was placed into the SureHyb 
chamber base and samples (100 µl) were pipetted into randomly assigned gasket wells. 
The microarray slide (porcine gene expression oligonucleotide microarray; 
4X44K) was placed on top of the gasket slide (oligonucleotide-side facing down) 
followed by the chamber top. The assembled chamber was clamped together and 
rotated to ensure air bubbles were mobile and the solution fully covered the array slide. 
Slides were incubated (65°C; 17 h) in a rotating hybridisation oven to allow the labelled 
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cRNA to anneal to the oligonucleotide probes. Following incubation, the chamber was 
disassembled and the gasket-microarray slide “sandwich” was placed in gene 
expression wash buffer 1. Once separated from the gasket slide, array slides were 
washed in gene expression wash buffer 1 (1 min; ambient temperature) and gene 
expression wash buffer 2 (1 min, ~31°C). Slides were scanned immediately to minimise 
the impact of environmental oxidants using Agilent High-Resolution Microarray 
Scanner (G2565BA). Slides were scanned (5 µm resolution; double pass) and the data 
from the images (.tif) were extracted using Agilent Feature Extraction Software 
(Version 10.7.3.1) using the grid and protocol supplied with the array slide to produce 
text files (.txt) of the signal intensity.  
 
Bioinformatics analysis 
The concentration of RNA for each sample was quantified from the absorbance at 260 
nm (Equation 2.11). 
  Equation 2.11 
Equation 2.11: Quantification of RNA using a manipulation of the Beer-Lambert law, 
where; c is RNA concentration (ng µl
-1
) A260 is absorbance at 260 nm, b is path-length 
(1 cm) and ε is RNA extinction coefficient (40 ng cm-1 µl-1).  
 
The signal intensity data from the scanned slides were analysed using GeneSpring GX 
11 (Agilent Technologies Ltd.). Agilent standard normalisations for one-colour arrays 
were applied to all data sets and spots of poor quality (low intensity, poor morphology 
or saturated intensity), controls and gene probes which were absent in more than 50% 
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of samples were excluded from further analysis. Expression data for each treatment 
group were normalised to controls (intact, unexposed skin) for each animal. The 
difference in the relative gene expression for different treatment groups (Table 2.8) 
were tested for statistical significance.  
 
Statistical analysis 
GraphPad Prism version 5.00 for Windows (GraphPad Software) was used for 
normality testing and statistical analysis of the data. The normal distribution of the data 
was assessed using a D’Agostino and Pearson omnibus normality test and Gaussian 
non-linear regression curve fit. Normally distributed data were expressed as mean ± 
standard deviation. Data which did not fit Gaussian distribution were expressed as mean 
± 95% confidence intervals. Significance was pre-defined at an alpha-level of 0.05. 
One-way analysis of variance (ANOVA) with a Bonferroni’s multiple 
comparisons post test was used for inter-group comparisons of data which met normal 
distribution criteria. A Student’s t-test was used to analyse differences between two 
normally distributed groups. Kruskal-Wallis one-way ANOVA with Dunns post test 
was used to analyse multiple inter-group comparisons for data that did not fit Gaussian 
distribution. Comparisons between two groups for data which did not meet normal 
distribution criteria were analysed using a two-tailed Mann-Whitney U test. Gene 
expression data were analysed pair wise using a t-test followed by Benjamini Hochberg 
multiple test correction with a false discovery rate (FDR) of 0.05.  
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Treatment Group Comparisons Statistical Test 
SM-exposed, damaged skin Unexposed damaged skin Paired t-test 
Unexposed, damaged skin + 
WoundStat™ treatment 
SM-exposed, damaged skin + 
WoundStat™ treatment 
Paired t-test 
SM-exposed, damaged skin 
SM-exposed, damaged skin + 
WoundStat™ treatment 
Unpaired t-test 
Table 2-8: Treatment group comparisons for gene expression data. 
Treatment sites on each animal were compared (paired t-test) or data were pooled for 
animals (n=6) and compared (unpaired t-test). All expression data were normalised to 
control (untreated) skin. 
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Chapter 3  
The Effect of Sulphur Mustard on 
Coagulation and the Efficacy of Haemostats 
in Untreated and SM-Treated Blood 
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INTRODUCTION 
Sulphur mustard exposure is known to have adverse chronic effects on coagulation e.g. 
thrombocytopenia and anaemia (Balali-Mood, et al. 2005, Mahmoudi, et al. 2005, 
Krumbhaar and Krumbhaar. 1919). However, there is little published on the acute 
effects of SM on blood coagulation and it is unclear what effect SM contamination 
would have on a haemorrhaging injury. Sulphur mustard has been shown to increase the 
expression of uPA in fibroblast cell culture (Detheux, et al. 1997).  Plasminogen is 
cleaved to form plasmin by uPA (Vasquez, et al. 1998). Plasmin is responsible for 
cleavage of the cross-linked fibrin clot to produce fibrin monomers, resulting in clot 
lysis (Pryzdial, et al. 1999). Thus it is possible that SM could enhance clot lysis through 
activation of uPA. Alternatively, it is known that SM alkylates a number of amino acid 
residues including; histidine, glutamic acid, aspartic acid and valine (Black, et al. 1997, 
Noort, et al. 1996). Thrombin is a key enzyme in the initiation and amplification phases 
of coagulation (Chapter 1 Figure 1.5) and its active site contains histidine, serine and 
aspartic acid residues.  Therefore, it is also possible that SM could alkylate crucial 
amino acid residues resulting in conformational or functional changes to thrombin 
leading to reduced coagulation. 
Thrombelastography (TEG) is an established clinical method of assessing 
coagulation of whole blood (Bowbrick, et al. 2000, Karoutsos, et al. 1999, Kaufmann, 
et al. 1997, Williams, et al. 1999). The technique has also been used to measure the 
clotting efficacy of haemostatic products in vitro using uncontaminated porcine blood 
(Kheirabadi, et al. 2009, Kheirabadi, et al. 2010). Therefore, TEG appears to be a 
suitable model for investigating the effects of SM on blood coagulation in untreated and 
haemostat-treated blood. 
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Aims  
To utilise thrombelastography to investigate;  
 the effect of SM on blood coagulation in vitro and in vivo,  
 whether haemostatic products were efficacious and,  
 whether the presence of SM had an adverse effect on the clotting efficacy of 
haemostatic products.  
 
MATERIALS AND METHODS  
Full details of the methods used in this study are described in Chapter 2. Briefly, the in 
vitro clotting efficacy of haemostatic products (Table 2.2) was evaluated in untreated 
and SM-treated blood using thrombelastography (Figure 3.1). Clotting efficacy was 
assessed by a number of thrombelastography parameters (time to initial fibrin 
formation; R time, clotting kinetics; K time and α-angle, total clot strength; maximum 
amplitude, total clot elasticity; shear elastic modulus strength and overall coagulation 
index). The coagulation parameters of arterial blood samples from the circulation of 
animals which had been exposed to SM with and without subsequently decontaminated 
with WoundStat™ in vivo were also measured. Full details of the methods used to 
perform the in vivo SM challenge and subsequent WoundStat™ treatment (where 
applicable) are detailed in Chapter 2. However, the results are shown here rather than in 
Chapters 5 or 6 to allow comparison between the in vitro and in vivo results.   
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Figure 3.1: Testing strategy for haemostatic products in untreated and SM-
contaminated blood. 
  
Effect of SM on coagulation parameters and 
instrument validation (channel bias)
Haemostat efficacy – untreated blood
Decontaminant ability evaluated in vitro 
Haemostat efficacy – SM-contaminated blood
Validation /
Characterisation
Product Assessment
Further Evaluation
(Chapter 4)
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RESULTS 
Instrument validation – channel bias  
Due to the potential risk of contaminating the TEG machine with SM, only two 
machines (Channels 5  – 8) were used with SM contaminated blood (SM and SM plus 
haemostat treated). The two other machines were only used for uncontaminated blood 
(control and haemostat treated).  There was no statistically significant difference 
between individual channels (Figure 3.2). 
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Figure 3.2: Time to initial fibrin formation (R time) for the 8 channels used. 
Data acquired from SM-treated blood (channels 1 – 4) and control (untreated blood) 
(channels 5 – 8), expressed as mean ± S.D. (n= 45).  
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Effect of sulphur mustard on in vitro coagulation parameters 
Time to initial fibrin formation (R Time) was not significantly affected by SM 
contamination (Figure 3.3). There was a significant, negative correlation between α 
angle and K Time (p < 0.001) for both the control and SM treatment groups (Figure 
3.4).  However, no significant difference was found between the two groups. 
Sulphur mustard did not significantly affect the total clot strength or elasticity 
(maximum amplitude and SEMS, respectively) nor did it affect the overall coagulation 
index (Table 3.1).  
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Figure 3.3: Initial fibrin formation (R Time; min) of whole blood following the 
addition of SM (4 mM). 
Individual values are shown as well as mean (central line; n=45) and standard 
deviation (outermost lines).  
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Figure 3.4: Clotting kinetics (K Time; min, α angle; degrees) of whole blood 
following the addition of SM (4 mM). 
The correlation between clotting parameters K time and α angle was determined to be 
significant by Spearman correlation coefficient (p value <0.001 for both control and 
SM treated blood, n=45). 
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Table 3-1: Total clot strength and elasticity of whole blood following application of 
SM. 
Data are shown for maximum amplitude, shear elastic modulus strength (SEMS) and 
coagulation index.  Data expressed as mean (± 95% confidence intervals; n= 45). 
  
Treatment Group Control (n=45) SM treated (n=45) 
Maximum Amplitude 
(mm) 
72.8 (71.5 – 74.2) 66.2 (61.2 – 71.3) 
SEMS (dynes cm
-2
) 3569 (3502 – 3637) 3244 (2997 – 3491) 
Overall Coagulation 
Index (CI) 
3.6 (3.4 – 3.9) 2.6 (1.9 – 3.3) 
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The in vitro efficacy of test haemostats tested using thrombelastography  
Four haemostatic products (WoundStat™, VitaGel™, FastAct® and ProQR®) 
significantly decreased R Time compared to control blood (p < 0.001; Figure 3.5). 
However, three products were not effective in vitro with no statistically significant 
difference in R Time compared to control values (QuikClot ACS+
®, Celox™ and 
HemCon
®
; Figure 3.5).  
The same four haemostats (WoundStat™, VitaGel™, FastAct® and ProQR®) 
also significantly improved clotting kinetics (reduced K time and increased α-angle) 
compared to control blood (Table 3.2).  
VitaGel™ significantly increased the total clot strength (maximum amplitude), 
clot elasticity (shear elastic modulus strength) and overall coagulation index compared 
to control (untreated) samples (p < 0.05; Table 3.2 and Figures 3.6 and 3.7).   
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Figure 3.5: Initial fibrin formation (R Time; min) of whole blood following addition 
of haemostatic products. 
Haemostats tested included: WoundStat™; WS, VitaGel™; VG, Celox™; CX, 
FastAct
®
; FA, ProQR
®
; PQR, HemCon
®
; HC and QuikClot ACS+
®
; QCS. Untreated 
blood served as a control. Individual values are mean ± standard deviation of n=6. 
Statistically significant differences are shown, where *** represents a p value of 
<0.001. 
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Table 3-2: Clotting kinetics (K Time and α-angle) and clot strength (maximum 
amplitude) of whole blood  following addition of haemostatic products. 
Haemostats tested included: WoundStat™, VitaGel™, Celox™, FastAct®, ProQR®, 
HemCon
®
, and QuikClot ACS+
®
. Untreated blood served as a control. Statistically 
significant differences are shown, where * and ** represent a p-value of <0.05 and 
<0.01, respectively.  Data expressed as mean (± 95% confidence intervals; n= 6 to 45). 
 
Treatment Group 
K Time (min) 
 
Alpha angle 
(degree) 
Maximum 
Amplitude (mm) 
Control (n=45) 
2.3 
(1.9 – 2.6) 
58.5 
(54.8 – 62.1) 
72.8 
(71.5 – 74.2) 
WS 
(n=6) 
***0.8 
(0.8 – 0.8) 
***80.7 
(80.3 – 81.1) 
74.7 
(72.9 – 76.5) 
VG 
(n=6) 
**1.0 
(0.75 – 1.2) 
**77.0 
(75.6 – 78.4) 
*79.2 
(75.6 – 82.8) 
CX 
(n=6) 
2.4 
(1.9 – 2.9) 
56.1 
(46.7 – 65.6) 
72.4 
(65.4 – 79.4) 
FA 
(n=6) 
**1.1  
(0.8 – 1.5) 
**75.7 
(70.7 – 80.8) 
75.6 
(69.8 – 81.4) 
PQR 
(n=6) 
***1.0 
(0.9 – 1.4) 
**72.7 
(69.1 – 76.3) 
73.0 
(68.9 – 77.4) 
HC 
(n=6) 
1.7 
(1.4 – 2.0) 
64.0 
(58.8 – 69.2) 
75.0 
(71.5 – 78.4) 
QCS 
(n=6) 
2.6 
(1.8 – 3.4) 
57.6 
(50.6 – 64.7) 
71.6 
(6739 – 75.3) 
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Figure 3.6: Total clot elasticity (shear elastic modulus strength; SEMS, dynes cm
-2
) 
of whole blood following addition of haemostatic products. 
Haemostats tested included: WoundStat™, VitaGel™, Celox™, FastAct®, ProQR®, 
HemCon
®
, and QuikClot ACS+
®
. Untreated blood served as a control. Data are 
expressed as mean, 95% confidence intervals and inter-quartile range represented by 
the mid-line, outer lines and box, respectively (n= 6 to 45). Statistically significant 
differences are shown, where * represents a p-value of <0.05.  
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Figure 3.7: Overall assessment of coagulation (Coagulation Index; CI) of whole 
blood following addition of haemostatic products. 
Haemostats tested included: WoundStat™, VitaGel™, Celox™, FastAct®, ProQR®, 
HemCon
®
, and QuikClot ACS+
®
. Untreated blood served as a control. Coagulation 
Index provides an overall score for clotting based on R Time, K Time, alpha angle and 
maximum amplitude. Data are expressed as mean, 95% confidence intervals and inter-
quartile range represented by the mid-line, outer lines and box, respectively (n= 6 to 
45). Statistically significant differences are shown, where * represents a p value of 
<0.05. 
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The effect of sulphur mustard on coagulation haemostat-treated blood coagulation in 
vitro 
The four haemostats (WoundStat™, VitaGel™, FastAct® and ProQR®) that were 
effective at reducing R Time in uncontaminated blood were not affected by SM 
contamination (Figure 3.8). The other haemostats tested (QuikClot ACS+
®
, HemCon
®
 
and Celox™) were ineffective in reducing the time to initial clot formation (Figure 3.8). 
WoundStat™, VitaGel™, FastAct® and ProQR® significantly increased overall 
clotting kinetics (decreased K time and increased α-angle) in SM-contaminated blood 
compared to control (untreated) blood (Table 3.3). Moreover, no significant difference 
in clotting kinetics (K time and α-angle) was observed between naive and SM-
contaminated blood for the haemostats. 
Interestingly, the ability of WoundStat™ to increase total clot strength and 
elasticity was compromised in SM-contaminated blood, with significant decreases in 
maximum amplitude and shear elastic modulus strength (2- and 4.1-fold decreases, 
respectively) compared to control (untreated) blood (p < 0.01) and WoundStat™ treated 
uncontaminated blood  (p < 0.01; Table 3.3 and Figure 3.9). Sulphur mustard also 
significantly decreased the coagulation index for this group compared to both control 
(untreated) blood and WoundStat™-treated uncontaminated blood (p < 0.01; Figure 
3.10). The relative efficacy of the haemostatic products to coagulate blood (with or 
without addition of SM) is summarised in Table 3.4. 
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Table 3-3: Clotting kinetics (K Time and α-angle) and clot strength (maximum 
amplitude) of whole blood following addition of SM and haemostatic products. 
Haemostats were tested in combination with SM. Haemostats tested included: 
WoundStat™, VitaGel™, Celox™, FastAct®, ProQR®, HemCon®, and QuikClot 
ACS+
®
. Untreated blood and SM-exposed served as negative and positive controls, 
respectively. Statistically significant differences between haemostat + SM and control 
are shown, where *, ** and *** represent a p value of <0.05, <0.01 and <0.001, 
respectively. Black line represents significant difference between haemostat (naive 
blood) and haemostat (SM-contaminated blood) treatment groups. Data are expressed 
as mean (± 95% confidence intervals; n= 6 to 45).  
Treatment 
Group 
K Time (min) 
 
Alpha angle 
(degree) 
Maximum Amplitude 
(mm) 
Control (n=45) 
2.3  
(1.9 – 2.6) 
58.5 
(54.8 – 62.1) 
72.8 
(71.5 – 74.2) 
SM 
(n=45) 
2.2  
(1.9 – 2.6) 
60.7  
(56.6 – 64.9) 
70.6  
(67.8 – 73.3) 
WS 
(n=6) 
***0.8 
(0.8 – 0.8) 
***80.7 
(80.3 – 81.1) 
74.7 
(72.9 – 76.5) 
WS + SM 
(n=6) 
*1.1 
 (0.7 – 1.6) 
**76.3 
 (71.7 – 80.8) 
**36.5 
 (22.1 – 50.8) 
VG 
(n=6) 
**1.0 
(0.75 – 1.2) 
**77.0 
(75.6 – 78.4) 
*79.2 
(75.6 – 82.8) 
VG + SM 
(n=6) 
***0.9 
 (0.7 – 1.0) 
***79.4  
(77.3 – 81.4) 
**78.9 
 (75.7 – 82.1) 
CX 
(n=6) 
2.4 
(1.9 – 2.9) 
56.1 
(46.7 – 65.6) 
72.4 
(65.4 – 79.4) 
CX + SM 
(n=6) 
2.8 
 (1.5 – 4.2) 
48.2 
 (28.4 – 68.0) 
66.5 
 (48.0 – 85.0) 
FA 
(n=6) 
**1.1 
 (0.8 – 1.5) 
**75.7 
(70.7 – 80.8) 
75.6 
(69.8 – 81.4) 
FA + SM 
(n=6) 
**1.0 
 (0.7 – 1.3) 
***77.7 
 (73.2 – 82.2) 
**78.3  
(75.4 – 81.2) 
PQR 
(n=6) 
***1.0 
(0.9 – 1.4) 
**72.7 
(69.1 – 76.3) 
73.0 
(68.9 – 77.4) 
PQR + SM 
(n=6) 
**1.1  
(0.8 – 1.3) 
**75.8 
 (72.5 – 79.1) 
**76.6  
(75.3 – 77.9) 
HC 
(n=6) 
1.7 
(1.4 – 2.0) 
64.0 
(58.8 – 69.2) 
75.0 
(71.5 – 78.4) 
HC + SM  
(n=6) 
2.8  
(1.5 – 4.1) 
51.3 
 (39.5 – 63.2) 
75.0 
 (72.5 – 77.4) 
QCS 
(n=6) 
2.6 
(1.8 – 3.4) 
57.6 
(50.6 – 64.7) 
71.6 
(6739 – 75.3) 
QCS + SM  
(n=6) 
2.9  
(1.8 – 4.0) 
52.0 
 (40.8 – 63.1) 
71.6  
(50.8 – 72.7) 
*
*
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Table 3-4: Thrombelastography parameters results for haemostat (naive blood) and 
haemostat (SM-contaminated blood) treatment groups presented as a “traffic-light 
chart”. 
The colours represent the clotting efficacy of each product; where a significant 
worsening (red; -), no significant difference (yellow; 0) or a significant improvement 
(green; +) in coagulation parameters measured compared to the control (untreated) is 
shown for each of the treatment groups.  
Treatment 
Group 
R Time K Time α angle MA G CI 
WS + + + 0 0 0 
WS + SM + 0 0 - - - 
VG + 0 0 + + + 
VG + SM + + + + + 0 
CX 0 0 0 0 0 0 
CX + SM 0 0 0 0 0 0 
FA + 0 0 0 0 0 
FA + SM + 0 0 0 0 0 
PQR + +  0 0 0 
PQR + SM 0 + + 0 0 0 
HC 0 0 0 0 0 0 
HC + SM  0 0 0 0 0 0 
QCS 0 0 0 0 0 0 
QCS + SM  0 0 0 0 0 0 
Coagulation parameter significantly improved compared to control + 
No significant difference compared to control 0 
Coagulation parameter significantly worse than control - 
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The effect of sulphur mustard on blood coagulation in vivo 
Thrombelastography parameters were also measured for animals challenged with a 
percutaneous SM challenge via superficially damaged skin with and without 
decontamination using WoundStat™. These measurements were conducted to 
investigate whether SM or WoundStat™ had an effect on systemic coagulation (when 
applied percutaneously to superficially damaged skin). Statistically significant 
differences in either R time, total clot strength or coagulation index were not observed 
between the two treatment groups (Figure 3.11 – 13). Additionally, no statistically 
significant difference was observed for the “SM-exposed” time points (60 – 360 min) 
compared to the unexposed baseline sample for either treatment group.   
An area of concern identified by the in vitro studies was the decreased clot 
strength following treatment of blood with a combination of WoundStat™ and SM 
(Figure 3.9 and Table 3.4). However, WoundStat™ or SM treatment alone did not 
cause an adverse effect in vitro. No statistically significant difference was observed 
between SM only and SM + WoundStat™ treated animals in relation to clot strength. 
This study also measured clot lysis at 30 min (after the start of coagulation, R time). 
Clot lysis (30 min after R time) for both treatment groups was less than 1% at all time 
point measured.   
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Figure 3.11: Initial fibrin formation (R Time; min) of whole blood (from systemic 
circulation) following percutaneous application of sulphur mustard (SM) and 
subsequent application of WoundStat™ (SM+WS) to superficially damaged skin. 
Values are expressed as mean ± standard deviation (n=6).  
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Figure 3.12: Total clot strength (maximum amplitude) of whole blood (from systemic 
circulation) following percutaneous application of sulphur mustard (SM) and 
subsequent application of WoundStat™ (SM+WS) to superficially damaged skin. 
Values are expressed as mean ± standard deviation (n=6).  
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Figure 3.13: Overall assessment of coagulation (Coagulation Index; CI) of whole 
blood (from systemic circulation) following percutaneous application of sulphur 
mustard (SM) and subsequent application of WoundStat™ (SM+WS) to superficially 
damaged skin. 
Values are expressed as mean ± standard deviation (n=6).  
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DISCUSSION 
This study has shown that SM does not significantly affect coagulation in vitro and 
several haemostats have been identified that significantly enhance coagulation in SM-
contaminated blood. Several parameters of performance for one effective haemostat, 
WoundStat™ was found to be adversely affected by SM-contaminated blood. However, 
this was not observed in vivo.  
Thrombelastography has been previously validated for use as an in vitro method of 
monitoring coagulation and evaluating the efficacy of haemostats in whole blood 
(Kheirabadi, et al. 2009, Kheirabadi, et al. 2010, Ostomel, et al. 2006). However, there 
are a number of caveats that must be taken into consideration when interpreting and 
extrapolating the findings from this study.   
 
Relevance of application of test products 
Some of the test haemostats require sustained pressure to be applied in order to achieve 
cessation of haemorrhage (Pusateri, et al. 2003a, Pusateri, et al. 2003b, Ward, et al. 
2007, Kheirabadi, et al. 2005). Chitosan-based haemostats also have mucoadhesive 
properties and can seal the vessel rupture (Sambasivan, et al. 2009). Clearly testing 
these mechanisms of action could not be achieved using TEG. Therefore, only the 
intrinsic haemostatic capacity of products was evaluated. This may have resulted in 
some products not performing as well as anticipated based on previous in vivo data 
(Pusateri, et al. 2003a, Kheirabadi, et al. 2009). 
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Suitability of pig blood as a model for human blood 
The use of animal blood as a substitute for human blood has the potential limitation of 
not accurately modelling the response of human blood in vivo (Siller-Matula, et al. 
2008). This could result in the selection of an ineffective product or elimination of 
products that would otherwise be suitable. The pig has been previously described as a 
suitable model for researching in vitro blood coagulation (Velik-Salchner, et al. 2006, 
Olsen, et al. 1999) although there are key differences. Notably, pig’s blood coagulates 
more easily than human blood due to increased intrinsic coagulation pathway activity 
(Olsen, et al. 1999). Also, there are differences in the platelet surface protein GPIIb/IIIa 
between human and porcine blood which may affect total clot strength (Royo, et al. 
1998). However, total clot strength measured by TEG was comparable between human 
and porcine blood (Kessler, et al. 2011). Ideally, the findings of this study should be 
further validated with human blood but the number of samples required may make this 
unfeasible. 
Use of citrated blood 
Sodium citrate is an effective anticoagulant (through chelation of calcium ions) and 
increases the viability window for use in coagulation studies (Mann et al. 2007). 
However, the blood must be reactivated using calcium chloride. Thrombelastography 
parameters for recalcified citrated blood differ significantly to those for native blood 
(Camenzind, et al. 2000). Therefore, it is possible that the haemostatic ability of some 
products may also be affected by recalcified citrated blood. In light of the potential 
limitations, the key findings of this study will be discussed. 
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Sulphur mustard did not have a significant effect on any of the coagulation parameters 
measured regardless of whether the blood was obtained from unexposed animals (and 
exposed to SM in vitro) or from animals exposed to SM percutaneously (10 µl via 
superficially damaged skin). This was surprising as SM is able to alkylate proteins 
found in blood (Black, et al. 1997, Noort, et al. 1996), thus it is reasonable to postulate 
that SM could alkylate proteins key to coagulation such as thrombin. However, if 
reactions with coagulation factors do occur they are not sufficient to adversely affect 
coagulation as measure by TEG. As the SM-treated blood was used exclusively on two 
TEG machines there is the possibility that this was due to machine or channel bias. 
However, no statistically significant difference in R time results for control blood were 
observed when individual channels were compared (Figure 3.2).  
Sulphur mustard has also been shown to increase expression of uPA (Detheux, 
et al. 1997). This enzyme cleaves inactive plasminogen to produce the active serine 
protease, plasmin (Vasquez, et al. 1998).  Plasmin cleaves the cross-linked fibrin mesh 
resulting in thrombolysis (Pryzdial, et al. 1999). Therefore, it is possible that SM could 
increase the rate of clot lysis through activation of uPA.  In the TEG study in which 
blood was contaminated in vitro, clot viscosity was only measured until maximum 
amplitude was reached so observation of any subsequent effects on clot lysis was 
unlikely. However, clot lysis was also measured for whole blood obtained from animals 
exposed percutaneously to SM (via superficially damaged skin) in vivo. There were no 
statistically significant differences in clot lysis between the baseline (0 min; unexposed) 
samples and the samples obtained post SM challenge (60 – 360 min post challenge). 
Therefore, reported changes in haematology for SM exposure victims (Mahmoudi, et al. 
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2005) which could affect coagulation may occur at later time points to those measured 
in this study.    
Four haemostats (WoundStat™, FastAct®, VitaGel™ and ProQR®) significantly 
increased the rate of coagulation (reduction in R Time) and overall clotting kinetics (K 
time and alpha-angle) compared to control blood. However, VitaGel™ was the only 
haemostat to significantly increase shear elastic modulus strength (SEMS) and overall 
coagulation index in untreated blood compared to control blood. The mechanisms of 
action for FastAct
®
 and VitaGel™ are similar: both are liquid formulations which 
contain thrombin. Thrombin is a key clotting factor in the amplification and 
propagation phases of coagulation and cleaves fibrinogen to fibrin to produce a fibrin 
clot (Monroe, et al. 2002). This would be expected to result in a reduction in both R and 
K Time and an increase in α-angle (Kawasaki, et al. 2004, Johansson, et al. 2008, 
Rivard, et al. 2005). Thrombin is also a potent platelet agonist (Brass. 2003). Activated 
platelets provide a platform for the propagation phase of coagulation, as well as 
providing structural support to the fibrin clot mesh resulting in increased total clot 
strength (Monroe and Hoffman. 2006).  
In general, SM did not have a significant effect on haemostat performance. One 
notable exception was the SEMS and coagulation index values for WoundStat™ plus 
SM treatment group which were significantly lower compared to both the control and 
WoundStat™ only treatment groups. The SEMS is derived from the maximum 
amplitude thrombelastography parameter and is representative of total clot elasticity.  
Clot strength is a direct function of the dynamic properties of fibrin and platelet binding 
via GPIIb/IIIa receptor (Mousa, et al. 2000). Therefore, the addition of SM in 
combination with WoundStat™ may cause a structural or functional change in 
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GPIIb/IIIa integrin, platelet or fibrin or a change in platelet number. As the full 
haemostatic mechanism of WoundStat™ has yet to be elucidated, it is difficult to 
postulate which particular aspect(s) of WoundStat™-induced coagulation was affected 
by SM. Although, it is likely that the propagation phase of coagulation is the affected 
phase of coagulation as R time, K time and alpha-angle were unaffected by SM in 
combination with WoundStat™. Samples were analysed in duplicate with all four 
treatment groups analysed at the same time using blood from the same animals. 
Therefore, it is unlikely that variations in fibrin concentration or platelet number 
between the test conditions were responsible for this effect. However, the coagulation 
parameters of blood obtained from animals treated with SM and WoundStat were 
measured and there was not a statistically significant difference in clot strength when 
compared to the baseline sample (unexposed; 0 min) or animals exposed to SM only 
(Figure 3.12 and 3.13). Therefore, the effects on clot strength seen in vitro may be 
related to SM or WoundStat™ dose, or due to direct interactions between 
SM/WoundStat™ and platelets.    
Three haemostats (QuikClot ACS+
®
, HemCon
®
 and Celox™) were not found to 
significantly enhance any of the coagulation parameters measured compared to the 
control. This was surprising, as the products are reported to be effective in vivo in the 
literature (Ahuja, et al. 2006, Pusateri, et al. 2003b, Arnaud, et al. 2007). However, 
Kheirabadi et al. (2009) also observed a lack of in vitro efficacy for HemCon
®
 and 
Celox™. The poor performance of these products in this model could be due to the lack 
of physical compression that would normally be applied under conditions of actual use. 
Also, the mucoadhesive properties of chitosan-based haemostats (HemCon
®
 and 
Celox™) play a key role in arresting bleeding by forming a seal at the site of vessel 
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rupture a mechanism that would be absent in vitro. Nevertheless, all three products are 
supposed to be able to clot blood via electrostatic interactions with red blood cells 
(Kozen, et al. 2008, Kozen, et al. 2007, Monroe and Hoffman. 2006, Najjar, et al. 2004, 
Hampton and Mitchell. 1966), and so this complete lack of efficacy was unexpected.  
 
Conclusions 
Thrombelastography provides a suitable in vitro model for the quantification of 
haemostat efficacy in untreated and SM-treated blood. This study has identified that SM 
had no measurable effect on TEG coagulation parameters. Subsequent studies using 
blood obtained from animals exposed to SM in vivo are in agreement with the in vitro 
findings. A number of haemostatic products have been identified which are able to 
significantly increase the rate of clotting and are not impeded by the presence of SM. 
These haemostats could be effective as haemostatic decontaminants and warrant further 
testing. 
 
Recommendations for future work 
 Haemostatic products should be assessed for ability to decontaminate skin 
(intact and damaged) in vitro (Chapter 4). 
 The effect of SM on coagulation should be evaluated using human blood to 
establish whether there are species-specific effects. 
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Chapter 4  
The effect of superficial damage on the 
percutaneous absorption of SM and efficacy 
of haemostats as decontaminants in vitro 
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INTRODUCTION 
Damaged skin has been shown to have a higher permeability to hydrophobic 
compounds than undamaged skin in vitro (Borrás-Blasco, et al. 1997) and in vivo 
(Gunther, et al. 1998; Jakasa, et al. 2006). As previously described in Chapter 1, the 
primary barrier to dermal absorption is generally regarded to be the SC (Blank. 1965, 
Monash. 1958).  If the SC were removed due to a penetrating injury or abrasion, it is 
reasonable to postulate that the penetration of SM would be increased and this could 
result in increased toxicity. However, there is little in the published literature to 
substantiate this hypothesis.   
As described in Chapter 1, current in-service decontaminants fall into two broad 
categories; reactive decontaminants and adsorptive (passive) decontaminants. In this 
Thesis the adsorptive properties of some haemostats were exploited to investigate 
whether they would be suitable as decontaminants. In addition, liquid haemostats 
(containing activated clotting factors) were combined with a novel reactive 
decontaminant to assess efficacy as a decontaminant.   
The static diffusion cell system is an established technique for measuring the 
dermal absorption of chemicals including SM (Chilcott, et al. 2005, Schmook, et al. 
2001). This ex vivo approach is also in line with the “3 Rs” ethical framework as it 
significantly reduces the number of animals needed for the required screening study.  
 
  
 
120 
 
Aims 
To utilise the static diffusion cell system to investigate;  
 the effect of skin damage on the rate and extent of dermal absorption of SM in 
vitro, 
 the efficacy of candidate haemostats as decontaminants for undamaged skin and 
damaged skin in vitro.  
 
MATERIALS AND METHODS 
Full details of methods employed in this study are described in Chapter 2. Briefly, the 
dermal absorption of 
14
C-SM through split-thickness, intact or superficially damaged 
porcine skin was measured using a static diffusion cell system. Skin was superficially 
damaged by the removal of the upper skin layers (nominal 100 µm removed). This 
uniform damage was achieved using an electric dermatome (as described in Chapter 2). 
The decontamination efficacy of each test haemostatic products (Table 2.2) was 
evaluated, with standard military decontaminants (Table 2.3) used as to bench-mark 
efficacy. Up to 5 treatment groups (n=6) and a control group (untreated; n=6) were 
assessed per experiment. Table 4.1 outlines the treatment groups included in each 
experiment (study 1 – 4). Dermal absorption was measured over a 24 h period and the 
amount of 
14
C-SM remaining in the test product, skin and receptor fluid was measured 
at the end of the study. Ineffective products were eliminated from further evaluation (in 
vivo damaged skin model; Chapter 6) as shown in Figure 4.1.  
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Table 4-1: Treatment group designation for the studies described in Chapter 4. 
Up to 4 haemostats (n=6) were tested per experiment (WoundStat™; WS, QuikClot 
ACS+
®
; QC, ProQR
®; PQR, Celox™; CX, HemCon®; HC, FastAct®; FA, VitaGel™; 
VG, tetraglyme, oxime and polyethyleneimine; TOP, FastAct
®
 in combination with 
TOP; FA + TOP and VitaGel™ in combination with TOP; VG + TOP). The military 
decontaminants (fuller’s earth; FE, Reactive Skin Decontamination Lotion®; RSDL® 
and M291) were included as a positive controls (n=6). Studies 1 – 3 measured SM 
penetration through undamaged (abdominal flank) skin and study 4 measured SM 
penetration through superficially damaged (dorsum) skin. Undamaged dorsal skin 
served as a validation control (as described in Chapter 2). 
  
 Undamaged skin Damaged skin 
Study number 1 2 3 4 
Treatment group 
Control Control Control Control 
WS FA FA + TOP Damaged control 
QC VG VG + TOP WS (damaged) 
PQR HC M291 QC (damaged) 
CX TOP  PQR (damaged) 
FE RSDL
®
  FE (damaged) 
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Figure 4.1: Decision process flow chart for haemostatic product down-selection to 
identify suitable product to test in vivo. 
 
Comparison of 14C-SM absorption in 
undamaged and damaged skin
14C-SM absorption – undamaged skin
14C-SM absorption – damaged skin (down-
selected products)
14C-SM “off-gassing” from down-selected 
products
Identify best performing product for further 
evaluation (in vivo)
Do products 
meet criteria?
Eliminate from 
study
Eliminate from 
study
Do products 
meet criteria?
Validation /
Characterisation
Product Assessment
No
No
Yes
Yes
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RESULTS 
Penetration of SM – difference between damaged and undamaged skin 
There was a significant (2 – 3 fold) increase in the maximum rate of absorption (Jmax) of 
14
C (derived from 
14
C–SM) penetration through dorsal skin following damage (p<0.05; 
Figure 4.2 and Table 4.2). There were no significant differences in the absorption 
kinetics (Jmax) or the total amount of 
14
C (derived from 
14
C–SM) penetrating through the 
skin neither between individual batches of abdominal skin nor between undamaged 
dorsal and abdominal skin (Table 4.2 and Figure 4.3). However, the recovery of 
14
C-
SM from one batch of abdominal skin (study 2; Figure 4.4) was significantly greater 
than the other abdominal skin samples.  
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Figure 4.2: The cumulative absorption of 
14
C (derived from 
14
C-SM) into the receptor 
fluid through split thickness undamaged and damaged (top 100 µm removed) control, 
dorsal skin. 
Values are expressed as mean ± 95% confidence intervals (n=6).  
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Figure 4.3: Cumulative absorption of 
14
C (derived from 
14
C–SM) penetrating split-
thickness, undamaged abdominal and dorsal skin. 
Values are expressed as mean ± S.D. (n=6) for studies 1 – 3 (undamaged; abdominal 
skin, solid line) and study 4 (undamaged; dorsal skin, dashed line).  
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Table 4-2: The maximum rate of absorption (Jmax) and total absorption at 24 h of 
14
C 
(derived from 
14
C–SM) through split-thickness undamaged and damaged skin. 
Average values (mean ± S.D.) are shown for control treatment group for each study 
(n=6). Studies 1 – 3 used undamaged abdominal flank skin, whilst study 4 used 
undamaged and damaged dorsal skin. Statistically significant differences between 
undamaged and damaged skin are indicated, where ** represents a p-value of <0.01. 
  
 
Maximum rate of 
absorption 
(µg cm
-2
 h
-1
) 
Total absorption at 24 h  
(µg cm
-2
) 
Undamaged 
Abdominal 
Study 1 5.9 ± 3.2** 104.1 ± 57.4** 
Study 2 5.7 ± 2.3** 61.2 ± 14.9** 
Study 3 8.5 ± 4.9** 106.4 ± 56.1** 
Undamaged 
Dorsum 
Study 4 6.5 ± 2.6** 74.9 ± 35.5** 
Damaged 
Dorsum 
Study 4 18.5 ± 4.2 222.4 ± 48.2 
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Figure 4.4: The distribution of 
14
C (derived from 
14
C–SM) recovered from the skin 
surface (swab), within the skin and receptor chamber fluid 24 h post exposure 
Data are expressed as logged mean ± S.D. (n=6). Studies 1 – 3 used undamaged 
abdominal flank skin, whilst study 4 used undamaged and damaged dorsal skin. 
Statistical significance differences between undamaged and damaged skin are shown, 
where * and ** represents p-values of <0.05 and <0.01, respectively for swab
a
, skin
b
 
and receptor fluid
c
.  
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Effectiveness of haemostatic products as decontaminants for sulphur mustard – 
undamaged skin  
WoundStat™ and fuller’s earth both significantly reduced the dermal absorption 
(p<0.01; rate and extent) of 
14
C (derived from 
14
C–SM) through undamaged skin over a 
24 h period (Table 4.3 and Figure 4.5). In comparison with untreated (control) skin, the 
total amount penetrating into the receptor fluid over 24 h was reduced by 92 ± 2.7% 
(83.6 ± 54.7 µg cm
-2
 vs. 7.1 ± 2.3 µg cm
-2
) and 90 ± 5.1% (83.6 ± 54.7 µg cm
-2
 vs. 8.7 
± 4.3 µg cm
-2
) following treatment with fuller’s earth and WoundStat™, respectively. 
There was not a statistically significant difference in total dermal absorption for cells 
treated with QuikClot ACS+
®, Celox™ or ProQR® compared to the control group 
(Table 4.3).   
The amount of 
14
C (derived from 
14
C–SM) recovered from the skin after 24 h 
was significantly reduced for diffusion cells treated with WoundStat™ or fuller’s earth 
compared to control diffusion cells (p<0.01; Figure 4.6). There was no significant 
difference in the amount of 
14
C (derived from 
14
C–SM) recovered from skin treated 
with QuikClot ACS+
®
, ProQR
®
 or Celox™ and control (untreated) (Figure 4.6). 
Significant increases in the amount recovered from the skin surface (swab) were seen 
for ProQR
®
 (14-fold) and fuller’s earth (109-fold) compared to control values (p<0.01). 
The amount recovered from the haemostat was significantly higher for WoundStat™ 
compared to Celox™ (p<0.001) and QuikClot ACS+® (p<0.05) and fuller’s earth 
compared to Celox™ (p<0.01; Figure 4.6). 
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Figure 4.5: Cumulative absorption of 
14
C (derived from 
14
C–SM) penetrating 
undamaged skin following application of haemostatic products 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC, ProQR®; PQR 
and Celox™; CX. A standard military decontaminant (fuller’s earth; FE) was included 
as a positive control. Values are expressed as mean ± S.D. (n=6). 
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Table 4-3: The maximum rate of absorption (Jmax) and total absorption at 24 h of 
14
C 
(derived from 
14
C–SM) through split thickness undamaged skin following application 
of haemostatic products. 
Average values (mean ± S.D.) are shown for control and treatment groups (n=6). 
Statistically significant differences between control and decontaminated skin are 
indicated, where ** represents a p-value of <0.01.   
  
Treatment Group 
Maximum rate of absorption 
(µg cm
-2
 h
-1
) 
Total absorption at 24 h 
(µg cm
-2
) 
Control 5.9 ± 3.2 104.1 ± 57.4 
WS 0.3 ± 0.1** 8.9 ± 4.3** 
FE 0.1 ± 0.09** 7.1 ± 2.3** 
QC 3.3 ± 1.6 44.0 ± 24.0 
PQR 7.1 ± 4.4 76.5 ± 44.5 
CX 8.2 ± 1.9 139.3 ± 60.6 
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Figure 4.6: The distribution of 
14
C (derived from 
14
C–SM) recovered from 
undamaged skin at 24 h post-exposure following application of haemostatic products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC, ProQR®; PQR 
and Celox™; CX. A standard military decontaminant (fuller’s earth; FE) was included 
as a positive control. Individual values are mean ± S.D. (n=6). Statistically significant 
differences between control and treated cells are shown, where ** represents a p-value 
of <0.01 for skin
a
, swab
b
 and receptor fluid
c
.   
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VitaGel™ and FastAct® both significantly increased the rate and extent of 14C (derived 
from 
14
C–SM) dermal absorption over a 24 h period compared to the control group 
(p<0.01; Figure 4.7 and Table 4.4). In comparison with the control group, the total 
amount penetrating into the receptor fluid over 24 h was increased by 657% (61.2 ± 
14.9 µg cm
-2
 vs. 401.9 ± 115.4 µg cm
-2
) and 512% (61.2 ± 14.9 µg cm
-2
 vs. 313.2 ± 
75.6 µg cm
-2
) for VitaGel™ and FastAct®, respectively.  Following treatment with 
HemCon
®
, there was a significant increase in the total amount of 
14
C (derived from 
14
C–SM) penetrating the skin (p<0.05; Figure 4.7 and Table 4.4). The rate of absorption 
was also significantly higher following treatment with HemCon
®
 (p<0.01). The rate of 
absorption was significantly reduced (p<0.05) following application of Reactive Skin 
Decontamination Lotion
®
 (RSDL
®
) or tetraglyme, oxime and polyethyleneimine 
(TOP). However, there was no significant difference in the total amount absorbed 
through the skin at 24 h (Table 4.4) in these treatment groups.   
Statistically significant reductions in the amount of 
14
C (derived from 
14
C–SM) 
recovered within the skin compared to the control group were observed for diffusion 
cells treated with FastAct
®
 and VitaGel™ (p<0.01; Figure 4.8). Significant increases in 
the amount recovered from the skin surface (swab) were seen for RSDL
®
 and TOP 
treatment groups compared to the control group (Figure 4.8). The amount of  
recoverable 
14
C (derived from 
14
C–SM) remaining in the test products, HemCon® and 
RSDL
®
 was significantly higher than the amount of 
14
C (derived from 
14
C–SM) 
recovered from the novel decontaminant, TOP and the liquid haemostats; FastAct
®
 and 
VitaGel™ (Figure 4.8).  
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Figure 4.7: Cumulative absorption of 
14
C (derived from 
14
C–SM) penetrating 
undamaged skin following application of haemostatic products. 
Haemostats tested included: HemCon
®
; HC, FastAct
®; FA and VitaGel™; VG. A novel 
reactive decontaminant (tetraglyme, oxime and polyethyleneimine; TOP) was also 
evaluated. A standard military decontaminant (Reactive Skin Decontamination Liquid
®
; 
RSDL
®
) was included as a positive control. Individual values are mean ± S.D. (n=6) 
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Table 4-4: The maximum rate of absorption (Jmax) and total absorption at 24 h of 
14
C 
(derived from 
14
C–SM) through split-thickness, undamaged skin following 
application of haemostatic products. 
Average values (mean ± S.D.) are shown for control and treatment groups (n=6). 
Statistically significant differences between control and decontaminated skin are 
indicated, where * and ** represents a p-value of <0.05 and <0.01, respectively.   
 
Treatment Group 
Maximum rate of absorption 
(µg cm
-2
 h
-1
) 
Total absorption at 24 h 
(µg cm
-2
) 
Control 5.7 ± 2.3 61.2 ± 14.9 
HC 10.4 ± 2.3* 275 ± 83.9** 
RSDL 1.7 ± 1.0** 87.6 ± 71.2 
TOP 3.0 ± 0.9* 72.4 ± 23.8 
FA 19.6  ± 6.6** 313.2 ± 75.7**5 
VG 23.0 ± 12.2** 401.8 ± 115.4** 
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Figure 4.8: The distribution of 
14
C (derived from 
14
C–SM) recovered from 
undamaged skin at 24 h post-exposure following application of haemostatic products. 
Haemostats tested included: HemCon
®
; HC, FastAct
®; FA and VitaGel™; VG. A novel 
reactive decontaminant (tetraglyme, oxime and polyethyleneimine; TOP) was also 
evaluated. A standard military decontaminant (Reactive Skin Decontamination Liquid
®
; 
RSDL
®
) was included as a positive control. Values are expressed as mean ± S.D. (n=6). 
Statistically significant differences between control and treated cells are shown, where 
** represents a p-value of <0.01 for skin
a
, swab
b
 and receptor fluid
c
.   
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The significant enhancement in dermal absorption of 
14
C (derived from 
14
C–SM) 
observed following treatment with FastAct
®
 and VitaGel™ (Figure 4.7) was absent 
when these products were applied to contaminated skin in combination with TOP 
(Figure 4.9). However, the maximum rate and total absorption of 
14
C-SM following 
FastAct
®
 + TOP and VitaGel™ + TOP treatments were not statistically different to 
control (untreated) skin (Table 4.5).  
The military decontaminant (M291) significantly reduced the amount of 
14
C 
(derived from 
14
C–SM) absorbed through undamaged skin over a 24 h period (p<0.01; 
Table 4.5 and Figure 4.9). The amount of 
14
C-SM recovered from the skin was 
significantly lower in the M291 treatment group (9-fold decrease) compared to the 
control group (p<0.01; Figure 4.10). Significant increases in the amount recovered from 
the skin surface (swab) were seen for all treatment groups compared to control group 
(p<0.01; Figure 4.10). The amount of 
14
C (derived from 
14
C–SM)  recovered from 
M291 was significantly higher than amount retained in either the FastAct
®
 + TOP or 
VitaGel™ + TOP treatment groups (Figure 4.10). 
  
 
137 
 
 
Figure 4.9: Cumulative absorption of 
14
C (derived from 
14
C–SM) penetrating 
undamaged skin following application of haemostatic products. 
Haemostats tested included: FastAct
®
 in combination with TOP; FA + TOP and 
VitaGel™ in combination with TOP; VG + TOP. A military decontaminant (M291) was 
included as a positive control. Individual values are mean ± S.D. (n=6). 
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Table 4-5: The maximum rate of absorption (Jmax) and total absorption at 24 h of 
14
C 
(derived from 
14
C–SM) through split-thickness, undamaged skin following 
application of haemostatic products. 
Average values (mean ± S.D.) are shown for control and treatment groups (n=6). 
Statistically significant differences between control and decontaminated skin are 
indicated, where ** represents a p-value of <0.01.   
  
Treatment Group 
Maximum rate of absorption 
(µg cm
-2
 h
-1
) 
Total absorption at 24 h 
(µg cm
-2
) 
Control 8.5 ± 4.9 106.3 ± 56.1 
FA + TOP 4.0 ± 2.0 123.3 ± 42.3 
VG + TOP  4.0 ± 0.5 148.2 ± 42.3 
M291 0.3 ± 0.1** 7.7 ± 1.3** 
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Figure 4.10: The distribution of 
14
C (derived from 
14
C–SM) recovered from 
undamaged  skin at 24 h post-exposure following application of haemostatic 
products. 
Haemostats tested included: FastAct
®
 in combination with TOP; FA + TOP and 
VitaGel™ in combination with TOP; VG + TOP. A military decontaminant (M291) was 
included as a positive control. Individual values are mean ± S.D. (n=6). Statistically 
significant differences between control and treated cells are shown, where * and ** 
represents p-values of <0.05 and <0.01 for skin
a
, swab
b
 and receptor fluid
c
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Summary of results using undamaged skin 
A summary of data from studies 1 – 3 is presented in Figure 4.11 and Table 4.6. 
WoundStat™ was the only haemostat tested that was consistently comparable in 
efficacy to the “benchmark” military products (fuller’s earth and M291). Moreover, 
three products (HemCon
®
, VitaGel™ and FastAct®) caused a significant increase in the 
total absorbed dose of 
14
C (derived from 
14
C–SM). Therefore, the products selected for 
further evaluation using superficially damaged skin in vitro were WoundStat™, 
QuikClot ACS+
®
 and ProQR
®
.  
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Figure 4.11: The total amount of 
14
C (derived from 
14
C–SM) penetrating undamaged 
skin 24 h post-exposure following application of haemostatic products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC, ProQR®; PQR, 
Celox™; CX, HemCon®; HC, FastAct®; FA, VitaGel™; VG, tetraglyme, oxime and 
polyethyleneimine; TOP, FastAct
®
 in combination with TOP; FA + TOP and VitaGel™ 
in combination with TOP; VG + TOP. The military decontaminants (fuller’s earth; FE, 
Reactive Skin Decontamination Lotion
®
; RSDL
®
 and M291) were included as a positive 
controls. Penetration values have been normalised to control values for their respective 
study. Individual values are shown as well as mean (central line; n=6) and S.D. 
(outermost lines).   
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Table 4-6: Dermal absorption of 
14
C (derived from 
14
C–SM), rate and extent at 24 h 
presented as a “traffic-light chart” following application of haemostatic products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC, ProQR®; PQR, 
Celox™; CX, HemCon®; HC, FastAct®; FA, VitaGel™; VG, tetraglyme, oxime and 
polyethyleneimine; TOP, FastAct
®
 in combination with TOP; FA + TOP and VitaGel™ 
in combination with TOP; VG + TOP. The military decontaminants (fuller’s earth; FE, 
Reactive Skin Decontamination Lotion
®
; RSDL
®
 and M291) were included as a positive 
controls. The colours represent the efficacy of each product; where a significant 
increase (red; +), no significant difference (yellow; 0) or a significant decrease (green; 
-) in either rate or extent of absorption compared to the control is shown for each of the 
treatment groups. 
  
Treatment Group Rate of Absorption Extent of absorption 
WS - - 
QCS 0 0 
PQR 0 0 
VG + + 
FA + + 
TOP - 0 
FA + TOP 0 0 
VG + TOP 0 0 
CX 0 0 
HC + + 
FE - - 
RSDL 0 0 
M291 - - 
Significant increase compared to control + 
No significant difference compared to control 0 
Significant decrease compared to control - 
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Effectiveness of haemostatic products as decontaminants for sulphur mustard – 
damaged skin 
Decontamination of damaged skin with WoundStat™, QuikClot ACS+® and fuller’s 
earth consistently led to a significant reduction in the amount of 
14
C (derived from 
14
C–
SM) absorbed through damaged skin over a 24 h period (p<0.01; Figure 4.12 and Table 
4.7). However, there was no significant difference in total 
14
C (derived from 
14
C–SM) 
penetrating through the skin between controls and skin treated with ProQR
®
.   
The amount of 
14
C (derived from 
14
C–SM) recovered from the skin was 
significantly lower following treatment with WoundStat™, QuikClot ACS+® or fuller’s 
earth compared to control diffusion cells (p<0.01; Figure 4.13). The amount within the 
skin was not reduced for diffusion cells treated with ProQR
®
. Significantly more 
14
C 
(derived from 
14
C–SM) was recovered from the skin surface (swab) for cells treated 
with either fuller’s earth or ProQR® compared to the control group. Significantly less 
14
C-SM was distributed within the haemostat for the QuikClot ACS+
®
 treatment group 
compared to ProQR
®
 (p<0.001) and fuller’s earth (p<0.05).  There was also a 
significant difference in the amount recovered from the haemostat between the ProQR
®
 
and WoundStat™ treatment groups.  
Fuller’s earth was the only treatment less effective in decreasing 14C-SM 
penetration through damaged skin compared to undamaged skin (Figure 4.14).  
WoundStat™ was the only candidate haemostat to significantly reduce the penetration 
of 
14
C (derived from 
14
C–SM) through both undamaged and damaged skin (Table 4.8).  
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Figure 4.12: Cumulative absorption of 
14
C (derived from 
14
C–SM) through damaged 
skin following application of haemostatic products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC and ProQR®; 
PQR. A standard military decontaminant (fuller’s earth; FE) was included as a positive 
control. All values are mean ± S.D. (n=6). 
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Table 4-7: The maximum rate of absorption (Jmax) and total absorption at 24 h of 
14
C 
(derived from 
14
C–SM) for damaged skin following application of test haemostatic 
decontaminants. 
Average values (mean ± S.D.) are shown for control and treatment groups (n=6). 
Statistically significant differences between undamaged and damaged skin are 
indicated, where ** represents a p-value of <0.01.   
  
Treatment Group 
Maximum rate of absorption 
(µg cm
-2
 h
-1
) 
Total Absorption at 24 h 
(µg cm
-2
) 
Control damaged 18.5 ± 4.2 222.4 ± 48.2 
QC 6.5 ± 0.7** 72.8 ± 6.5** 
PQR   15.4 ± 4.1 156.5 ± 43.6 
WS 1.7 ± 0.7** 37.2 ± 12.2** 
FE 2.9 ± 1.0** 55.7 ± 14.9** 
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Figure 4.13: The distribution of 
14
C (derived from 
14
C–SM) recovered from damaged 
skin at 24 h post-exposure following application of haemostatic products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC and ProQR®; 
PQR. A standard military decontaminant (fuller’s earth; FE) was included as a positive 
control. Individual values are mean ± S.D. (n=6). Statistically significant differences 
between damaged control and treated cells are shown, where ** represents a p-value of 
<0.01 for skin
a
, swab
b
 and receptor fluid
c
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Figure 4.14: The total amount of 
14
C (derived from 
14
C–SM) penetrated through 
undamaged and damaged porcine skin at 24 h post-exposure following application of 
haemostatic products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC and ProQR®; 
PQR. A standard military decontaminant (fuller’s earth; FE) was included as a positive 
control. Penetration values are expressed as a percentage of control values for their 
respective study. Individual values are mean ± S.D. (n=6).   
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Significant increase compared to control + 
No significant difference compared to control 0 
Significant decrease compared to control - 
 
Table 4-8: Dermal absorption (rate and extent at 24 h) of 
14
C (derived from 
14
C–SM) 
through damaged and undamaged skin following application of haemostatic 
products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC and Pro QR®; 
PQR. The military decontaminant (fuller’s earth; FE) was included as a positive 
control. The colours represent the efficacy of each product; where a significant 
increase (red; +), no significant difference (yellow; 0) or a significant decrease (green; 
-) in either rate or extent of absorption compared to the control is shown for each of the 
treatment groups.  
Treatment group 
Rate of 
Absorption 
Extent of 
absorption 
WoundStat
™
 
Undamaged - - 
Damaged - - 
QuikClot ACS+
®
 
Undamaged 0 0 
Damaged - - 
ProQR
®
 
Undamaged 0 0 
Damaged 0 0 
Fuller’s earth 
Undamaged - - 
Damaged - - 
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Desorption characteristics of the test products at ambient temperatures 
Statistically significant differences in the amount of 
14
C (derived from 
14
C–SM) 
recovered between unoccluded and occluded groups were observed for the haemostats 
ProQR
®
 and QuikClot ACS+
®
 at ambient temperatures (p<0.01; Figure 4.15). There 
was no reduction in the amount of 
14
C (derived from 
14
C–SM) recovered from the 
unoccluded group for the haemostat, WoundStat™ or the “bench-mark” decontaminant 
fuller’s earth compared to the occluded product controls.  
  
 
150 
 
 
 
Figure 4.15: Desorption of 
14
C (derived from 
14
C–SM) at ambient temperatures 
(21°C) at 3 h post-exposure following application of haemostatic products. 
Haemostats tested included: WoundStat™; WS, QuikClot ACS+®; QC and ProQR®; 
PQR. A standard military decontaminant (fuller’s earth; FE) was included as a positive 
control. Data are expressed as the percentage loss in recovery for unoccluded cells 
compared to occluded cells. Individual values are mean ± S.D. (n=6). Statistically 
significant differences between unoccluded and occluded cells are shown where ** 
represents a p-value of <0.01.   
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DISCUSSION 
This study has shown that defined, superficial skin damage leads to a significant loss of 
barrier function (as demonstrated by enhanced dermal absorption of 
14
C derived from 
14
C–SM) which can be effectively mitigated by the timely application of certain 
haemostatic products. 
It is important to consider the limitations of experimental models to avoid 
erroneous interpretation of the results.  Whilst the use of static diffusion cells has been 
subject to extensive validation (Franz. 1978, Chilcott, et al. 2007, Chilcott, et al. 2001, 
Ng, et al. 2010), the following factors need consideration. 
 
Suitability of pig skin as a model for human skin 
The use of ex vivo animal skin has the potential limitation of not accurately predicting 
human absorption in vivo (Bartek, et al. 1972). Obtaining human skin from elective 
surgical procedures would eliminate the need for using alternative species, but 
obtaining enough suitable human skin (free from overt pathology) is subject to many 
practical issues and so availability is poor. However, dermal absorption through pig 
skin has been shown to correlate well with human skin for a number of chemicals 
(Bartek, et al. 1972, Hawkins and Reifenrath. 1986, Reifenrath, et al. 1991, Reifenrath, 
et al. 1984) including SM (Hawkins and Reifenrath. 1986, Chilcott, et al. 2001, 
Reifenrath, et al. 1991). Moreover, use of pig skin in vitro facilitates a direct 
comparison with in vivo models of superficial skin damage (see Chapter 5). Additional 
in vitro studies with human skin could be conducted to further validate the findings of 
this present study. 
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Suitability of frozen skin tissue 
Although the physical barrier properties of skin have been shown to be unaffected by 
freezing at -20°C (Harrison, et al. 1984, Nakai, et al. 1999), skin enzymatic function is 
likely to be compromised (Wester, et al. 1998). Glutathione S-transferases catalyse 
conjugation of SM with glutathione to detoxify the cell in a phase II reaction (Black, et 
al. 2010). The conjugation reaction increases the solubility of SM and thus may have an 
effect on the rate of dermal absorption.  Sulphur mustard and its analog (2-chloroethyl 
ethyl sulphide; CEES) have been shown to interact with both CYPs and lactate 
dehydrogenase (Mol and De Vries-Van de Ruit. 1992, Gray, et al. 2010, Pons, et al. 
2001). Sulphur mustard analog, 2-chloroethyl ethyl sulphide (CEES) has been shown to 
inhibit CYPs resulting in increased reactive oxygen species (ROS) production and 
potentially increased ROS-dependent cell death (Gray, et al. 2010). Therefore, 
biotransformations which occur in vivo that could potentially affect toxicity (local or 
systemic) may not be present in vitro. This could be resolved by the use of viable, 
unfrozen skin. Viability of the skin tissue would need to be maintained with the 
continual replacement of a physiological compatible receptor medium such as tissue 
culture medium (Collier, et al. 1989). However, SM must have sufficient solubility in 
the receptor fluid used to ensure sink conditions are maintained. Good correlation 
between in vitro and in vivo absorption rates of SM (Chilcott, et al. 2007, Nagy, et al. 
1946, Chilcott, et al. 2001) suggests that the absence of any active transport 
mechanisms does not significantly impact on dermal absorption of SM. 
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Speciation of 
14
C-moieties 
In this study, liquid scintillation counting was used to measure the quantity of the 
14
C-
radioisotope derived from 
14
C-SM present in the samples. This analytical method does 
not differentiate between the original compound (SM) and any subsequent breakdown 
products. Therefore, it is assumed that the amount of 
14
C-radiolabel detected is 
equivalent to the corresponding amount of SM (determined by reference to standard 
solutions prepared and analysed simultaneously). Degradation of 
14
C-SM by the test 
product may occur (particularly with the reactive decontaminants e.g. RSDL
®
) or by 
hydrolysis on the skin surface or in the dermal layers. This could mean that 
14
C detected 
in the skin or in the skin surface (swab) is in fact a hydrolysis breakdown product e.g. 
thiodiglycol or thiodiglycol sulfoxide. To address this problem, speciation of the 
14
C-
label would be required.  Previously, liquid chromatography combined with mass 
spectrometry (LC-MS) has been used to speciation SM and its metabolites (Noort, et al. 
2004, Noort, et al. 2000). These may include TDG and protein adducts or conjugates. 
However, prior in vitro studies by Chilcott et al. (2001) have noted that there is little 
hydrolysis of SM within the epidermal layers (Chilcott, et al. 2001). This is presumably 
due to the fact that SM can partition into the lipid environment of the SC and is 
“protected” from the more aqueous environment of the epidermis and dermis. 
Therefore, 
14
C detected on the skin surface (swab) or within the skin is possibly intact 
SM.  
 
 
154 
 
Receptor chamber fluid 
An important caveat of the static diffusion cell system is the lack of a functioning 
cutaneous circulation and thus potential for accumulation of penetrant in the receptor 
fluid medium (Bronaugh and Stewart. 1985, Cooper and Berner. 1985, Grummer and 
Maibach. 1991). Therefore, the penetrant must be sufficiently soluble in the receptor 
fluid medium to ensure the rate of absorption is not limited (Wester and Maibach. 
1992). A decrease in the thermodynamic activity gradient between donor and receptor 
chambers could result in underestimation of the absorption of the chemical in vitro. The 
presence of ethanol in the receptor fluid (50% aqueous ethanol) increases the solubility 
of SM and allows rapid hydrolysis (half-life = 30 s) (Chilcott 2000). Therefore, infinite 
sink conditions in the receptor chamber should be maintained. However, aqueous 
ethanol has its own limitations as it is clearly not a direct physiological representation 
of blood. Nonetheless, SM absorption studies (porcine skin) using aqueous ethanol as a 
receptor medium have shown good in vitro-in vivo correlation (Chilcott, et al. 2007, 
Chilcott, et al. 2001). Furthermore, the dermal absorption rates measured in vitro with 
human skin (79 and 294 µg cm
-2
 h
-1
 for full thickness skin and epidermal membranes, 
respectively) are in agreement with reported penetration rates using human volunteers 
(60 – 240 µg cm-2 h-1) (Chilcott, et al. 2000, Renshaw. 1946). Aqueous ethanol has also 
been shown to more accurately model in vivo dermal absorption of lipophilic chemicals 
than physiological saline solution (with and without the addition of bovine serum 
albumin) (Kasting, et al. 1997).  
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Relevance of topical product application 
Generally, topical “in-service” decontaminants are not left in situ for 24 hours: current 
doctrine dictates that users remove any residual decontaminant after use. Previous 
decontamination studies with RSDL
®
 and fuller’s earth were performed under more 
realistic conditions where the decontaminants were removed after two minutes of 
dermal contact (Taysse, et al. 2007). Therefore, the extended time the products were 
left in contact in the skin could result in desorption of SM (or SM degradation products; 
Chapter 1; Figure 1.8) from the test product and ultimately enhanced absorption of SM. 
However, the aim of the study was to identify a haemostatic decontaminant which can 
safely remain within a wound for a minimum of several hours. Furthermore, it is critical 
that SM does not undergo desorption from the product to present a secondary exposure 
hazard. Thus, whilst the duration over which each decontamination production was in 
contact with the skin is not in alignment with supplier’s instructions for use, this 
approach represents a “worst case scenario” and represents a highly conservative 
approach to the assessment of product efficacy.        
In “real-life” situations, haemostats are applied within a wound with sustained 
pressure to help arrest bleeding. Correspondingly, in vivo efficacy studies have 
incorporated continuous pressure at the site of application for up to four minutes 
(Pusateri, et al. 2003a, Pusateri, et al. 2003b, Ward, et al. 2007, Kheirabadi, et al. 
2005). Furthermore, haemostats whose mechanism of action is via absorption of plasma 
may create a tamponade effect within the wound. This may increase pressure in the 
wound and enhance absorption of SM in the wound. In this present in vitro study, no 
additional pressure was applied to the skin. Therefore, it would desirable to develop a 
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method of applying uniform, sustained pressure to a haemostat to assess whether this 
has an effect on dermal absorption of 
14
C-SM. 
There are a number of published studies which have investigated the penetration 
of SM through undamaged human and porcine skin (Hattersley, et al. 2008, Chilcott, et 
al. 2000, Chilcott, et al. 2001). However, this is the first study to investigate the 
penetration of SM through superficially damaged skin. Taking account of the 
limitations noted above, the main findings of this study are discussed below: 
Superficial damage to the skin was found to significantly increase both the rate 
and extent of dermal absorption of 
14
C (derived from 
14
C–SM). This was anticipated, as 
the 100 µm layer removed corresponds to the SC and majority of the epidermal layer in 
swine (Qvist, et al. 2000) and the SC is generally regarded as the main barrier to 
percutaneous permeation (Blank. 1965). However, SM is a hydrophobic chemical (Log 
P 1.37) which can rapidly partition into the lipid-rich SC layer of the skin (Chilcott, et 
al. 2000, Rosenblatt, et al. 1996, Cullumbine. 1947). Therefore, the more aqueous 
dermal layer may provide a less favourable environment for the partitioning of SM. 
This could potentially reduce the rate and extent of absorption of lipophilic chemicals 
by reducing permeability, as previously described (Cross, et al. 2003). This was not 
observed in the present study. 
A statistically significant increase in the amount of 
14
C (derived from 
14
C–SM) 
recovered from within one batch of abdominal skin was observed (Figure 4.4). 
However, the difference in recovery equated to 3% of the applied dose and thus was a 
relatively small difference. This apparent discrepancy is likely to be a reflection of 
inherent inter-individual variation in barrier function and is within the range of reported 
variation (2 – 6 fold) (Southwell, et al. 1984, Schaefer and Redelmeier. 1996). Inter-
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individual differences in percutaneous penetration have been, in part, attributed to 
filaggrin and SC lipids in man. Filaggrin has also been identified in pig skin as 
contributing to SC permeability (Liu, et al. 2010) and difference in filaggrin and SC 
lipids may account for the apparent discrepancy in the data. This does also highlight the 
potential for decontaminants to have variable efficacy due to inter-individual 
differences. Each study was conducted with skin from one animal to try to limit 
variation between treatment groups in each study. Moreover, inter-study comparisons 
were conducted using values that were relative-to-control to account for inter-study 
variation due to skin from different animals. Therefore, this apparently anomalous 
result doesn’t reduce confidence in interpreting these data.     
WoundStat™ was found to significantly reduce the rate and extent of dermal 
absorption through both intact and superficially damaged skin. Both WoundStat™ and 
fuller’s earth are comprised of hydrous montmorillonite or smectite granules (Ward, et 
al. 2007). Smectites are mineral clays with an expanding crystal lattice structure that 
has a high ion-exchange capacity and can absorb organic molecules into the interlayer 
space (Liu and Zhang. 2007). This allows WoundStat™ to absorb plasma to locally 
increase clotting factor concentrations and promote coagulation (Carraway, et al. 2008, 
Ward, et al. 2007). This has also been attributed to fuller’s earth decontaminating 
properties (Wattana and Bey. 2009). Fuller’s earth has shown efficacy against SM in 
vitro and in vivo (Chilcott, et al. 2001, Taysse, et al. 2007, Taysse, et al. 2011). 
Presumably the ability of WoundStat™ to decontaminant undamaged and damaged skin 
with an equivalent efficacy to fuller’s earth is due to their similar structures that allow 
the passive adsorption and sequestering of SM.     
 Fuller’s earth (FE) was the only treatment less effective in decreasing 14C-SM 
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penetration through damaged skin compared to undamaged skin. Reduced 
decontamination efficacy of FE in damaged skin has also been observed in vivo 
(Bjarnason, et al. 2008). The decrease in efficacy could potentially be due to increased 
TEWL following the removal of the SC. Increased water vapour at the skin surface 
could result in formation of a FE solution. This could allow the SM to be mobilised 
from FE and be potentially available for dermal absorption. A similar discrepancy in 
decontamination efficacy between dry FE and FE solutions has been previously 
reported in vivo (Bjarnason, et al. 2008). 
QuikClot ACS+
®
 was shown to be ineffective in reducing the rate or extent of 
14
C-SM permeation through intact skin. However, it was found to significantly reduce 
the rate and extent of 
14
C-SM absorption through superficially damaged skin. ProQR
®
 
was shown to be ineffective in both intact and superficially damaged skin. Surprisingly, 
both haemostats are thought to share the same mechanism of action as WoundStat™ 
(passive absorption of liquid into the interlayer space) (Kheirabadi, et al. 2009). Thus it 
is possible that the differences in efficacy are due to different binding capacities for 
hydrophobic chemicals: ProQR
®
 contains a hydrophilic polymer (Ho and Hruza. 2007) 
whilst QuikClot ACS+
®
 is comprised of partially-hydrated zeolite beads (Ostomel, et 
al. 2006). Thus product design features that assist in absorption of water from blood 
may actually inhibit the absorption of hydrophobic chemicals. Although QuikClot 
ACS+
®
 did significantly reduce dermal absorption; it was not found to successfully 
sequester 
14
C-SM; the significant “off-gassing” of the SM-contaminated product could 
present a secondary exposure hazard. QuikClot ACS+
®
 has been reported to generate 
heat when binding water. Thus, it is conceivable that a similar, exothermic reaction may 
be responsible for promoting volatilisation of SM (Arnaud, et al. 2007). Infrared 
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thermography could be used to measure the surface temperature of QuikClot ACS+
®
 
when in contact with SM to establish whether an exothermic reaction is the cause of the 
volatilisation.   
Reactive Skin Decontamination Liquid
®
 (RSDL
®
) and the novel decontaminant 
TOP (comprised of tetraglyme, oxime and poly(ethyleneimine)) were not found to 
significantly reduce the extent of 
14
C-SM dermal absorption through intact skin. Both 
products are reactive decontaminants and enhance the hydrolysis of SM to produce non-
toxic degradation products including TDG (Sawyer et al. 1991). The ineffectiveness of 
RSDL
®
 was unexpected as it has previously been shown to be effective as a 
decontaminant in vivo (Taysse, et al. 2007). This apparent lack of efficacy could be due 
to the combination of occlusion and lack of 
14
C speciation. 
Both RSDL
®
 and TOP are viscous liquids and it is probable that they form an 
occlusive layer on the skin. This could potentially increase dermal absorption by 
reducing evaporation of SM from the skin surface. It has been previously reported that 
80% of the applied dose evaporates under unoccluded conditions, thus occlusion would 
increase the amount available for dermal absorption (Renshaw. 1946, Chilcott, et al. 
2001). Moreover, occlusion of the skin has been shown to disrupt barrier function of the 
SC via increased hydration in the skin layer (Ryatt, et al. 1988, Zhai and Maibach. 
2002). Increases in dermal absorption of certain chemicals (dependent on partition 
coefficient) have been observed following occlusion (Ryatt, et al. 1988). One 
degradation product of SM (TDG) is much less hydrophobic than SM (log P value -
0.77) (Reddy, et al. 2005). Therefore hydration-dependent barrier disruption is likely to 
enhance the permeation of TDG and may result in increased 
14
C-label detected in the 
receptor fluid. Moreover, the lack of speciation of radiolabelled products means the 
14
C 
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radiolabel detected in the receptor fluid could be attributed to a 
14
C radiolabelled-
degradation product and not 
14
C-SM. This may not be a cause for concern for non-toxic 
SM degradation products. However, the overall project objective is to identify a product 
which is suitable for decontaminating SM- or organophosphate-contaminated wounds. 
Therefore, a conservative approach is taken as some organophosphate degradation 
products are toxic and so irreversible sequestration is desirable (Munro, et al. 1999).        
Liquid haemostats (FastAct
® and VitaGel™) significantly increased both the 
extent and rate of dermal absorption of 
14
C-SM through intact skin. This is possibly due 
to the formation of an occlusive barrier which reduces evaporative loss, as seen for the 
reactive decontaminants; RSDL
®
 and TOP. However, the formation of a SM-haemostat 
(aqueous) solution may also have an effect on the rate of absorption. The presence of a 
hydrophobe such as SM in an aqueous solution results in disruption of the hydrogen 
bonding network between water molecules in the solution.  The inability of SM to form 
hydrogen bonds with water molecules in the aqueous haemostat results in the formation 
of a solvation or hydration shell around the SM molecule. This reduces the translational 
and rotational entropy of the water molecules and thus is unfavourable in terms of free 
energy within the system. Therefore, it is more thermodynamically favourable for SM 
to partition from the aqueous haemostat into the less aqueous SC. This could partially 
account for the increase in the amount and rate at which SM is absorbed into the skin 
layers. Increased penetration (resulting in increased lesion severity) has been observed 
in vivo following pre-wetting of the skin (Renshaw. 1947).  Interestingly, there was a 
correlation between enhancement of 
14
C-SM absorption and decreased recovery from 
the skin following FastAct
®
 and VitaGel™ treatment. One conceivable explanation is 
that the occlusive layer also reduces TEWL which eventually results in increased 
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hydration status of the SC. Conversely, this may provide a less thermodynamically 
favourable environment for lipophilic chemicals such as SM as the SC may become a 
more aqueous environment. Therefore, SM could preferentially partition into the 
receptor fluid rather than remaining within the SC, forming a reservoir as previously 
described (Hattersley, et al. 2008). This could potentially account for the enhanced 
dermal absorption (rate and extent) as well as the reduced skin recovery at 24 h post-
exposure. 
Interestingly, the penetration enhancement effect of FastAct
®
 and VitaGel™ 
was diminished when used in combination with TOP. Two components of TOP 
tetraglyme (tetraethylene glycol dimethyl ether) and oxime have been shown to degrade 
SM and reduce percutaneous absorption (Gordon et al 2002). Therefore, it is possible 
that TOP in combination with either FastAct
®
 and VitaGel™ is relatively efficacious in 
sequestering and detoxifying SM thus reducing the amount available for absorption.  
Significant increases in the rate and extent of absorption of 
14
C-SM were also 
observed for the chitosan-based haemostat, HemCon
®
. The other chitosan-based 
haemostat Celox™ was ineffective in reducing dermal absorption. The formulation of 
the products may have contributed to their poor performance as decontaminants as 
HemCon
® (bandage) and Celox™ (flake-like haemostat) could potentially form an 
occlusive layer, reducing evaporative loss of SM and thus increasing the dose available 
for dermal absorption. 
Chitosan-based haemostats promote coagulation via electrostatic interactions 
between positive-surface charges of the polysaccharide and the negative-surface 
charges of erythrocytes, resulting in aggregation of platelets and erythrocytes (Najjar, et 
al. 2004). Sulphur mustard has been shown to form degradation products which have a 
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positively-charged sulphonium ion and therefore may not bind to chitosan-based 
haemostats.  
Conclusions 
The Franz-type static diffusion cell system provides an in vitro method for measuring 
the ability of haemostats to decontaminant undamaged and damaged skin exposed to 
SM. The dermal absorption of SM is significantly increased in damaged skin. This 
study has identified a haemostat, WoundStat™, which can significantly reduce the 
dermal absorption of SM through both intact and superficially damaged porcine skin. 
This is most probably due to the high ion-exchange capacity and expanding nature of 
the smectite-based product which allows the adsorption and sequestration of SM in the 
interlayer space. The decontamination efficacy of WoundStat™ in this study is 
comparable with the military decontaminants fuller’s earth and M291.   
Recommendations for future work 
 WoundStat™ should be evaluated in an in vivo superficial wound pig model to test 
its ability to reduce SM lesion severity (Chapter 5) 
 The vapour-phase and contact desorption characteristics for the haemostats should 
be evaluated using gas-chromatography and mass-spectrometry. 
 Liquid-chromatography should be used for the speciation of 14C-labelled products 
permeating into the receptor fluid and those recovered from within the skin layers, 
to establish whether they are breakdown products or parent compound (SM).  
 The binding capacity for the haemostats should be assessed using an Enslinn test 
(Thorps. 1963) to measure the maximum binding capacity for SM.  
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Chapter 5  
The toxic effects of sulphur mustard (SM) 
when applied via superficial damaged skin 
with respect to early time-point sequelae of 
gross clinical signs, microscopic and gene 
expression changes and toxicokinetics 
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INTRODUCTION 
Superficial damage to the skin increases both the rate and total amount of SM 
penetrating through the skin in vitro (Chapter 4). Thus it is reasonable to postulate that 
removal of the upper skin layers (SC and epidermis) will also increase dermal 
absorption in vivo. This poses a substantial problem when treating or decontaminating 
individuals who have sustained injuries potentially contaminated with toxic chemicals 
such as SM. However, there are limited in vivo toxicokinetic data when SM is applied 
percutaneously (Clemedson, et al. 1963, Zhang and Wu. 1987, Tripathi, et al. 1995). 
No measurable SM was detectable in the circulation when applied percutaneously to 
undamaged pig skin (Brown and Rice. 1997, Zhang and Wu. 1987) . This study is the 
first to investigate the effect of skin damage on the toxicokinetics and distribution of 
14
C-SM. 
 Microscopic changes 24 h after SM exposure in undamaged pig skin are 
characterised by significant neutrophil infiltrate, collagen degeneration, severe capillary 
necrosis and congestion and microblister formation at the epidermal/dermal junction 
(Brown and Rice. 1997). Few definite structural changes have been described at early 
time points (6 h post exposure) in undamaged skin (Brown and Rice. 1997).  The 
removal of the SC and epidermis is likely to result in an increase in the rate of 
absorption but the effect on lesion progression is unclear. It would be reasonable to 
postulate that removal of the skin barrier is likely to result in a more severe injury. 
However, the primary cytotoxic target for SM is basal keratinocytes (Black, et al. 2011) 
and thus the removal of the layer may reduce the skin lesion. Gold et al. (1994) 
observed slight-moderate erythema and slight necrosis at 48 h post exposure when SM 
was applied to a full-thickness skin injury in hairless guinea pig. However, lesion 
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severity was based on clinical observations and was not histologically scored thus the 
microscopic effects are largely undefined. This study aims to identify early time-point 
microscopic changes associated with SM exposure to superficial damaged skin.  
Changes in gene expression following percutaneous exposure to SM have been 
reported for undamaged skin. Major gene categories activated by SM include apoptosis, 
inflammation, cell cycle regulation, cytoskeleton regulation and oncogenes (Vallet, et 
al. 2012, Gerecke, et al. 2009, Dillman III, et al. 2006, Sabourin, et al. 2004, Sabourin, 
et al. 2002, Rogers, et al. 2004). However, the use of a murine model in such studies 
may not accurately model percutaneous absorption of SM in human skin, which is of 
particular concern when investigating early time point expression changes. At present 
there are no published gene expression studies for SM-exposed damaged skin. The aim 
of this study is to establish the early time point (6 h) effects of SM toxicity to gain 
understanding of any additional mechanisms involved when SM is applied to 
superficially damaged skin.   
The domestic pig (Sus scrofa domestica) is an established model for evaluating 
SM-induced cutaneous lesions (Price, et al. 2009, Chilcott, et al. 2007, Reid, et al. 
2001). Sulphur mustard has been shown to induce microblistering in pig which is 
comparable with the blistering seen in humans (Brown and Rice. 1997, Mitcheltree, et 
al. 1989). Therefore the pig is considered a suitable model for characterising SM lesion 
development and SM distribution when applied to damaged skin. 
 
  
 
166 
 
Aims 
The purpose of this study was to investigate in vivo;  
 the toxicokinetics of SM when applied to superficially damaged skin  
 SM lesion development in damaged skin and 
 the effect of SM on relative gene expression in damaged skin.   
 
MATERIALS AND METHODS  
Full details of methods employed in this study are described in Chapter 2. Briefly, 
dermal absorption of 
14
C-SM through superficially damaged porcine skin was measured 
in vivo (Figure 5.1). The distribution of 
14
C-SM in the blood, dosing site and organs was 
measured by liquid scintillation counting. The SM lesion progression was measured 
using a range of biophysical instruments (LDI, SRS and TEWL) and lesion severity was 
assessed by histopathology. Sulphur mustard-induced changes in gene expression were 
investigated using oligonucleotide microarrays.   
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Figure 5.1: Experiment flow chart for characterisation of SM dermal toxicity and 
toxicokinetics when applied to superficially damaged skin. 
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RESULTS 
Gross clinical observations (digital photography):  
There were no remarkable visual changes seen over the 6 h study period for the control 
(undamaged skin) site and damaged skin site. 
Blanching at the exposure site was observed at 60 min for all animals (n=6; 
Table 5.1 and Figure 5.2a). Erythema was only observed in four out of six animals with 
the median time to observable erythema at the exposure site being 120 min (Table 5.1 
and Figure 5.2b). All animals developed an ulcerated area or skin erosion directly 
below the SM droplet with 6 h (Table 5.1 and Figure 5.2c). Oedema at the exposure site 
was noted in five out of six animals (median time; 60 min). 
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Figure 5.2: Representative photographs of skin exposure sites. 
Doughnut-shaped blanching (B) 1 h post challenge (a), development of erythema (E) 2 
h post challenge (b), and ulceration of skin (U) 5 h post challenge (c). 
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 Onset and occurrence of visual signs of dermal toxicity 
Time point (min) Erythema Blanching Ulceration Oedema 
Baseline (0/6) (0/6) (0/6) (0/6) 
60 (0/6) 6 (6/6) (0/6) 3 (3/6) 
120 3 (3/6) (1/6) (0/6) 2 (4/6) 
180 1 (3/6) (1/6) 2 (2/6) 1 (3/6) 
240 (3/6) (0/6) 3 (5/6) (3/6) 
300 (1/6) (0/6) (5/6) (2/6) 
360 (1/6) (0/6) 1(6/6) (2/6) 
 
Table 5-1: The time to onset and occurrence of gross clinical signs of toxicity 
following the application of SM to superficially damaged skin. 
Physical changes to the skin (oedema and ulceration) and skin colour changes 
(reddening; erythema or blanching) at the exposure site were scored by one individual. 
Numbers shown in italics indicates the number of animals first presenting with clinical 
sign. The numbers in brackets indicate number of animals presenting with this clinical 
sign at specific time points (n=6).  
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Biophysical Measurements  
Skin colour (skin reflectance spectroscopy)  
Values for all three CIELAB parameters (L*a*b*) for control (undamaged skin) 
showed no statistically significant change over the 6 h study period (Figures 5.3 – 5.5). 
Removal of the SC and epidermis resulted in statistically significant increases in skin 
redness and hue (p<0.05; Figures 5.4 and 5.5). Increases in skin hue (b*) correspond to 
increases in yellowness of the skin.   However, removal of the upper skin layers did not 
result in a statistically significant difference in skin brightness (L*) compared to control 
(untreated) sites (Figure 5.3). Liquid SM exposure did not result in statistically 
significant differences in skin colour or brightness parameters compared to unexposed 
damaged skin (Figures 5.3 – 5.5).  
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Figure 5.3: Skin lightness (expressed as the CIELAB colour scale parameter, L*) 
following superficial damage with and without exposure to SM compared to 
undamaged control site. 
All values are expressed as mean ± 95% confidence intervals (n=6).   
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Figure 5.4: Skin erythema (expressed as the CIELAB colour scale parameter, a*) 
following superficial damage with and without exposure to SM compared to 
undamaged control site. 
All values are expressed as mean ± 95% confidence intervals (n=6).  
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Figure 5.5: Skin hue (expressed as the CIELAB colour scale parameter, b*) 
following superficial damage with and without exposure to SM compared to 
undamaged control site. 
All values are expressed as mean ± 95% confidence intervals (n=6). 
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Skin surface temperature (infrared thermography) 
Skin surface temperature for control (undamaged skin) site remained constant 
throughout the 6 h study period. A statistically significant decrease in average skin 
surface temperature was observed following superficial damage to the skin (removal of 
SC and epidermis; Figure 5.6). However, there were no statistically significant 
differences in skin surface temperatures between the damaged skin treatment groups for 
the remainder of the study. Sulphur mustard exposure did not produce any obvious 
visual changes in the thermographs when applied to damaged skin (Figure 5.7).    
 
Cutaneous blood perfusion (laser Doppler imaging) 
Sulphur mustard significantly reduced dermal blood flow at the exposure site 120 min 
post application of 
14
C-SM. A statistically significant reduction in maximal perfusion 
unit was observed for the SM exposed site compared to the damaged (unexposed) site 
(p<0.05; Figure 5.8). This reduction in perfusion unit corresponded with the appearance 
of a distinct low flux area (blue-purple) (Figure 5.7).   
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Figure 5.6: Skin surface temperature following superficial damage with and without 
exposure to SM compared to undamaged control site. 
All values are expressed as mean ± S.D. (n=6). 
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Figure 5.7: Representative skin perfusion images (laser Doppler imaging) and 
thermographs (infrared thermography) following superficial damage with (SM) and 
without (damaged) exposure to SM. 
 
 
Skin perfusion Skin surface temperature
Perfusion units
Time (min) Damaged SM Damaged SM
Predamage
0
60
120
180
240
300
360
0 250 500 750 1000 20 25 30 35 C
 
178 
 
 
 
Figure 5.8: Maximum blood perfusion at treatment sites following superficial 
damage with and without exposure to SM expressed as perfusion units. 
All values are expressed as mean ± 95% confidence intervals (n=6). Dashed box 
represents a statistically significant difference between the treatment sites where * and 
** represent a p-value of <0.05 and <0.01, respectively.   
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Skin barrier integrity (transepidermal water loss) 
Superficial damage to the skin surface resulted in significantly increased TEWL 
compared to control (undamaged) values (Figure 5.9). However, SM exposure did not 
have a significant effect on TEWL during the six hour study period (Figure 5.9). A 
significant increase in TEWL over the six hour study period was observed for control 
(undamaged) skin (p<0.002; Figure 5.9). 
  
 
180 
 
 
 
Figure 5.9: Transepidermal water loss (TEWL) following superficial damage to skin 
with and without exposure to SM. 
Control (undamaged) TEWL values are also shown. All values are expressed as mean ± 
95% confidence intervals (n=6). 
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Radiometric Analysis 
Maximum blood concentrations of 
14
C derived from 
14
C-SM were attained 120 minutes 
post exposure (Figure 5.10).  Elimination kinetics derived from these data are 
summarised in Table. 5.2. The results shown are an estimation of the elimination 
kinetics, which appear to fit a first order kinetic model. Further time-points would be 
required to provide a more accurate estimation. 
Overall, 6.3 ± 1.6% of the applied dose of 
14
C-SM was recovered from the skin, 
skin surface swabs, organs and blood samples. The total amount of 
14
C derived from 
14
C-SM in the  systemic circulation was estimated from the 360 min blood sample and 
the estimated total blood volume, assuming even distribution of 
14
C throughout the 
blood.  The skin surface swabs and skin accounted for the largest percentage of 
14
C 
derived from 
14
C-SM recovered (45.9 ± 9.6% and 35.3 ± 7.5%, respectively; Figure 
5.11).  
The amounts of 
14
C derived from 
14
C-SM recovered from internal organs (6 
hours post-challenge) totalled 1327 ± 297 ng. Predominant distribution was in the 
kidney, followed by liver and small intestine when the data were expressed as ng of 
14
C-SM per g of organ weight (Figure 5.12).  
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Figure 5.10: Semi-logarithmic plot of blood concentration against time for 
calculation of elimination kinetic parameters of 
14
C (derived from 
14
C-SM) from 
whole blood following application of 10 µL droplet of 
14
C-SM via superficially 
damaged skin. 
All values are expressed as mean ± S.D. (n=6). Kinetic parameters were subsequently 
calculated using equation described in Chapter 2. 
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Elimination Parameters 
T½ (min) 425 ± 60 
Cmax (ng ml‐
1
) 60.8 ± 64 
Slope (pg ml‐
1
 min‐
1
) ‐64.7 ± 9.0 
Kel (pg ml‐
1 
min‐
1
) 149 ± 21 
C0 (ng ml‐
1
) 67.5 ± 7.0 
Vd (L) 190 ± 22 
D (mg) 11.5 ± 0.5 
Table 5-2: Elimination kinetic parameters following 
14
C-SM challenge via damaged 
skin. 
Values are expressed as mean ± S.D. of n=6 animals and are derived from linear 
regression analysis of a semi-logarithmic plot of whole blood concentration against 
time. Equations used as described in Chapter 2. Half life (T½) was calculated from the 
Equation 2.8. The value of C0 was calculated as the y-intercept of the line of best fit 
(and so is equal to the theoretical whole blood concentration at time of challenge). The 
peak concentration (Cmax) was the largest concentration measured directly from whole 
blood samples. The elimination constant (Kel) was calculated by multiplying the slope 
by -2.303 (Equation 2.9). The apparent volume of distribution (Vd) was calculated from 
Equation 2.10. The apparent dose (“D”) was subsequently calculated from Equation 
2.11, using Vd and Cmax values; the actual applied dose was 11.5 mg. 
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Figure 5.11: Recovery of 
14
C derived from 
14
C-SM from skin surface swabs, skin, 
blood and organs expressed as a log percentage of the total amount of 
14
C recovered. 
Individual values (n=6) are shown in addition to the mean (central line; n=6) and S.D. 
(outermost lines). 
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Figure 5.12: Recovery of 
14
C derived from 
14
C-SM in internal organs expressed as ng 
(SM) per g (organ weight). 
All values are expressed as mean ± S.D. (n=6). 
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Histology 
The occurrence and severity of histopathological changes are summarised in Table 5.3. 
Histological examination confirmed that the use of a dermatome achieved complete 
removal of the SC and epidermis (Figure 5.13 and 5.14). The remaining intact 
epithelium (at the edge of the treatment site) was histologically normal, as were the hair 
follicles and other adnexal structures (Figure 5.13). All control (intact skin) slides 
appeared normal.  
There were no significant microscopic changes between the unexposed and SM-
exposed damaged skin sites. Both groups showed mild, perivascular, 
polymorphonuclear neutrophil (PMN) infiltrate in the dermis as well as increased 
PMNs within the capillary lumen (Figure 5.14 – 5.16). 
The changes noted in both the SM-exposed and unexposed damaged skin sites 
were consistent with an acute, inflammatory response, secondary to the tissue damage 
caused by the dermatome. The changes included escharification, variable haemorrhage, 
and a mild, perivascular to diffuse, PMN infiltrate with degenerate PMNs on the 
exposed, damaged surface. Hyper-eosinophilic, dermal collagen (degenerate) at the 
surface of the exposed dermis was also present.   
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Lesion 
Treatment Group 
Control 
(n=6) 
Damaged 
(n=6) 
Damaged + SM 
(n=6) 
Surface and follicular 
keratinocyte 
degeneration/necrosis 
Occurrence 0 0 0 
Severity Normal (6) Normal (6) Normal (6) 
Subepidemal 
separation/vesiculation 
Occurrence 0 0 0 
Severity Normal (6) Normal (6) Normal (6) 
Blood vessel dilation-
dermal 
Occurrence 0 2 4 
Severity Normal (6) 
Normal (4) 
Minimal (2) 
Normal (2) 
Minimal (4) 
Perivascular to diffuse, 
neutrophilic cell 
infiltrate-dermal 
Occurrence 0 6 6 
Severity Normal (6) Mild (6) Mild (6) 
Sero-cellular crusting- 
surface 
(Escharification) 
Occurrence 0 6 6 
Severity Normal (6) 
Mild  (1) 
Moderate (5) 
Minimal (2) 
Mild  (4) 
Table 5-3: Occurrence and severity of histopathological findings for control 
(untreated) and damaged skin with and without SM exposure. 
Lesions were histopathologically scored where; marked> moderate> mild> minimal> 
normal indicates the severity of the lesion.  Number in brackets indicates number of 
animals in each severity group (n=6). 
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Figure 5.13: Histopathology of superficially damaged skin showing junction of intact 
and damaged epidermis. 
Escharification (*) and a mild, PMN infiltrate are seen. The adjacent, intact epidermis 
is normal (Ep). The haematoxylin and eosin stained section was viewed by light 
microscopy with bright field illumination at 20x zoom objective lens. 
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Figure 5.14: Histopathology of superficially damaged skin showing complete loss of 
epidermis and replacement with an eschar and exposed, dermal collagen (*). 
A mild, PMN infiltrate (arrow) is present associated with superficial blood vessels 
(Cap). The haematoxylin and eosin stained section was viewed by light microscopy with 
bright field illumination at 20x zoom objective lens. 
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Figure 5.15: Histopathology of superficially damaged skin showing epidermal loss, 
marked surface haemorrhage (Haem) with fibrin and cellular debris. 
Neutrophilic cell infiltrate is also shown (arrow). The haematoxylin and eosin stained 
section was viewed by light microscopy with bright field illumination at 10x zoom 
objective lens. 
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Figure 5.16: Histopathology of superficially damaged skin following SM exposure. 
Partial to complete loss of the epidermis observed. Neutrophilic cell infiltrate are 
present (arrow). The haematoxylin and eosin stained section was viewed by light 
microscopy with bright field illumination at 10x zoom objective lens.     
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Genomic Analysis 
Relative mRNA levels for gene transcripts for the different treatment sites were 
compared to identify up-regulated or down-regulated genes (as described in Chapter 2). 
Differential expression was defined as a false discovery rate (FDR) corrected p value 
<0.05 and ≥ 2-fold change in relative mRNA levels. Approximately 1.4% of total 
transcripts (43663 probes) were found to have an altered expression pattern. Damaged 
(unexposed) skin had 397 transcripts whose relative mRNA levels were statistically 
different to control (untreated) skin. Sulphur mustard-exposed damaged skin had 206 
transcripts whose relative mRNA levels statistically significantly differed to control 
(untreated) skin. Of these differentially expressed transcripts, 136 were shared by both 
unexposed and SM exposed damaged skin. 
There were 118 differentially expressed transcripts in SM treated animals 
(unexposed vs. SM-exposed, damaged skin). Sequences that did not match any genes 
currently registered on GenBank or Unigene were listed as unknowns. Sequences that 
did not have a characterised gene product (based on GenBank Accession number and 
Unigene identifier) were excluded from further in silico validation analysis. However, a 
full list of differently expressed gene transcripts (≥1.5-fold change); including those 
with uncharacterised or predicted gene products is provided in Appendix 1 (Table 2 and 
3). From the genes that met these criteria (≥2-fold change), 1 gene transcript was found 
to be up-regulated (Table 5.4) and 36 gene transcripts were found to be down-regulated 
(Table 5.6).  
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Table 5-4: Differentially up-regulated gene transcripts in the skin following 
14
C-SM 
percutaneous challenge via superficially damaged skin. 
Fold changes were determined by the mean expression ratio of SM exposed: unexposed 
damaged skin. Statistically significance differences in relative gene expression were 
identified by parametric t-test with a Benjamini and Hochberg False Discovery Rate 
(FDR) multiple-testing correction applied. Statistical significance was predefined as 
corrected p-value ≤0.05.  
  
Gene product 
GenBank accession 
number 
Fold 
change 
Corrected p-
value 
Thioredoxin interacting protein NM_001044614 2.2 0.0002 
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Gene product 
GenBank 
accession number 
Fold 
change 
Corrected p-
value 
S-antigen (arrestin) NM_214079 6.6 0.01 
methionine adenosyltransferase I, 
alpha 
NM_001243187 6.6 0.01 
Dual oxidase 2 NM_213999 4.5 0.01 
Uroplakin 2 NM_214012 4.4 0.002 
Fc fragment of IgA, receptor for NM_001123112 4.3 0.0007 
Adrenergic alpha-1D receptor NM_001123073 3.9 0.008 
Chromogranin B NM_214081 3.9 0.04 
Nitric oxide synthase 2 (inducible) NM_001143690 3.5 0.01 
Mucin 13, cell surface associated NM_001105293 3.5 0.006 
Progesterone receptor membrane 
component 2 
NM_001097521 3.5 0.03 
Prostaglandin G/H synthase 2 NM_214321 3.4 0.002 
immunoglobulin superfamily, member 
1 
AK349537 3.4 0.004 
outer dense fibre protein 2-like EW159310 3.2 0.02 
prostaglandin-endoperoxide synthase 
2 (prostaglandin G/H synthase and 
cyclooxygenase) 
NM_214321 3.2 0.002 
NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 8, 19kDa 
AK236557 3.1 0.0003 
albumin NM_001005208 2.9 0.009 
PR domain containing 10 AK239583 2.9 0.004 
progestin and adipoQ receptor family 
member VIII 
NM_213740 2.7 0.01 
adenosine monophosphate deaminase 
1 
NM_001123076 2.7 0.0003 
retrotransposon-like 1 NM_001134358 2.6 0.0005 
gastrin NM_001004036 2.6 0.01 
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Table 5-5: Differentially down-regulated gene transcripts in the skin following 
14
C-
SM percutaneous challenge via superficially damaged skin. 
Fold changes were determined by the mean expression ratio of SM exposed: unexposed 
damaged skin. Statistically significance differences in relative gene expression were 
identified by parametric t-test with a Benjamini and Hochberg False Discovery Rate 
(FDR) multiple-testing correction applied. Statistical significance was predefined as 
corrected p-value ≤0.05.  
  
pancreatic lipase-related protein 1 NM_001142897 2.5 0.004 
steroid sulfatase (microsomal), 
isozyme S 
DN129273 2.5 0.02 
CHD3-like protein EU780792 2.5 0.003 
MARC 2PIG Sus scrofa cDNA 5', 
mRNA sequence 
BF190050 2.3 0.02 
multicatalytic proteinase subunit K AY610111 2.3 0.002 
hepatocyte nuclear factor 4, alpha NM_001044571 2.3 0.0002 
WD repeat domain 46 AK348376 2.2 0.007 
cytochrome P450 2C33 NM_214414 2.2 0.008 
tumour necrosis factor, alpha-induced 
protein 8-like 2 
NM_001204370 2.2 <0.0001 
annexin A9 NM_001243348 2.2 <0.0001 
carnitine palmitoyltransferase 1B 
(muscle) 
NM_001007191 2.1 0.004 
MARC 2PIG Sus scrofa cDNA 5', 
mRNA sequence 
BI360438 2.0 0.03 
creatine kinase, muscle NM_001129949 2.0 0.02 
kinesin family member C1 AK233842 2.0 0.03 
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DISCUSSION 
This study has demonstrated that direct application of SM to superficial wounds results 
in rapid onset of erythema and ulceration and a significant decrease in perfusion at the 
skin exposure site. The pig is an established model for investigating the effects of SM in 
vivo (Price, et al. 2009, Chilcott, et al. 2007, Renshaw. 1946, Reid, et al. 2001). 
However, use of this model has the following limitations. 
 
Relevance of animal model 
The human dermal response to SM is unique in the fact that currently used animal 
models do not typically produce the classical gross, bullous blister (Renshaw. 1946, 
Mcadams. 1956). This could potentially mean that decontaminants that are effective in 
animal models may not have sufficient efficacy in humans. However, dermal/epidermal 
separation resulting in microblistering has been observed in porcine skin in response to 
SM exposure (Brown and Rice. 1997, Mitcheltree, et al. 1989). As previously described 
the structure of pig skin closely resembles that of human skin (Bartek, et al. 1972) and 
penetration rates of SM through intact skin in vitro are akin to human skin (Reifenrath, 
et al. 1991). Therefore, the pig provides a suitable model for decontaminant efficacy 
testing.      
Length of study period 
Previous studies have followed lesion development over a considerably longer time 
period (>24 h) than this study (Graham, et al. 2000, Reid, et al. 2000). This study 
investigated early time point (up to 6 h) effects of SM which negated the need to 
recover the animals. The use of terminal anaesthesia was considered a substantial 
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refinement to experimental animal welfare.  Previous studies reporting histopathology 
conducted at early time points (≤ 6 h) following SM exposure via undamaged skin 
showed few definite structural alterations (Brown and Rice. 1997). However, the time 
course for cutaneous lesion progression following SM exposure via superficially 
damaged skin was unknown. Therefore, the absence of significant differences between 
the unexposed and SM-exposed damaged skin observed in this study are consistent with 
previous investigations.  
Influence of SM-induced systemic effects on unexposed skin  
As SM was applied to damaged skin, a damaged (unexposed) skin site from each 
animal served as the untreated control for differential gene expression analysis and 
histopathology. This has the potential limitation of being influenced by SM via the 
systemic circulation (Elsayed and Omaye. 2004). However, there was no detectable 
14
C-SM present at this site (damaged, unexposed skin), although it is feasible that SM 
may have caused systemic inflammatory changes which may have altered dermal gene 
expression at unexposed sites. Use of an unexposed site on the same animal is 
consistent with previous studies investigating SM effects on cutaneous gene expression 
where systemic effects due to dermal SM exposure were not reported (Dillman III, et al. 
2006, Rogers, et al. 2004).  
Differences in microarray slide annotation 
A manufacturing fault with the microarray gasket slides resulted in some arrays having 
to be repeated using a new batch of oligonucleotide microarray slides. However, the 
new batch of slides was subsequently identified as a different technology during 
analysis using GeneSpring software. This required a custom technology file to be 
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created and translation from one slide version to another to allow sample comparison 
between the different versions. However, differences in annotations between the two 
versions could have resulted in some probes becoming redundant. This may have 
impacted on the number or identity of genes that were differentially expressed 
following SM exposure. The effect of translating the data between different slide 
versions was assessed by comparing the differentially expressed gene list using each 
version of the array slide as the primary template for translation of the other slide 
version. Fold-change and statistical analysis were then conducted on both data sets. No 
differences in the identity or number of genes differentially expressed were found 
between the data sets. 
Quantification of gene expression changes 
Quantitative real-time polymerase chain reaction (qRT-PCR) is considered the “gold 
standard” for validation of results obtained from microarray experiments (Wang, et al. 
2006). Due to time constraints, qRT-PCR could not be performed on gene transcripts 
identified as differentially expressed using the microarray platform. Therefore, the 
reported differences in gene expression between treatment groups are relative and use 
of qRT-PCR would be desirable to quantify and validate gene transcript expression 
changes reported in this Thesis.  
Speciation of 
14
C radiolabelled products 
As discussed earlier (Chapter 4) the use of liquid scintillation counting to quantify the 
amount of 
14
C-SM does not allow for speciation of the 
14
C-radiolabel isotope. 
Therefore, this approach assumes that the amount of 
14
C-SM present is equivalent to the 
amount of 
14
C isotope measured. It has been previously shown that SM is conjugated or 
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hydrolysed in vivo (Black, et al. 1993, Capacio, et al. 2004) so the 
14
C isotope could be 
attributed to a conjugate or hydrolysis product. Speciation of radiolabelled compounds 
using chromatography (gas or liquid) and mass spectrometry would determine if these 
compounds were the SM parent molecule or a hydrolysis product/conjugate. These 
techniques have been previously used to identify SM metabolites (Noort, et al. 2004, 
Noort, et al. 2000). Although these limitations should be considered when interpreting 
and extrapolating data to human SM injuries they do not negate the usefulness of this 
model and the findings described below.  
Removal of the skin barrier layer (SC and epidermis) greatly reduced the lag 
time between SM challenge and the appearance of advanced signs of exposure 
compared to published data for undamaged skin (Smith, et al. 1997, Graham, et al. 
2000, Reid, et al. 2000). Skin erosions or ulcerations were observed in all animals (4 h 
median time) within 6 h compared to previously reported delay of up to 24 h. Thus, one 
speculative conclusion from this study is that the latency period seen for SM injuries 
could be in part due to delayed absorption and not exclusively due to delays caused by 
cellular processes described in Chapter 1, such as DNA damage or inflammatory-
mediated responses (Papirmeister, et al. 1985, Arroyo, et al. 2001a). 
Blanching of the skin surrounding the SM droplet was noted in all animals 
within 60 min of exposure. Maximal blood flow, as measured by LDI, in the skin was 
also significantly reduced following SM exposure. Reduced perfusion at the exposure 
site could be attributable to either SM-induced necrotic capillary congestion or 
vasoconstriction of the blood vessels in the dermis. Histopathological analysis revealed 
capillary dilation and congestion of subepidermal capillaries with perivascular 
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inflammatory cell infiltrate. This is consistent with previous studies which also 
observed significantly reduced skin perfusion at the lesion site (Brown, et al. 1998).    
Sulphur mustard has been shown to cause significant changes in vascular 
permeability in a dose-dependent manner (Zhang, et al. 1995b). It has been postulated 
that this may be mediated by SM-induced prostaglandin release (Zhang, et al. 1995b). 
Oedema at the exposure site was also observed in two thirds of the animals. Therefore, 
SM may cause inflammatory-mediated, extra-vascularisation of fluid resulting in 
localised oedema and reduced perfusion at the exposure site. There was evidence of 
oedema in the histology sections of SM exposed skin although, the SM-exposed, 
damaged skin was not overtly different to the unexposed damaged skin.     
Skin reflectance spectroscopy has been previously used to assess SM and 
thermal burn progression and severity (Chilcott. 2000). Removal of the SC and 
epidermis resulted in statistically significant increases in both skin redness (a*) and hue 
(b*). The increase in the two parameters can be attributed to punctate haemorrhage and 
inflammation (skin redness) and sero-cellular crusting or escharification (skin 
yellowness) following the removal of the upper skin layers. These observations were 
confirmed by histopathology. Sulphur mustard did not have a statistically significant 
effect on CIELAB (L*a*b*) parameters compared to damaged (unexposed) skin. This 
was unexpected as erythema was visible in half the animals at 2 h post challenge. 
Previous studies have observed statistically significant changes in skin redness (a*) at 1 
h post challenge (Chilcott. 2000). However, removal of the upper skin layers resulted in 
the unexposed skin becoming erythematous. Therefore, although a qualitative 
difference in skin redness was observed between the SM-exposed and unexposed skin it 
was not deemed statistically significant in terms of a* value. 
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Transepidermal water loss has been previously been used as a measure of skin 
barrier function (Chilcott. 2000). Unsurprisingly, removal of the upper (100 µm) skin 
layers (equating to loss of SC and epidermis) with a dermatome resulted in significantly 
increased TEWL rates compared to undamaged control values. Over the 6 h study 
period no statistically significant differences were observed between either of the 
damaged groups regardless of SM exposure. This is consistent with findings from 
previous studies using undamaged skin porcine models (Chilcott. 2000). A significant 
increase in TEWL was observed for the control (untreated) skin (p<0.002). This may 
possibly be attributed to combined effects of constant air flow (>0.5 m s
-1
) and low 
humidity within the chemical fume hood resulting in an increase water gradient 
between the skin and the surrounding air. Alternatively, it could be due to diurnal 
variation or changes in skin physiology resulting from cumulative effects of 
anaesthesia.  
Histopathology confirmed that the use of an electric dermatome achieved 
complete removal of the SC and epidermis. One concern with skin from the same 
animal serving as a control was that SM could induce a systemic inflammatory response 
which could affect the surrounding dorsal skin. However, no significant microscopic 
changes in control (untreated) gross skin structure were observed. There were no 
significant difference in microscopic findings between SM-exposed and unexposed 
damaged skin groups. This was unexpected as there were significant differences in both 
blood perfusion and the amount of 
14
C derived from 
14
C-SM within the skin between 
the two sites. However, the presence of a few definite structural alterations at 6 h post 
exposure is in agreement with previous SM studies using undamaged skin (Brown and 
Rice. 1997, Greenberg, et al. 2006). Work by Brown et al. (1997) also observed 
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perivascular PMN infiltrate, seen in this study. Focal vacuolation and limited pyknotic 
nuclei in basal keratinocytes have also been reported (Brown and Rice. 1997, 
Greenberg, et al. 2006, Kan, et al. 2003). Removal of the epidermis in this study would 
prevent this being observed and the acute inflammatory response resulting from the 
initial tissue damage (removal of skin layers) may mask any additional 
histopathological changes caused by SM at this early time point.   
Radiolabelled (
14
C) SM was rapidly absorbed through superficial damaged skin 
into the circulation. Total recovery from the skin, skin surface swabs, blood and internal 
organs samples equated to 6.2 ± 1.6% of the applied dose. This corresponds to the 
percentage dose penetrated in the ex vivo isolated perfused porcine skin flap (IPPSF) 
model at a comparable time-point (Riviere, et al. 1995). The largest proportion of 
14
C 
derived from 
14
C-SM recovered 6 h post-challenge was from the skin surface swabs and 
the skin at the exposure site (3.5 ± 1.6% and 2.2 ± 0.5% of applied dose, respectively). 
Once absorbed, the majority of the 
14
C resided within the skin or blood which is in 
agreement with previous studies (Hambrook, et al. 1992). At early time-points, a large 
fraction of SM within the skin is still mobile but there is debate as to whether it is 
conjugate/hydrolysis product (Hambrook, et al. 1992, Spoo, et al. 1995) or the parent 
compound, SM (Hattersley, et al. 2008). 
Toxicokinetics of SM in the blood appeared to fit a first-order elimination 
model. This was in agreement with Zhang and Wu (1987) for SM exposure via 
subcutaneous route. Blood concentrations of 
14
C derived from 
14
C-SM peaked at 120 
min post-exposure with a calculated half-life of 460 ± 62 min. However, the previous 
study did not detect any SM in the blood via the percutaneous route (Zhang and Wu. 
1987). This could be attributed to the difference in absorption between superficially 
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damaged and undamaged skin. However, the previous study quantified SM by flame 
photometric gas chromatography (GC-FP) detection where as this study used liquid 
scintillation counting to quantify 
14
C-isotope. Thus the 
14
C-isotope detected could be a 
conjugate or hydrolysis product of SM and not intact SM. Alternatively GC-FP may not 
be sensitive enough to detect these changes.   
The distribution of radioactivity
 
within internal organs tends to suggest that the 
main route of excretion is in the urine followed by the faecal route. Accumulation of 
radiolabelled SM in the kidneys and small intestine has also been shown in rodent 
models (Hambrook, et al. 1992).  Hepatic metabolism of SM has previously been 
documented (Davison, et al. 1961) and both conjugates and hydrolysis products of SM 
have previously been detected in the urine of exposed subjects or animals (Black, et al. 
1992, Maisonneuve, et al. 1993).  
The aim of the microarray studies was to identify potential genes of interest 
affected by SM exposure which warrant further investigation. Overall, only one gene 
transcript, thioredoxin interacting protein (TXNIP), met the 2-fold increase in relative 
gene expression threshold following SM exposure. However, seven out of the top ten 
up-regulated gene transcripts (≥ 1.5-fold change) were TXNIP. Thioredoxin interacting 
protein (also known as Vitamin D3 up-regulated protein 1) is a pro-apoptotic member 
of the α-arrestin family (Kim, et al. 2012, Patwari, et al. 2009) but has not previously 
been identified as being up-regulated following SM exposure (Dillman III, et al. 2006, 
Sabourin, et al. 2004, Rogers, et al. 2004). Thioredoxin interacting protein is thought to 
be involved in the regulation of keratinocyte differentiation (Zhou, et al. 2010, 
Champliaud, et al. 2003). Sulphur mustard is known to promote keratinocyte terminal 
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differentiation via intracellular calcium influx which promotes cornified envelope 
development (Rosenthal, et al. 1998, Popp, et al. 2011, Eckert, et al. 1993). 
Thioredoxin interacting protein has also been shown to be involved in NLRP3 
inflammasome activation and subsequently interleukin-1beta (IL-1β) production (Zhou, 
et al. 2010) and has been shown to be induced by oxidative stress mediated by an influx 
of calcium into the cytoplasm (Kim, et al. 2012). Interleukin-1β mRNA levels have 
been shown to be increased as early as 6 h post SM exposure (Sabourin, et al. 2000, 
Vallet, et al. 2012, Sabourin, et al. 2002). Therefore, TXNIP could provide a potential 
therapeutic target for reducing inflammation caused by SM exposure and warrants 
validation and further investigation.  
Down regulated gene transcripts indentified were mostly involved in 
inflammatory/immune response, oxidative stress response, cell signalling or cell 
differentiation/proliferation. Dual oxidase 2 is a member of the NADP oxidase family 
and has NADPH/Ca
2+
-dependent hydrogen peroxide-generating activity in the airway 
epithelium (Ameziane-El-Hassani, et al. 2005). 
Prostaglandin G/H synthase 2 also known as cyclooxygenase-2 (COX-2) has 
been previously been shown to be up-regulated in response to SM exposure and is 
involved in the acute phase inflammatory response caused by SM (Gerecke, et al. 2009, 
Wormser, et al. 2004) which is in direct contrast to the findings of this present study. 
The previous studies investigated the effects at later time points to this study. Therefore, 
it is conceivable that SM-induced COX-2 expression may be time-dependent.  
Calcium plays a key role in SM-induced cytotoxicity and terminal 
differentiation of keratinocytes (Rosenthal, et al. 1998).  Chromogranin B interacts with 
inositol 1,4,5-triphosphate receptors (IP3R) to modulate Ca
2+
 release from intracellular 
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stores and subsequent Nuclear Factor κB (NF κB) activity (Heidrich, et al. 2008). 
Calcium via CaM can also induce intrinsic mitochondrial pathways of apoptosis 
(Simbulan-Rosenthal, et al. 2006).  Calcium and CaM are also thought to induce nitric 
oxide production via nitric oxide synthase (Spratt, et al. 2007). 
Relative mRNA expression of inducible nitric oxide synthase (iNOS) was found 
to be down-regulated following SM exposure. This is in disagreement with other 
published studies where increases in iNOS function following SM exposure were 
observed (Gao, et al. 2008, Steinritz, et al. 2009). However, in a keratinocyte wound 
model, SM exposure was found to decrease iNOS expression (Ishida, et al. 2008). 
Nitric oxide (NO), produced by iNOS, has a role in wound healing (Schwentker, et al. 
2002) and SM-induced iNOS inhibition has been attributed to delayed wound healing 
(Ishida, et al. 2008). This apparent disagreement between studies could be dependent on 
SM dose, the use of immortalised keratinocytes versus normal human epithelial 
keratinocytes or due to the relative increase in iNOS as a result of wounding.  
Interestingly, SM-induced down-regulation of gene transcripts which do not 
appear to have a defined role in the skin was observed. One potential explanation is that 
the dermal layers contain a large number of cells with distinct functions e.g. vascular 
endothelial cells in papillary capillaries or neutrophils. Microarrays were performed 
with total RNA pooled from many cell types in whole skin and reflect the global 
response to SM in the tissue. Therefore, SM-induced down-regulation of adrenergic 
alpha-1D receptor observed could be associated with vascular cells in the sample and 
not directly involved in keratinocyte response to SM. Likewise down-regulation of IgA 
Fc receptors is likely to be associated with the PMN infiltrate observed in the dermis.  
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Uroplakin II (UPK2) is a membrane-associated protein that is critical for barrier 
function in the urothelium. Uroplakin II has also been associated with the 
transcriptional regulator, interferon regulatory factor-1 (IRF-1), which promotes 
terminal cell differentiation in the urothelium (Varley, et al. 2008). Interferon 
regulatory factor-1 is believed to have a role in the regulation of cornified envelope 
genes during keratinocyte terminal differentiation (Nakanishi, et al. 1997) and DNA 
damage-induced apoptosis (Tamura, et al. 1995). Aberrant expression of IRF-1 has 
been attributed to the development of bullous pemphigoid which is characterised by 
subepidermal blistering (Odanagi, et al. 2004). Therefore, UPK2 may have an 
additional role in skin epithelium barrier function that has yet to be characterised.  
S-antigen, a member of the arrestin/β-arrestin protein family has been 
previously identified as down-regulated in response to SM exposure (Rogers, et al. 
2004). This protein is normally associated with regulation of light activated 
phosphorylated rhodopsin (Brown, et al. 2010). S-antigen may also be involved in 
regulation of oxidative stress and inflammation although its role has yet to be fully 
elucidated (Brown, et al. 2010, Khurana, et al. 2008). Mucin 13 is a membrane-bound, 
O-linked glycoprotein localised in the epithelium (Singh and Hollingsworth. 2006). 
Whilst a defined function for mucin 13 in the skin is currently unknown, other members 
of the mucin family are associated with cell adhesion and immune modulation (Rounds, 
et al. 1999).   
Lack of protein and gene function characterisation is a major disadvantage of 
using the pig compared with the mouse. However, pig skin provides a more accurate 
representation of human skin in terms of dermal absorption compared to mouse skin 
(Bartek, et al. 1972). Therefore, further work to characterise the biological function of 
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porcine genes would be advantageous and could expand the use of the pig to study the 
genomic effects of SM. However, it is worth noting that when SM is applied to 
damaged skin, differentially expressed genes are predominantly down regulated in the 
skin. This is in contrast with the predominant upregulation of gene expression in the 
skin in response to SM applied to undamaged skin at similar time points (Gerecke, et al. 
2009). Moreover, it is unlikely the predominate down regulation observed is non-
specific as the expression of house-keeping genes such as calnexin and β-catenin was 
unaffected by SM exposure. Therefore, further investigations are needed to establish if 
there are differences in SM-induced toxicity between damaged and undamaged skin, to 
allow further development of medical countermeasures for SM-exposed damaged skin 
injuries.  
 
Conclusions  
The pig is an established model for investigating the progression of SM cutaneous 
lesion in vivo. This study has shown that removal of the SC and epidermis reduces the 
lag time between SM exposure and the appearance of advanced signs of toxicity. 
Sulphur mustard also significantly reduced perfusion rates at the exposure site within 6 
hours. However, no significant changes in skin colour, barrier function to water loss, or 
skin surface temperature were observed between SM-exposed and unexposed damaged 
skin. Furthermore, no significant microscopic changes were observed in SM-exposed 
skin compared to unexposed skin. Damaged associated with removal of the upper skin 
layers could potentially account for this. Sulphur mustard induced changes in relative 
mRNA levels in gene transcripts were primarily associated with oxidative stress, 
inflammatory response and keratinocyte terminal differentiation. 
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Recommendations for future work 
 This pig model should be used to assess the decontaminant efficacy of 
WoundStat™ in vivo (Chapter 6). 
 Liquid-chromatography should be used for the speciation of sample containing 
14
C-isotope to determine whether they contain the parent compound (SM) or a 
conjugate/hydrolysis product.  
 Relative changes in mRNA levels observed using microanalysis should be 
quantified and validated using qRT-PCR. 
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Chapter 6  
WoundStat™ is effective in reducing SM-
induced toxicity when applied to superficially 
damaged skin in vivo 
  
 
210 
 
INTRODUCTION 
WoundStat™ has been shown to significantly reduce the penetration of 14C-SM through 
superficially damaged skin in vitro (Chapter 4). However, superficial damage to the 
skin has been shown to reduce the time to appearance of advanced signs of toxicity and 
allows rapid systemic distribution in vivo of SM (Chapter 5). Changes in blood flow 
following SM exposure were apparent at an early time point and this may provide a 
useful measure by which the efficacy of WoundStat™ can be measured. Changes in 
relative expression of a number of genes including: iNOS, TXNIP and DUOX2 were 
also observed. The down-regulation in gene expression observed for iNOS was in 
agreement with previous in vitro wounded skin studies (Ishida, et al. 2008). However, 
other in vivo studies using undamaged skin have observed an increase in iNOS gene 
expression following SM exposure (Steinritz, et al. 2009). This suggests that the 
combined physical injury (removal of upper skin layers) and SM exposure may result in 
gene expression changes which have not be previously described by other in vivo 
studies. Therefore, SM therapeutic targets identified for undamaged skin may not be 
suitable for damaged skin.  
A number of in vivo studies have evaluated decontamination of SM using 
undamaged skin (Chilcott, et al. 2007, Taysse, et al. 2007, Taysse, et al. 2011, 
Wormser, et al. 2002). However, there is only one published study examining the 
efficacy of decontamination regimes in vivo when SM is applied to hairless guinea pigs 
via damaged skin (Gold, et al. 1994). Furthermore, this study used limited endpoints, 
namely gross clinical observations at 48 h, by which to determine the efficacy of 
decontamination. Therefore, conclusions drawn solely on these data are likely to be 
relatively subjective.  
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Whilst both the pig and the hairless guinea-pig are thought to provide good animal 
models of percutaneous penetration (Barbero and Frasch. 2009, Simon and Maibach. 
2000) the smaller blood volume of the guinea pig would prevent extensive acquisition 
of blood samples. This would limit the number of samples available for radiometric and 
genomic analyses. The pig has been shown to be a suitable animal model for 
characterising SM-induced cutaneous lesions (Chapter 5). Therefore, this model was 
used to evaluate the efficacy of WoundStat™ as a decontaminant.       
 
Aims 
The purpose of this study was to evaluate the decontamination efficacy of WoundStat™ 
in vivo. The efficacy of WoundStat™ was assessed by measuring;  
 the toxicokinetics and distribution of 14C-SM,  
 SM lesion development and, 
 the effect of WoundStat™ decontamination of SM-exposed skin on gene 
expression. 
 
MATERIALS AND METHODS 
Full details of methods employed in this study are described in Chapter 2. Briefly, the 
efficacy of WoundStat™ to reduce the severity of SM lesions and dermal absorption of 
14
C-SM through superficially damaged porcine skin was measured in vivo (Figure 6.1). 
A 2 g bolus of WoundStat™ was applied to two damaged skin treatment sites: SM-
exposed and unexposed at 30 s post-challenge. WoundStat™ remained in situ for 60 
min before removal and was retained for radiometric analysis. The decontaminant was 
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removed for two reasons; (i) to allow biophysical measurements to be taken and (ii) to 
simulate a potential real-life scenario in which any haemostat/decontaminant would be 
removed once an appropriate medical facility was reached.  
As described for Chapter 5, the distribution of 
14
C derived from 
14
C-SM (blood, 
dosing site and organs), lesion severity and progression and genomic changes were 
measured to evaluate decontamination efficacy of WoundStat™.  
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Figure 6.1: Experiment flow chart for evaluating WoundStat™ as a decontaminant 
against SM applied to superficially damaged skin. 
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RESULTS 
Gross clinical observations (digital photography) 
There were no remarkable visual changes seen over the 6 hour study period for the 
control (undamaged skin) site or damaged skin sites with and without WoundStat™. 
WoundStat™ reduced the appearance of skin blanching at the exposure site: 2 animals 
exhibited blanching at 60 min (Table 6.1) compared to all of the animals not receiving 
decontamination (n=6; Chapter 5, Table 5.1).  
Erythema was observed in three out of six animals with the median time to 
observable erythema at the exposure site being 120 min (Table 6.1 and Figure 6.2). In 
two animals the erythematous area was surrounded by ring-like blanching. One animal 
had a considerable amount of dried blood at the exposure site and thus it was difficult to 
observe blanching or any additional erythema (Figure 6.2).  
WoundStat™ also prevented the appearance of ulceration at the exposure site 
(n=6; Table 6.1) which was observed in all of the animals not receiving 
decontamination (n=6; Chapter 5, Table 5.1). The frequency of oedema at the exposure 
site following WoundStat™ treatment was half that of the control group (2 out of 6 
animals; Table 6.1) and the mean time between SM challenge and the appearance of 
oedema was increased from 100 min to 180 min (Tables 5.1 and 6.1). 
In two of the animals, wetting on the surface of the WoundStat™ was evident 
within 1 min of application to the SM-exposed site (Figure 6.2). The area on the surface 
corresponded to the location at which the SM droplet was applied so presumably 
represented SM absorbed into the product. 
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Figure 6.2: Representative photographs of skin exposure sites. 
Development of erythema (E) 2 h post challenge (a),evidence of haemorrhage (H) at the 
skin surface 4 h post challenge (b), evidence of wetting on the surface of WoundStat™ 
(*) possibly SM (c). 
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Table 6-1: Onset and occurrence of visual signs of SM dermal toxicity following 
WoundStat™ decontamination of SM-exposed, superficially damaged skin. 
Physical changes to the skin (oedema and ulceration) and skin colour changes 
(reddening; erythema or blanching) at the exposure site were scored by one individual. 
Numbers shown in italics indicates the number of animals first presenting with clinical 
sign. The numbers in brackets indicate number of animals presenting with this clinical 
sign at specific time points (n=6).  
 
  
 Onset and occurrence of visual signs of dermal toxicity 
Time point (min) Erythema Blanching Ulceration Oedema 
Baseline (0/6) (0/6) (0/6) (0/6) 
60 (0/6) 2 (2/6) (0/6) (0/6) 
120 3 (3/6) (0/6) (0/6) 1 (1/6) 
180 (2/6) (0/6) (0/6) (1/6) 
240 (2/6) (0/6) (0/6) 1 (2/6) 
300 (2/6) (0/6) (0/6) (1/6) 
360 (2/6) (0/6) (0/6) (0/6) 
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Biophysical Measurements  
Skin colour (skin reflectance spectroscopy)  
Values for all three CIELAB parameters (L*a*b*) for control (undamaged) skin 
showed no statistically significant change over the 6 h study period (Figures 6.3 – 6.5). 
There was also no significant difference in CIELAB values for control (untreated) sites 
between the two groups of animals (p-value>0.05 for L*, a* and b* values; Figures 5.3 
– 5 and 6.3  – 5). As previously described, the removal of the SC and epidermis resulted 
in statistically significant increases in skin redness and hue (p<0.05; Figures 6.4 and 
6.5).  
However, treatment with WoundStat™ resulted in a statistically significant 
decrease in skin brightness (L*) compared to control (undamaged) skin at all time 
points measured post-challenge (p<0.05; Figure 6.3). There was no significant 
difference between sites receiving SM challenge and WoundStat™ decontamination 
and those receiving only WoundStat™ for skin colour or brightness parameters 
measured (Figures 6.3 – 6.5). 
Overall, there was not a statistically significant difference in skin brightness 
between SM-exposed skin with and without decontamination with WoundStat™ 
(Figure 6.6). However, there was a statistically significant difference between the two 
groups at 300 min post-challenge (p<0.05; Figure 6.6). No statistically significant 
difference in skin colour (a* and b*) was observed between SM-exposed skin with and 
without decontamination with WoundStat™ (Figures 6.7 – 6.8). 
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Figure 6.3: Skin lightness (expressed as the CIELAB colour scale parameter, L*) 
following superficial damage and treatment with WoundStat™ with (WS + SM) and 
without (WS) prior exposure to SM.  
Undamaged (control) and damaged unexposed sites provided a negative and positive 
control, respectively. All values are expressed as mean ± 95% confidence intervals 
(n=6). 
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Figure 6.4: Skin erythema (expressed as the CIELAB colour scale parameter, a*) 
following superficial damage and treatment with WoundStat™ with (WS + SM) and 
without (WS) prior exposure to SM.  
Undamaged (control) and damaged unexposed sites provided a negative and positive 
control, respectively. All values are expressed as mean ± 95% confidence intervals 
(n=6). 
  
0 60 120 180 240 300 360
0
10
20
30
40 Control WS WS +SMDamaged
Time (min)
S
k
in
 R
e
d
n
e
s
s
 (
a
*)
 
220 
 
 
 
Figure 6.5: Skin hue (expressed as the CIELAB colour scale parameter, b*) 
following superficial damage and treatment with WoundStat™ with (WS + SM) and 
without (WS) prior exposure to SM.  
Undamaged (control) and damaged unexposed sites provided a negative and positive 
control, respectively. All values are expressed as mean ± 95% confidence intervals 
(n=6). 
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Figure 6.6: Skin lightness (expressed as the CIELAB colour scale parameter, L*) for 
the two treatment groups: superficial damage and SM challenge with 
decontamination with WoundStat™ (WS + SM) and without (SM; Chapter 5). 
Damaged unexposed sites provided a positive control. All values are expressed as mean 
± 95% confidence intervals (n=6). 
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Figure 6.7: Skin erythema (expressed as the CIELAB colour scale parameter, a*) for 
the two treatment groups: superficial damage and SM challenge with 
decontamination with WoundStat™ (WS + SM) and without (SM; Chapter 5). 
Damaged unexposed sites provided a positive control. All values are expressed as mean 
± 95% confidence intervals (n=6). 
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Figure 6.8: Skin hue (expressed as the CIELAB colour scale parameter, b*) for the 
two treatment groups: superficial damage and SM challenge with decontamination 
with WoundStat™ (WS + SM) and without (SM; Chapter 5). 
Damaged unexposed sites provided a positive control. All values are expressed as mean 
± 95% confidence intervals (n=6). 
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Skin surface temperature (infrared thermography) 
There was not a statistically significant change in skin surface temperature for control 
(undamaged) skin over the 6 h study period (p>0.05; Figure 6.9). As previously 
described, a statistically significant decrease in average surface skin temperature was 
observed following superficial damage to the skin (removal of SC and epidermis) for all 
but two time points (240 and 300 min; Figure 6.9). However, there was not a 
statistically significant difference in skin surface temperature between the damaged skin 
and WoundStat™ (+/- SM) treatment groups (Figure 6.9) and SM did not produce any 
obvious visual changes in the thermographs (Figure 6.10). Decontamination with 
WoundStat™ did not result in a statistically significant change in skin surface 
temperature compared to SM-exposed non-decontaminated skin (Figure 6.11)   
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Figure 6.9: Skin surface temperature following superficial damage and treatment 
with WoundStat™ with (WS + SM) and without (WS) prior exposure to SM.  
Undamaged (control) and damaged unexposed sites provided a negative and positive 
control, respectively. All values are expressed as mean ± S.D. (n=6). 
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Figure 6.10: Representative skin surface thermographs (infrared thermography) 
following superficial damage and application of WoundStat™ with (WS + SM) and 
without (damaged + WS) exposure to SM. 
Thermographs of damaged skin with and without SM exposure (but no WoundStat™ 
treatment) are shown for comparison (shaded in gray). Damaged skin (without SM) 
thermographs were from the same animal. Damaged and SM exposed skin (SM) 
thermographs are from Chapter 5.    
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Figure 6.11: Skin surface temperature for the two treatment groups: superficial 
damage and SM challenge with decontamination with WoundStat™ (WS + SM) and 
without (SM; Chapter 5). 
Damaged unexposed sites provided a positive control. All values are expressed as mean 
± S.D. (n=6). 
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Cutaneous blood perfusion (laser Doppler imaging) 
A statistically significant difference between WoundStat™ treated damaged skin (with 
and without SM exposure) was observed at 180 and 240 min post exposure (p<0.05; 
Figure 6.12). However, this decrease was transient and blood flow (measured as 
perfusion units) was not significantly different at 300 min onwards.  
Decontamination with WoundStat™ significantly increased blood flow at the 
exposure site compared to SM only treatment site for all time points except 360 min 
post-challenge (Figure 6.13).  Furthermore, the distinct area of low flux observed for 
SM-exposed skin not receiving decontamination was not present in WoundStat™ 
treated animals (Figure 6.14). 
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Figure 6.12: Maximum blood perfusion at the treatment site following superficial 
damage and treatment with WoundStat™ with (WS + SM) and without (WS) prior 
exposure to SM expressed as perfusion units. 
Damaged unexposed sites provided a positive control. All values are expressed as mean 
± 95% confidence intervals (n=6). Dashed box represents a statistically significant 
difference between WoundStat™ only (WS) and SM and WoundStat™ (WS + SM) 
treatment sites where ** represent a p-value of <0.01.   
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Figure 6.13: Maximum blood perfusion at the treatment site for the two treatment 
groups: superficial damage and SM challenge with decontamination with 
WoundStat™ (WS + SM) and without (SM; Chapter 5). 
Damaged unexposed sites provided a positive control. All values are expressed as mean 
± 95% confidence intervals (n=6). Dashed box represents a statistically significant 
difference between the treatment groups (SM vs. WS + SM) sites where * and ** 
represent a p-value of <0.05 and <0.01, respectively.   
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Figure 6.14: Representative skin perfusion images (laser Doppler imaging) following 
superficial damage and application of WoundStat™ with (WS + SM) and without 
(damaged + WS) exposure to SM. 
Laser Doppler images of skin with and without SM exposure (but no WoundStat™ 
treatment) are shown for comparison (shaded in gray). Damaged skin (without SM) 
images were from the same animal. Damaged and SM exposed skin (SM) images are 
from Chapter 5.   
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Skin barrier integrity (transepidermal water loss) 
Removal of the SC and epidermis regardless of additional treatment (WoundStat™ 
and/or SM) resulted in a statistically significant increase in TEWL compared to control 
(undamaged) values (p<0.01; Figure 6.15). There was not a statistically significant 
difference between WoundStat™ treated skin with or without prior SM-exposure 
(Figure 6.15). Decontamination of SM-exposed skin significantly increased TEWL over 
the 6 h study period, the one exception being 5 h post SM challenge (Figure 6.16).     
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Figure 6.15: Transepidermal water loss (TEWL) following superficial damage and 
treatment with WoundStat™ with (WS + SM) and without (WS) prior exposure to 
SM.  
Undamaged (control) and damaged unexposed sites provided a negative and positive 
control, respectively. All values are expressed as mean ±95% confidence intervals 
(n=6). 
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Figure 6.16: Transepidermal water loss (TEWL) following superficial damage and 
SM challenge with and without decontamination with WoundStat™. 
Damaged unexposed sites provided a positive control. All values are expressed as mean 
± 95% confidence intervals (n=6). 
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Radiometric Analysis 
Concentrations of 
14
C derived from 
14
C-SM in the blood peaked 120 min post-challenge 
for both WoundStat™ treated and untreated groups (Figure 6.17). However, 
WoundStat™ treatment post-exposure significantly reduced the amount of 14C derived 
from 
14
C-SM measured in the blood at all time points measured (p<0.001; Figure 6.16).  
Elimination kinetics derived from a semi-logarithmic plot of the 
14
C-SM blood 
concentrations are summarised in Table. 6.2. The results shown are an estimation of the 
elimination kinetics, which appear to fit a first order kinetic model. Further time-points 
would be required to provide a more accurate estimation. Elimination parameters 
measured including; peak concentration, slope and elimination constant were 
significantly reduced whilst the volume of distribution was significantly increased in 
WoundStat™- treated animals (Table 6.2). However, there was not a significant 
difference in either the half-life of 
14
C-SM or calculated SM dose (from the semi-
logarithmic plot) between the animal treatment groups. 
Overall, 101 ± 8.4% of the applied 
14
C-SM dose was recovered from the 
combined 
14
C derived from 
14
C-SM totals for the skin, skin surface swabs, organs and 
blood samples. The amount of 
14
C derived from 
14
C-SM in the total systemic circulation 
was estimated from the 360 min blood sample and the estimated total blood volume, 
assuming even distribution of 
14C throughout the blood. Recovery from WoundStat™ 
accounted for the largest percentage of total amount recovered (99.9 ± 8.6%; Figure 
6.18). Use of WoundStat™ as a decontaminant significantly reduced the amount of 14C-
SM recovered from the skin and skin surface swabs compared to non-decontaminated 
animals (p<0.001; Figure 6.19). 
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The total amount of 
14
C-SM (calculated from 
14
C recovery) distributed in the internal 
organs (6 h post-challenge) on average was 886 ± 280 ng (Figure 6.20). In the 
WoundStat™-treated animals the predominant distribution in the organs when 
expressed as ng 
14
C-SM per g organ weight, was the same non-decontaminated animals; 
primarily the kidneys, followed by the liver and small intestine (Figure 6.20). 
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Figure 6.17: Semi-logarithmic plot of blood concentration against time for 
calculation of elimination kinetic parameters of 
14
C (derived from 
14
C-SM) from 
whole blood following application of 10 µL droplet of 
14
C-SM via superficially 
damaged skin with (WS + SM) and without (SM) decontamition with WoundStat™. 
All values are expressed as mean ± S.D. (n=6).  
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Elimination Parameters 
 WS + SM SM (Chapter 5) 
T½ (min) 468 ± 121 425 ± 60 
Cmax (ng ml‐
1
) **33.0 ± 7.4 60.8 ± 64 
Slope (pg ml‐
1
 min‐
1
) *‐34.4 ± 13.3 ‐64.7 ± 9.0 
Kel (pg ml‐
1 
min‐
1
) *79.1 ± 30.7 149 ± 21 
C0 (ng ml‐
1
) **35.9 ± 8.7 67.5 ± 7.0 
Vd (L) **371 ± 83 190 ± 22 
D (mg) 11.7 ± 0.3 11.5 ± 0.5 
Table 6-2: Elimination kinetic parameters following 
14
C-SM challenge via damaged 
skin with and without WoundStat™ treatment. 
Individual values are average ± S.D. of n=6 animals and are derived from linear 
regression analysis of a semi-logarithmic plot of whole blood concentration against 
time. Equations used as described in Chapter 2. Half life (T½) was calculated from 
Equation 2.8. The value of C0 was calculated as the y-intercept of the line of best fit 
(and so is equal to the theoretical whole blood concentration at time of challenge). The 
peak concentration (Cmax) was the largest concentration measured directly from whole 
blood samples. The elimination constant (Kel) was calculated by multiplying the slope 
by -2.303 (Equation 2.9). The apparent volume of distribution (Vd) was calculated from 
Equation 2.10. The apparent dose (“D”) was subsequently calculated from Equation 
2.11, using Vd and Cmax values; the actual applied dose was 11.7 mg. Statistically 
significant differences between the SM only and WS + SM treatment groups are shown, 
where * and ** represent a p-value of 0.05 and 0.01, respectively.   
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Figure 6.18: Recovery of 
14
C-SM from the samples (WoundStat™; WS, skin surface 
swabs; swab, skin, blood and organs) expressed as a log percentage of the total 
amount of 
14
C-SM recovered. 
Individual values (n=6) are shown as well as mean (central line; n=6) and S.D. 
(outermost lines). 
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Figure 6.19: Recovery of 
14
C-SM from the samples (WoundStat™, skin surface 
swabs and skin) expressed as a log amount of 
14
C-SM (µg) recovered for 
decontaminated (WS + SM) and non-decontaminated (SM) animals. 
All values are mean ± standard deviation (n=6). Significant differences between the 
treatment groups (WS + SM vs. SM) are shown where *** represents a p-value of 
<0.001.   
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Figure 6.20: Recovery of 
14
C-SM from internal organs expressed as ng (SM) per g 
(organ weight) for decontaminated (WS + SM) and non-decontaminated (SM) 
animals. 
All values are expressed as mean ± S.D. (n=6).Statistically significant differences 
between the treatment groups (WS + SM vs. SM) are shown are shown, where * 
represent a p-value of <0.05.  
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Histology 
Use of a dermatome was previously shown to remove the SC and epidermis of the skin 
(Chapter 5, Figure 5.12 and 5.13). This was also seen in WoundStat™ treated animals 
(Figure 6.21 and 6.22). All control (untreated) skin slides appeared normal.  
There were only minimal changes observed between the unexposed and SM-
exposed WoundStat™-treated damaged skins. There was minimal blood vessel dilation 
in the unexposed skin (WoundStat™-treated) but no blood vessel dilation was observed 
in SM-exposed skin receiving WoundStat™ treatment. The occurrence and severity of 
histopathological changes are summarised in Table 6.3. Both groups showed mild, 
perivascular PMN infiltrate in the dermis (Figure 6.21). Foci of fine, granular material 
was observed on the skin surface of half the samples from both groups. This was 
attributed to the presence of residual WoundStat™. Escharification and haemorrhage 
was slightly more severe in the WoundStat™ treated (with and without SM exposure) 
animals compared to animals which did not received WoundStat™ treatment (Figure 
6.21). Hyper-eosinophilic, dermal collagen (which was interpreted as degenerate) at the 
surface of the exposed dermis was also present in animals receiving WoundStat™ 
treatment.   
Overall, the microscopic changes seen in the two treatment sites (WoundStat™ 
with and without prior SM-exposure) were consistent with an acute, inflammatory 
response, secondary to the tissue damage caused by the dermatome. No significant 
changes were observed between the SM-exposed sites with and without 
decontamination with WoundStat™.   
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Table 6-3: Occurrence and severity of histopathological findings for control 
(untreated) and damaged skin +/- WoundStat™ with and without SM exposure. 
Lesions were histopathologically scored where; marked > moderate > mild > minimal 
> normal indicates the severity of the lesion.  Number in brackets indicates number of 
animals in each severity group. 
 
Lesion 
Treatment Group 
Control 
(n=6) 
Damaged 
(n=6) 
Damaged+ 
WS (n=6) 
WS + SM 
(n=6) 
Surface and 
follicular 
keratinocyte 
degeneration
/ necrosis 
Occurrence 0 0 0 0 
Severity Normal (6) Normal (6) Normal (6) Normal (6) 
Subepidemal 
separation/ 
vesiculation 
Occurrence 0 0 0 0 
Severity Normal (6) Normal (6) Normal (6) Normal (6) 
Blood vessel 
dilation-
dermal 
Occurrence 0 2 3 0 
Severity Normal (6) 
Normal (4) 
Minimal 
(2) 
Normal (2) 
Minimal (1) 
Normal (6) 
Perivascular 
to diffuse, 
neutrophilic 
cell 
infiltrate-
dermal 
Occurrence 0 6 6 6 
Severity Normal (6) Mild (6) Mild (6) Mild (6) 
Sero-cellular 
crusting- 
surface 
Occurrence 0 6 6 6 
Severity Normal (6) 
Mild  (1) 
Moderate 
(5) 
Mild  (1) 
Moderate (5) 
Mild  (2) 
Moderate 
(3) 
Marked (1) 
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Figure 6.21: Histopathology of superficially damaged skin following treatment with 
WoundStat™ showing epidermal loss, marked surface haemorrhage (Haem) with 
fibrin and cellular debris. 
Neutrophilic cell infiltrate is also shown (arrow). The haematoxylin and eosin stained 
section was viewed by light microscopy with bright field illumination at 20x zoom 
objective lens. 
  
Haem
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Figure 6.22: Histopathology of superficially damaged skin showing complete loss of 
epidermis and escharification and exposed dermal collagen (*). 
The haematoxylin and eosin stained section was viewed by light microscopy with bright 
field illumination at 20x zoom objective lens. 
*
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Figure 6.23: Histopathology of superficially damaged skin following treatment with 
WoundStat™ and SM showing loss of epidermis and escharification (E) 
Neutrophilic cell infiltrate is also shown (arrow). The haematoxylin and eosin stained 
section was viewed by light microscopy with bright field illumination at 20x zoom 
objective lens. 
 
  
E
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Genomic Analysis 
Relative mRNA levels for gene transcripts associated with skin from the different 
treatment sites were compared to identify up-regulated or down-regulated genes (as 
described in Chapter 2). Differential expression was defined as a Benjamini-Hochberg 
false discovery rate (FDR) corrected p value <0.05 and ≥ 2-fold change in relative 
mRNA levels. Approximately 0.6% of total transcripts (43663 probes) were found to 
have an altered expression pattern. Damaged (unexposed) skin treated with 
WoundStat™ had 107 transcripts whose relative mRNA levels statistically significantly 
differed to control (untreated) skin. Sulphur mustard-exposed, WoundStat™-treated 
damaged skin had 174 transcripts whose relative mRNA levels statistically significantly 
differed to control (untreated) skin. Of these differentially expressed transcripts, 74 
were shared by both unexposed and SM exposed, WoundStat™-treated damaged skin. 
As described in Chapter 5, sequences that did not have a characterised gene 
product (based on GenBank Accession number and Unigene identifier) were excluded 
from further in silico validation analysis. However, a full list of differently expressed 
gene transcripts; including those with uncharacterised or predicted gene products is 
provided in Appendix 1 (Tables 4 and 5).  
The effects of WoundStat™ decontamination on relative gene transcript 
expression were determined by comparing SM-exposed skin with and without 
WoundStat™ treatment. In total 91 gene transcripts were found to be differentially 
expressed at the 6 h time point. Following further data mining as described above, 22 
gene transcripts were found to up-regulated (Table 6.4) and 12 gene transcripts (Table 
6.5) were found to be down-regulated as a result of combined skin damage, SM-
exposure and WoundStat™ treatment.  
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Gene product 
GenBank 
accession 
number 
Fold 
change 
Corrected p-
value 
Haemoglobin subunit alpha 
(Alpha-globin) 
AK348963 7.1 0.0001 
procollagen C-endopeptidase 
enhancer 2 
AK235631 6.6 0.0001 
interleukin 6 (interferon, β2) NM_214399 6.6 0.02 
claudin 11 AY609490 5.6 0.00008 
superoxide dismutase 2, 
mitochondrial 
NM_214127 4.3 0.00008 
phosphoinositide-3-kinase, 
regulatory subunit 5 
NM_213851 3.7 0.0001 
amylase, alpha 2B (pancreatic) NM_214195 3.7 0.008 
amphiregulin NM_214376 3.7 0.0005 
carbonic anhydrase III, muscle 
specific 
NM_00100868
8 
3.3 0.0008 
reticulon 4 
NM_00112996
3 
3.1 0.0002 
signal sequence receptor, alpha 
NM_00118516
7 
2.7 0.0007 
NADH dehydrogenase 1β 
subcomplex subunit 8, 
mitochondrial 
AK236557 2.6 0.00008 
actin, alpha 1, skeletal muscle 
NM_00116779
5 
2.4 0.02 
glutaredoxin (thioltransferase) AK230519 2.4 0.0002 
glutamate dehydrogenase 1 AK235921 2.3 0.0006 
putative deoxyribonuclease 
TATDN1-like 
AK344100 2.3 0.0002 
glutamate dehydrogenase 1 AK235921 2.2 0.0001 
G-protein signalling modulator 3 
NM_00112311
9 
2.2 0.0001 
insulin-like growth factor binding 
protein 6 
AK240415 2.1 0.0001 
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Table 6-4: Differentially expressed upregulated gene transcripts in the skin following 
14
C-SM percutaneous challenge and WoundStat™ treatment via superficially 
damaged skin. 
Changes were determined by the mean expression ratio of WoundStat™ treated: 
WoundStat™ untreated SM-exposed damaged skin. Statistically significance differences 
in relative gene expression were identified by parametric t-test with a Benjamini and 
Hochberg False Discovery Rate (FDR) multiple-testing correction applied. Statistical 
significance was predefined as corrected p-value ≤0.05.  
  
matrix Gla protein NM_214116 2.1 0.0005 
proline-rich transmembrane 
protein 1 
NM_00112317
0 
2.1 0.0005 
serine/arginine-rich splicing 
factor 2 
AK235325 2.0 0.0001 
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Table 6-5: Differentially expressed down regulated gene transcripts in the skin 
following 
14
C-SM percutaneous challenge and WoundStat™ treatment via 
superficially damaged skin. 
Changes were determined by the mean expression ratio of WoundStat™ treated: 
WoundStat™ untreated SM-exposed damaged skin. Statistically significance differences 
in relative gene expression were identified by parametric t-test with a Benjamini and 
Hochberg False Discovery Rate (FDR) multiple-testing correction applied. Statistical 
significance was predefined as corrected p-value ≤0.05.  
  
Gene product 
GenBank accession 
number 
Fold 
change 
Corrected p-
value 
cytochrome P450 3A29 NM_214423 3.8 0.00009 
tyrosyl-DNA phosphodiesterase 1 BI347194 3.2 0.02 
claudin 20 NM_001159777 3.2 0.0001 
feline leukaemia virus subgroup 
C cellular receptor 1 
NM_001142846 3.0 0.001 
nuclear receptor coactivator 1 EU346671 2.4 0.0005 
DNA (cytosine-5-)-
methyltransferase 3β 
NM_001162404 2.3 0.0002 
glycerol-3-phosphate 
acyltransferase 
AK348444 2.3 0.0001 
chromosome 6 open reading 
frame 15 ortholog 
NM_001128447 2.1 0.0006 
nuclear receptor coactivator 3 NM_001114276 2.0 0.0005 
angiopoietin-like 7 NM_001142828 2.0 0.0008 
RNA binding motif protein 4B NM_001123188 2.0 0.00005 
lysine (K)-specific demethylase 
5C 
NM_001097433 2.0 0.01 
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DISCUSSION 
As demonstrated in this study, the timely application of WoundStat™ can reduce the 
frequency of advanced signs of SM dermal toxicity, namely ulceration and significantly 
reduce the amount of 
14
C radiolabel derived from 
14
C-SM recovered from the blood and 
skin. The pig has been previously shown to be a suitable model for investigating the 
effects of SM and establishing the efficacy of therapeutic treatments in vivo (Price, et 
al. 2009, Chilcott, et al. 2007, Renshaw. 1946, Reid, et al. 2001). The overall 
limitations of this study were consistent with those described in Chapter 5. Primarily 
these were the lack of radio-isotope speciation, lack of historical data on short time 
course effects and different microarray slide versions used. Additionally, there were 
limitations surrounding the use of WoundStat™ as a decontaminant. 
Application of WoundStat™ 
In “real-life” scenarios, haemostats are applied within a wound with sustained pressure 
to help arrest bleeding. Correspondingly, in vivo efficacy studies for WoundStat™ have 
incorporated continuous pressure at the site of application for up to four minutes (Ward, 
et al. 2007). Furthermore, the adsorptive nature of WoundStat™ may also create a 
tamponade effect within the wound. This may increase pressure in the wound and 
enhance absorption of SM in the wound. In this present in vivo study, no additional 
pressure was applied to the skin. Therefore, it would be desirable to develop a method 
of applying uniform, sustained pressure to a haemostat to assess whether this has an 
effect on dermal absorption of 
14
C-SM. 
 
252 
 
Potential cytotoxic effects of WoundStat™ 
Aluminium phyllosilicates such as WoundStat™ have recently been shown to elicit 
cytotoxicity in endothelial cells in vitro (Bowman, et al. 2011) and in vivo (Kheirabadi, 
et al. 2010, Gerlach, et al. 2010). However, the relevance of this when WoundStat™ is 
applied to damaged skin is unclear. According to the manufacturer WoundStat™ was 
subject to cytotoxicity testing using fibroblast cell culture and WoundStat™ was not 
found to affect viability of transformed epithelial cells (HeLa) when used in 
concentrations of up to 100 µg ml
-1
 (Bowman, et al. 2011). This may indicate that 
WoundStat™ is non–toxic, epithelial cells are resistance to WoundStat™ toxicity or the 
cell line used (transformed, immortalised HeLa cells) are resistant to toxicity. Gene 
expression could be compared for unexposed damaged skin with and without the 
application of WoundStat™ to establish whether WoundStat™ results in expression of 
pro-apoptotic or necrotic genes.  
Limitations to this model described in this chapter and Chapter 5 should be 
taken into consideration when drawing conclusions from the main findings of this study 
which are described below. 
WoundStat™ has demonstrated equivalent efficacy as a decontaminant to 
fuller’s earth in vitro, statistically significantly reducing both the amount of 14C derived 
from 
14
C-SM in the skin and penetrating through into the receptor fluid (Chapter 4). 
This efficacy was also evident in vivo as WoundStat™ treatment statistically reduced 
the amount of 
14
C-SM in the blood circulation and within the skin at the exposure site. 
Similar to the in vitro experiments, the majority of the applied dose was recovered from 
WoundStat™, providing evidence of good in vitro and in vivo correlation. The primary 
suggested mechanism of haemostatic action for WoundStat™ is adsorption of plasma 
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from blood resulting in localised concentration of clotting factors (Carraway, et al. 
2008, Ward, et al. 2007). Adsorption of toxic chemicals between the tetrahedral layers 
of fuller’s earth is the primary mechanism of action for fuller’s earth, an in-service 
military decontaminant (Wattana and Bey. 2009). Fuller’s earth has also been shown to 
be efficacious in reducing the severity of SM lesions in vivo (Taysse, et al. 2007). 
Therefore, it is probable that the reductions seen in 
14
C derived from 
14
C-SM in the 
circulation and skin at the exposure site are due to adsorption of 
14
C-SM by 
WoundStat™.  
A statistically significant decrease in the amount of 
14
C derived from 
14
C-SM 
detected in the liver was also observed following decontamination with WoundStat™. 
The liver has been previously shown to be important in the conjugation and subsequent 
elimination for SM and its metabolites (Hambrook, et al. 1992, Maisonneuve, et al. 
1993). WoundStat™ reduced dermal absorption of SM therefore it is probable that the 
amount of SM requiring metabolism and excretion is reduced. However, a statistically 
significant reduction in the amount of 
14
C isotope in the kidneys following 
WoundStat™ treatment was not observed. Urinary excretion is reported to be the 
primary route of elimination of SM and its metabolites (Black, et al. 1992, Davison, et 
al. 1961, Graham, et al. 2000, Hambrook, et al. 1992, Maisonneuve, et al. 1993). 
However, SM conjugates and hydrolysis products have been detected in the urine from 
several days up to 3 months post exposure (potentially from red blood cell adducts) 
(Hambrook, et al. 1992, Maisonneuve, et al. 1993). Therefore, 
14
C-labelled conjugates 
or hydrolysis products may be accumulating in the kidney. 
Application of WoundStat™ to the exposure site appeared to reduce or delay the 
onset of advanced signs of SM dermal toxicity. Ulcerations or necrotic skin erosions 
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were not observed in any of the WoundStat™-treated animals during the 6 h study 
period (compared to all animals in the control group). The mode of cell death induced 
by SM is known to be dose-dependent in keratinocytes (Dabrowska, et al. 1996, Kehe, 
et al. 2000, Rosenthal, et al. 1998). Therefore, the significant reduction of 
14
C-SM at 
the exposure site may have sufficiently reduced necrosis to prevent the development of 
skin erosions.  
Frequency of ring-like blanching at the exposure site was also decreased, with 
only a third of animals displaying this symptom compared to animals not receiving 
WoundStat™ treatment. Furthermore, blood perfusion at the exposure site was also 
improved following the application of WoundStat™. Whilst SM caused a transient 
decrease in perfusion units compared to WoundStat™-treated unexposed skin the 
development of a low blood flow foci on the laser Doppler images did not occur (Figure 
6.14). The effects of SM on dermal microvascular perfusion in undamaged skin are well 
documented (Brown, et al. 1998, Reid, et al. 2007, Graham, et al. 2002) and the effect 
of SM on damaged skin perfusion has been described in Chapter 5. However, the effect 
of decontaminating SM-exposed skin on cutaneous blood flow was not established prior 
to this study. Reduced dermal blood flow has been attributed to capillary necrosis and 
congestion (Reid, et al. 2007, Graham, et al. 2002). Therefore, it is probable that 
WoundStat™ treatment reduces inflammatory cell congestion of the subepidermal 
capillaries and so prevents a sustained decrease in perfusion at the exposure site.  
Surprisingly, haemorrhage and clot formation at the exposure site were more 
apparent in WoundStat™-treated animals (both visual and histological observations) 
compared to control animals. The addition of WoundStat™ combined with SM caused 
reduced clot strength in vitro in whole blood (Chapter 3). Although, the appearance of 
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haemorrhage was increased following WoundStat™ treatment (regardless of SM 
exposure) it is probable that WoundStat™ causes the coagulated blood to strongly 
adhere to the damaged skin surface which prevents removal by the cotton swabs.  
Transepidermal water loss was statistically significantly increased at 
WoundStat™ and SM treatment sites compared to SM only from 120 min post SM 
challenge. This was surprising as scab formation would expected be to increase barrier 
function and therefore reduce TEWL. However, there was not a significant difference 
between WoundStat™ treated skin with and without prior SM exposure suggesting the 
effect is due to WoundStat™ alone and not as a result of SM decontamination. The 
phenomenon of increased TEWL and delayed in barrier repair following the application 
of semi-occlusive dressings has been previously reported (Schunck, et al. 2005). 
Therefore, WoundStat™ may act as a barrier to TEWL and so the increased TEWL 
signal that would normally stimulate re-epithelisation and associated barrier mechanism 
may be absent. Although in open wounds, rapid formation of a barrier layer is required 
to prevent ingress of harmful substances or bacteria (Schunck, et al. 2005).  
Following WoundStat™ treatment, increased relative expression was observed 
for gene transcripts involved in inflammation, barrier function, regulation of cell 
differentiation/survival and oxidative stress. Interleukin-6 (IL-6) is a pleiotrophic 
cytokine, primarily produced by keratinocytes in the epidermis and fibroblasts in the 
dermis (Paquet and Piérard. 1996). Interleukin-6 modulates cell proliferation and 
differentiation and increased expression promotes wound healing (Sugawara, et al. 
2001, Gallucci, et al. 2000, McFarland-Mancini, et al. 2010). Increased expression of 
IL-6 following SM exposure has been observed as early as 3 h post challenge 
(Sabourin, et al. 2000, Vallet, et al. 2012, Gerecke, et al. 2009, Rogers, et al. 2004). 
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However, IL-6 antibodies have been shown to mitigate the inflammatory effects of SM 
induced IL-6 release (Arroyo, et al. 2004b). From this study it is not possible to 
determine whether increased IL-6 expression is in response to the physical insult 
(removal of upper layers) or chemical insult (SM). Therefore, it is difficult to determine 
whether this is a positive effect (promotion of wound healing) or negative effect 
(terminal differentiation of keratinocytes) of WoundStat™ treatment.  
Claudin 11 is a transmembrane protein which is thought to have involvement in 
the formation of tight junctions and maintenance of barrier function (Agarwal, et al. 
2009). Claudin 11 is generally associated with myelination (Bronstein, et al. 2000). 
However, recently it has been suggested that claudin-11 may be associated with IL-4 
activated macrophages (Van den Bossche, et al. 2012). Thus claudin-11 expression may 
be involved in the inflammatory response to SM. 
Amphiregulin (AREG) is cytokine and epidermal growth factor (EGF) receptor 
ligand which is involved in autocrine keratinocyte proliferation (Stoll, et al. 2009). 
Increased expression of AREG has been attributed to keratinocyte terminal 
differentiation and induction of keratins 1/10 (Wakita and Takigawa. 1999). 
Interestingly, SM has been shown to increase expression of AREG and keratin 1 in vivo 
(Dillman III, et al. 2005) and promote keratin 1/10 induction in vitro (Rosenthal, et al. 
1998). Furthermore, AREG has also been shown to be up-regulated in epidermolysis 
bullosa which is characterised by severe blistering at the epidermal-dermal junction 
similar to that caused by SM exposure (Niculescu, et al. 2011).  
Phosphoinositide-3-kinase, regulatory subunit 5 also known as p101 is a non-
catalytic subunit which forms a heterodimer with p110γ (catalytic subunit) to form a 
class 1 phosphoinositide-3-kinase γ (PI3Kγ) (Brock, et al. 2003). Class 1 PI3Kγs are 
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involved in cell signal transduction downstream of G-protein coupled receptors 
(Brazzatti, et al. 2011). PI3Kγ is able to activate the Akt signalling pathway which has 
numerous effector functions including cell survival, proliferation and differentiation 
(Cantrell. 2001). Activation of PI3Kγ has been shown to prevent anoikis or detachment 
induced apoptosis (Brazzatti, et al. 2011). Overexpression of the p101 subunit has been 
shown to enhance the activity of p110γ (Johnson, et al. 2007). Therefore increased 
expression of p101 may be a cellular defence mechanism to prevent anoikis which has 
previously been attributed to SM toxicity in vitro (Sourdeval, et al. 2006) and in vivo 
(Kan, et al. 2003).   
Oxidative stress is reported as a major contributor to the cytotoxic effects of SM 
and SM has been shown to increase ROS (Pal, et al. 2009, Laskin, et al. 2010, Gould, et 
al. 2009). Reactive oxygen species are known to cause DNA damage (Cooke, et al. 
2003), lipid perioxidation (Jafari. 2007) and protein oxidation (Pal, et al. 2009) and 
could therefore contribute to SM induced cytotoxicity. This study has identified a 
number of genes whose expression in the skin was increased by combined SM and 
WoundStat™ treatment; including SOD2 and CAIII. Superoxide dismutase (SOD2) has 
a role in the mitochondrial defence response to ROS (Figure 6.29) (Cadenas and 
Davies. 2000). Increased expression of SOD2 has been linked with protection against 
the apoptotic effects of ROS (Keller, et al. 1998). Increased expression of SOD2 in 
response to SM exposure has been previously observed (Gerecke, et al. 2009). 
Moreover, pre-treatment with SOD2 has been has been shown to reduce SM lesion 
severity (Eldad, et al. 1998). Thus increased SOD2 expression could reflect an adaptive 
cellular response against SM-induced oxidative stress. Carbonic anhydrase III (CAIII) 
is a metalloenzyme and is known to have an important role in oxidative stress response 
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(George, et al. 2011). It is thought that the enzyme catalyses the conversion of 
hydrogen peroxide to percarbonic acid as a means to protect cells from hydrogen 
peroxide induced apoptosis (Figure 6.29) (Kim, et al. 2004, Räisänen, et al. 1999)  
Sulphur mustard has been shown to spontaneously form carbonium ions 
(Chapter 1, Figure 1.9) in solution (Kang and Spears. 1987). Enzymatic reduction of 
carbonium ions by thioredoxin reductase, NADPH or CYPs results in the production of 
carbon-centred free radicals (Chapter 1, Figure 1.9) which can result in DNA damage 
(Brimfield, et al. 2012, Brimfield, et al. 2009).  
Reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase 1β is an 
accessory subunit of NADH-ubiquinone oxidoreductase (Complex I) (Dutta, et al. 
2006). It has been proposed that SM directly inhibits one or more of the enzymes in 
complex I (Martens and Smith. 2008). Impaired activity of NADH-ubiquinone 
oxidoreductase has been shown to enhance superoxide production (Hansford, et al. 
1997, Papa, et al. 2008). Again, this could be an adaptive response to combat SM-
induced oxidative stress and direct DNA damage by SM caused by increased free 
radical production. Sulphur mustard induced DNA strand breaks have been shown to 
increase poly (adenosine diphosphate-ribose) polymerase (PARP) activity which uses 
nicotinamide adenine dinucleotide (NAD
+
) as a substrate (Rosenthal, et al. 2001, Bhat, 
et al. 2006). Depletion of cellular NAD
+
 has been shown to induce necrotic cell death 
due to reduced cellular adenosine triphosphate (ATP) (Virag, et al. 2002, Platteborze. 
2003). Complex I is responsible for catalysing the oxidation of NADH to NAD
+
.   
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Figure 6.24: Summary of reactive oxygen species detoxification and cellular effects 
of oxidative stress. 
Superoxide anion is metabolised in mitochondria by manganese superoxide dismutase 
(MnSOD or SOD2) to produce hydrogen peroxide. This is further metabolised by 
catalase (CAT), peroxidises i.e. glutathione peroxidase (GPx) and thioredoxin 
reductases (TrxR) to produce water and oxygen. Carbonic anhydrase III (CAIII) 
involvement in hydrogen peroxide detoxification has also been implicated. However, if 
these detoxification systems become overwhelmed then accumulation of superoxide and 
hydrogen peroxide can occur, contributing to oxidative stress. Oxidative stress can 
result in protein oxidation, lipid peroxidation and DNA damage and may trigger cell 
death. Italics indicate that relative gene expression for this enzyme was found to be up-
regulated by decontamination of SM-exposed skin using WoundStat™.      
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Up-regulation of NADH-ubiquinone oxidoreductase in response to SM has been 
previously observed in vitro (Platteborze. 2003). Therefore, the increase in expression 
of NADH dehydrogenase 1β may be a response to maintain intracellular levels of ATP.  
Taken together this could suggest that a reduction in the dose of SM at the 
exposure site following WoundStat™ treatment allows increased expression of 
enzymes that are responsible for an adaptive cellular response against the formation of 
ROS as well as enzyme which respond to ROS-induced cell damage. However, a longer 
term study would be required to confirm whether the reduction of SM absorption at the 
exposure site was sufficient to prevent ROS-induced cellular death.  
Overall treatment with WoundStat™ resulted in the relative down regulation of 
genes involved in transcription/translation including histone and epigenetic 
modifications and cell signalling. Cytochrome P450 3A29 (CYPs) is a pig orthologue 
of human cytochrome P450 3A4 which is involved in the oxidation and metabolism of 
many xenobiotics in the body (Anzenbacherová, et al. 2005). Upregulation of rodent 
CYPs have been observed in the lung in response to a SM aerosol challenge (Pons, et 
al. 2001). Sulphur mustard has been shown to inhibit CYPs activity in vitro by 
uncoupling electron transport at flavoenzyme reductase, resulting in electrons being 
diverted to xenobiotic reduction (Brimfield, et al. 2009) which can lead to free radical 
formation (Testa. 1995). The reduction in SM absorption following decontamination 
with WoundStat™ may explain the apparent reduction in cytochrome P450 expression 
in the skin compared to SM-exposed skin which was not decontaminated. If the amount 
of SM in the skin were reduced then a reduction in the expression of enzymes involved 
the xenobiotic metabolism of SM would be expected.  
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Sulphur mustard-induced alterations to epigenetic processes have been suggested as an 
underlying mechanism for the delayed toxic effects of SM (Korkmaz, et al. 2008). 
Molecular mechanisms involved in epigenetic gene regulation include: modifications to 
histones by histone acetyltransferases and DNA methylation by DNA methyltransferase 
(Yang and Seto. 2007, Bestor. 2000). 
DNA methyltransferase 3β (DNMT3B) is involved in de novo methylation of 
DNA, in which a methyl group is covalently added to the 5-position of cytosine 
typically within gene promoter regions (Girault, et al. 2003, Yu, et al. 2012). 
Methylation of DNA is associated generally with the silencing of genes including 
potentially tumour suppressor genes which could lead to tumour promotion 
(Nandakumar, et al. 2011). Although the cellular damage attributed to the direct 
alkylation of DNA by SM is well established (Brookes and Lawley. 1960, Jowsey, et al. 
2012, Simbulan-Rosenthal, et al. 1999) there is little known about the epigenetic effects 
of SM. Methylation of DNA has been proposed as a possible mechanism which results 
in the delayed toxic effects of SM (Korkmaz, et al. 2008) through the down regulation 
of affected genes. However, it is not known whether DNA methylation or direct 
alkylation may also contribute to acute SM toxicity. Both nuclear receptor coactivator 1 
(NCOA1) and 3 (NCOA3) bind to oestrogen receptor-alpha and vitamin D receptor, 
respectively, to promote transcription of target genes (Bikle, et al. 2010). They are also 
able to induce transcription through disruption of nucleosome structure via histone 
acetyltransferase activity (Spencer, et al. 1997). Nuclear receptor coactivator 3 is 
thought to be in involved keratinocyte terminal differentiation (Bikle, et al. 2010). 
Although, there is also a proposed role for NCOA3 in keratinocyte proliferation and 
wound healing (Al-Otaiby, et al. 2012, Oda, et al. 2007).  
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Nuclear receptor coactivator 1 is also thought to have a role in increasing keratinocyte 
proliferation and subsequently the thickness of the epidermis (Kanda and Watanabe. 
2003). Down-regulation of keratinocyte proliferation following WoundStat™ treatment 
was unexpected. However, down regulation of these genes may also reduce promotion 
of gene expression associated with histone acetyltransferase activity.  
Angiopoietin-like 7 (ANGPTL7) is a member of the ANGPTL family and is a 
secreted glycoprotein and increased intracellular levels of ANGPTL7 have been shown 
to decrease fibronectin expression (Comes, et al. 2011). Fibronectin is an extracellular 
matrix protein (Faralli, et al. 2009) and is important in basement membrane stability 
(Zhang, et al. 1995a). Decreased expression of fibronectin in response to SM exposure 
and subsequent loss of cellular adhesion at the epidermal-dermal junction has been 
previously reported in vitro (Rosenthal, et al. 1998, Zhang, et al. 1995a). Therefore, 
reduced expression of ANGPTL7 may help to prevent blister formation.  
Some genes whose relative expression was differentially regulated do not appear 
to have an obvious role in SM pathogenesis or at present have an unknown function.  
RNA binding motif protein 4B is thought to be involved in suppression of 
translation during muscle cell differentiation (Lin and Tarn. 2009). Feline leukaemia 
virus subgroup C cellular receptor 1 (FLVCR) is involved in heme export from red 
blood cells to maintain iron haemostasis and is required for red blood cell 
differentiation (Yang, et al. 2010). As previously described in Chapter 5, the presence 
of blood vessels and other adnexal structure within the skin may result in genes being 
identified which do not have a direct role in cutaneous response to SM.  As previously 
suggested further characterisation of protein and gene function of the pig genome would 
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be hugely advantageous for the use of this model to investigate the genomic effects of 
SM.  
 
Conclusions  
This study has found that WoundStat™ has shown promise as a decontaminant for 
superficially damaged skin against SM in vivo. Data from Chapter 5 have shown that 
removal of the SC and epidermis reduces the lag time between SM exposure and the 
appearance of advance signs of toxicity. Timely application of WoundStat™ has been 
shown to reduce the overt (gross) signs of SM-induced skin damage and significantly 
decrease the amount of 
14
C-SM remaining within the skin at 6 h post-challenge. 
WoundStat™ also significantly reduced systemic absorption of 14C-SM, with decreased 
14
C-SM measured in the circulation and major routes of elimination and excretion (liver 
and small intestine). Furthermore, SM was previously shown to significantly reduce 
perfusion rates at the exposure site from 2 h post challenge onwards (Chapter 5) whilst 
only a transient decrease was observed in  WoundStat™ treated animals. However, no 
significant microscopic changes were observed in between the two treatment groups 
(SM only and SM + WoundStat™ decontamination). Treatment with WoundStat™ was 
found to increase the relative mRNA levels of gene transcripts associated with cellular 
response to oxidative stress and inflammation, barrier function, and regulation of cell 
differentiation/survival compared to animals not receiving decontamination. Overall 
treatment with WoundStat™ resulted in the relative down regulation of genes involved 
in transcription/translation including histone and epigenetic modifications and cell 
signalling. 
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Recommendations for future work 
This study has found that WoundStat™ has shown promise as a decontaminant for 
superficially damaged skin against SM in vivo.  
 Chromatographic analysis should be used to for the speciation of sample 
containing 
14
C-isotope to determine whether they contain the parent compound 
(SM) or a conjugate/hydrolysis product and thus to establish if the absorbed 
material is active/reactive. 
 Relative changes in mRNA levels observed using cDNA microarray analysis 
should be quantified and validated using qRT-PCR. 
 The efficacy of WoundStat™ as a haemostatic decontaminant should be 
evaluated in a SM-contaminated haemorrhaging wound model (Kheirabadi, et 
al. 2009). However, given recent safety concerns regarding embolised vessels in 
distal organs following WoundStat™ treatment (Kheirabadi, et al. 2010) 
reformulation of the product may be required. This could be achieved by 
containing product within non-woven surgical gauze similar to QuikClot 
ACS+
® 
(Kheirabadi, et al. 2009). However, further experiments would be 
required to ensure encasing WoundStat™ did not have an adverse impact on 
efficacy as a decontaminant. WoundStat™ efficacy as a decontaminant in vitro 
(static diffusion cell system; Chapter 4) correlated with the in vivo data (Chapter 
6). Therefore, the static diffusion cell system may be suitable for evaluating the 
decontaminant efficacy of a new formulation.        
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Chapter 7  
General Discussion 
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GENERAL DISCUSSION 
Contamination of wounds with highly toxic chemicals, such as SM, presents a hazard to 
civilian and military populations e.g. a “dirty bomb” scenario. Current decontamination 
regimes are contraindicated for intra-wound use and may adversely affect wound 
healing (Gibbs and Pooley. 1994, Sakula. 1961, Walters, et al. 2007). Therefore, there 
is a considerable need for the development of a skin decontaminant which is also safe 
for use on abraded skin and in open wounds. In addition to the capacity to 
decontaminate wounds, a product which could simultaneously clot haemorrhaging 
wounds would be of significant clinical benefit. 
The work reported in this Thesis has successfully demonstrated the feasibility of 
developing a product (WoundStat™) to simultaneously arrest bleeding and reduce the 
ingress of a CW agent. Moreover, WoundStat™ is also an effective skin decontaminant, 
being equivocal in performance to existing military topical decontamination products 
such as fuller’s earth, RSDL® and M291. 
To be considered suitable for use as a haemostatic decontaminant a product 
must maintain the ability to rapidly coagulate blood even in the presence of potentially 
toxic chemicals. The acute effects of SM on blood coagulation are not well established. 
Although it was presumed based on published literature that SM may have a deleterious 
effect on clot formation and stability due to its ability to alkylate critical active site 
residues of thrombin and increase expression of enzymes associated with clot lysis. 
However, the use of whole blood TEG by this thesis has demonstrated that SM has no 
discernible effect on coagulation, either following direct addition to blood in vitro or 
following percutaneous exposure in vivo. Furthermore, TEG identified four haemostatic 
products (WoundStat™, ProQR®, VitaGel™ and FastAct®) which significantly 
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enhanced coagulation in vitro. The performance of three of these products (ProQR
®
, 
VitaGel™ and FastAct®) was completely unaffected by the presence of SM. Clot 
strength was significantly reduced in blood treated with WoundStat™ and SM 
compared to native, control or WoundStat™ only treated blood. As clot strength is a 
direct function of platelet and fibrin binding via GPIIb/IIIa receptor (Mousa, et al. 
2000), it is possible that WoundStat™ in combination with SM affects the structure or 
function of GPIIb/IIIa integrins, platelets or fibrin. Although, these observations may be 
species specific as differences in GPIIb/IIIa integrins between human and porcine blood 
have been reported (Royo, et al. 1998). Sulphur mustard has been shown to increase u-
PA expression which promotes clot lysis via activation of plasmin.  Therefore, it is 
plausible that SM could prevent cross-linked fibrin clot formation through indirect 
activation of plasmin. However, the increased clot lysis observed with SM and 
WoundStat™ treated blood was limited to the in vitro findings as there was no 
significant difference in TEG parameters in vivo following SM percutaneous exposure 
and topical decontamination with WoundStat™. This suggests that the effects are either 
dose-dependent or require direct contact between SM, WoundStat™ and blood 
components.  
The other three products tested (QuikClot ACS+
®
, HemCon
® and Celox™) did 
not demonstrate efficacy in vitro. Whilst this is contrary to reported efficacy in vivo, it 
is in agreement with previous in vitro studies (Kheirabadi, et al. 2009). The successful 
products fell into two broad categories: absorptive granular products and liquid 
products containing activated clotting factors. The pro-coagulatory functions of the 
granular products are attributed to absorption of plasma in the interlayer or molecular 
spaces. Fuller’s earth and M291 are able to absorb and sequester chemicals in the 
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interlayer spaces and effectively decontaminant the skin surface. Thus it was proposed 
that products which were effective in absorbing plasma may also be efficacious as 
topical decontaminants.  
Measurement of percutaneous absorption of SM in vitro demonstrated good 
agreement with in vivo data and identified that superficial damage to the skin results in 
increased dermal and systemic absorption of SM. This further validates the use of in 
vitro diffusion cells for the initial screening of candidate decontaminants. Additionally, 
use of diffusion cells can minimise the number of animals required and so is in keeping 
with the “3 Rs” ethical framework. The pig was the chosen animal model in this Thesis 
as it is established for investigating SM toxicity in undamaged skin (Reid, et al. 2007, 
Chilcott, et al. 2007, Graham, et al. 2001, Graham, et al. 1999) and demonstrates good 
correlation with dermal absorption in man (Barbero and Frasch. 2009). There was no 
significant difference observed in either the rate or amount of SM percutaneous 
absorption through undamaged skin (control skin) between animals. However, there 
were significant differences in the amount of SM remaining within the skin. 
Interindividual differences in percutaneous absorption can be due, in part, to differences 
in the amount or ratio of filaggrin and intercellular lipids within the SC. Little is known 
about the role of filaggrin in the formation of reservoirs of active chemical within the 
SC (which could potentially contribute to systemic or dermal toxicity) which has been 
observed for SM (Hattersley, et al. 2008). Thus interindividual differences in filaggrin 
or intercellular lipids within the SC could present further challenges to topical 
decontamination in addition to contributing to differences in rate of percutaneous 
penetration through the skin.  
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Removal of the SC and epidermis using a dermatome resulted in the rapid onset of 
advanced signs of SM toxicity including ulceration, escharification and reduced dermal 
perfusion. Reduction in blood flow could be attributed to vasoconstriction as SM can 
act as a cholinergic agonist. However, SM can also down regulate expression of 
adrenergic receptors, responsible for vasoconstriction in the skin. Alternatively, 
reductions in blood flow could be attributed to capillary congestion identified by 
histological analysis. The increased rate of absorption in vivo correlated with earlier 
onset of advanced signs of toxicity than previously reported. This implies that the 
apparent latency in clinical signs associated with SM exposure may be due to the rate of 
absorption and not solely dependent of biochemical pathways as previously described. 
Additionally this thesis has demonstrated that some commonly used biophysical 
measurements may have limited value when investigating the effects of SM exposure 
via damaged skin as subtle changes in parameters could be masked by the initial injury. 
This thesis has built on previous work (Brown, et al. 1998, Chilcott. 2000, Braue, et al. 
2007) in demonstrating the usefulness of laser Doppler imaging in measuring SM lesion 
progression, particularly early time point changes in perfusion and when the skin is 
damaged. 
This Thesis is the first to examine the toxicokinetics and distribution of 
14
C-SM 
when applied percutaneously to superficially damaged skin. Absorption of 
14
C-SM into 
the circulation was rapid (dose peaked at 2 h post-challenge) and toxicokinetics of 
14
C-
SM in the blood followed a first-order one compartment model with a half life of 460 ± 
62 min. The apparent long half-life in the blood could be attributed to the absorption of 
residual SM remaining at the dose site (after removal at 60 min). Whilst it has been 
demonstrated that SM forms a skin reservoir within the SC in vitro (Hattersley, et al. 
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2008) it is not clear if reservoir of active SM forms in the dermis if the SC is removed. 
Alternatively SM rapidly spreads across the surface of the skin in vitro (Chilcott, et al. 
2000) and so could form a reservoir in the SC in the undamaged skin surrounding the 
area of damaged skin.  
In vitro static diffusion cell studies identified WoundStat™ as being 
comparable, as a decontaminant, with in-service military decontaminants (M291 and 
fuller’s earth). WoundStat™ is similar in structure to fuller’s earth and thus it is 
reasonable to postulate that WoundStat™ is able to adsorb SM in the interlayer spaces 
of the smectite clay structure.  
Overall, WoundStat™ showed in vivo efficacy as a decontaminant significantly 
reducing the amount of 
14
C-SM at the exposure site (skin and skin surface swabs) and 
systemically absorbed (blood, liver and small intestines). Treatment with WoundStat™ 
also prevented the appearance of signs of severe toxicity e.g. ulceration and reduced the 
occurrence of other clinical observations (blanching and erythema). The reduction in 
blanching at the exposure site corresponded with a significant increase in maximal 
blood flow at WoundStat™ treated exposure sites when compared with the SM only 
exposure sites. This not only supports the hypothesis that haemostats could have a dual 
function as a haemostatic decontaminants but also further validates the use of in vitro 
diffusion cells in the identification of potential decontaminants.  
The remaining haemostats tested were either ineffective or less efficacious than 
WoundStat™ (QuikClot ACS+® and Pro QR®) or significantly increased the dermal 
absorption of SM in vitro (VitaGel™, FastAct®, Celox™ and HemCon®). The 
significant increase in rate and amount of 
14
C-SM absorption could be attributable to 
the formation of an occlusive layer preventing evaporative loss and/or 
 
271 
 
thermodynamically favourable partitioning of hydrophobic SM from an aqueous 
solution into the lipid-rich SC.  The lack of efficacy for the other granular products is 
possibly due to preferentially adsorbing hydrophilic molecules.  
This Thesis sought to develop a defined animal model to characterise the early 
time point effects of SM exposure via superficially damaged skin. Overall, this has been 
achieved. However, further work to characterise the biological function of porcine gene 
products and a better identification of gene sequences would be advantageous in 
allowing more extensive microarray studies to be conducted using the pig model. The 
mouse is currently widely used for investigating the genomic effects of SM in vivo due 
to its size, cost, availability of reagents and information regarding gene function. 
Absorption of chemicals in murine skin has been shown to be unrepresentative of 
absorption in human skin (Lu, et al. 1992, Wester and Maibach. 1993). Moreover, this 
Thesis has shown that SM-induced pathology and gene expression in the skin are 
affected by decreased barrier function (removal of the SC and epidermis). Therefore, 
the gene expression changes observed in the murine model which has more permeable 
skin (decreased barrier function) may not be representative of the genomic response to 
SM in man. Thus, use of an animal model like the pig which has shown good 
correlation with human skin (Barbero and Frasch. 2009, Simon and Maibach. 2000) 
may more accurately reflect the time course of effects.  
Overall,  treatment of damaged skin with SM was associated with down 
regulation of gene expression (summarised in Table 7.1) which is in contrast to the 
general upregulation of gene expression observed following SM exposure of 
undamaged skin (Vallet, et al. 2012, Gerecke, et al. 2009). The majority of the genes 
whose relative mRNA levels were down-regulated are involved in 
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inflammatory/immune response, oxidative stress response or cell 
differentiation/proliferation. Some of the genes identified as down-regulated in this 
Thesis (Chapter 5) have been shown to be up-regulated in previous studies (Gao, et al. 
2008, Gerecke, et al. 2009, Wormser, et al. 2004, Steinritz, et al. 2009).  
Although, this may be attributed to the combined damaged to the skin 
(wounding plus SM) particularly in the case of inducible nitric oxide synthase (iNOS). 
Sulphur mustard has been shown to increase iNOS function in undamaged skin (Gao, et 
al. 2008, Steinritz, et al. 2009) but decreased function was observed in a keratinocyte 
wound model (Ishida, et al. 2008). Therefore, targets for SM injury therapies identified 
using undamaged skin may not be effective (or have an adverse effect) when used on 
wounded skin.  
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Treatment site 
(Skin was superficially damaged for all 
treatment sites) 
Number of genes 
upregulated 
Number of genes 
down regulated 
SM-exposed (vs. damaged unexposed) 1 18 
WoundStat™-treated SM exposed 
(vs. WoundStat™-treated unexposed) 
4 12 
WoundStat™-treated SM exposed 
(vs. SM exposed) 
18 8 
Table 7-1: Summary of differential gene expression in the skin following application 
of WoundStat™ and/or SM 
Differential gene expression was defined as a FDR corrected p-value of <0.05 and a 
fold change in relative mRNA levels of ≥ 2)  
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Thioredoxin interacting protein (TXNIP) was the only gene upregulated in damaged 
skin following exposure to SM (without decontamination). Thioredoxin interacting 
protein decreases detoxification of ROS through the inhibition of H2O2 metabolism by 
thioredoxin contributing to oxidative stress (Zhou, et al. 2010, Cadenas and Davies. 
2000). A monofunctional SM analogue (CEES) reduces thioredoxin activity, although, 
the observed reduction in activity was attributed to decreased thioredoxin reductase 
activity and not increased TXNIP expression (Jan, et al. 2010). Thus inhibition of 
TXNIP may reduce cell death associated with SM-induced toxicity. Additionally 
TXNIP has been attributed to linking oxidative stress to increased inflammation via 
NLRP3 inflammasome binding which results in increased IL-1β production (Zhou, et 
al. 2010).  
Surprisingly, decontamination of SM-exposed damaged skin using 
WoundStat™ increased the relative expression of gene transcripts (compared to SM-
exposed damaged skin without decontamination) involved in inflammation, barrier 
function, regulation of cell differentiation/survival and oxidative stress. Some genes 
(IL-6, amphiregulin, p101) have a well characterised role in inflammation or cell 
regulation (proliferation, differentiation or survival) and have been previously been 
shown to up-regulated by SM and may contribute to SM pathogenesis (Gerecke, et al. 
2009, Sabourin, et al. 2004, Rogers, et al. 2004). Interestingly, IL-6 has been observed 
to contribute to SM damage in the dermal layer and inhibition of the cytokine (by anti-
IL-6 antibodies) may reduce associated inflammation (Arroyo, et al. 2004b).  
Both AREG and p101 are associated with activation of downstream effector 
pathways involved in cell death and terminal differentiation (Wakita and Takigawa. 
1999; Cantrell. 2001). Although they appear to have opposing effects in terms of 
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vesication as AREG is up-regulated in blistering diseases (epidermolysis bullosa) 
affecting the epidermal-dermal junction (Niculescu, et al. 2011) and activation of 
PI3Kγ (p101 is a subunit) prevents anoikis or detachment-induced apoptosis (Brazzatti, 
et al. 2011). Therefore, it is unclear whether WoundStat™ sufficiently reduces the 
dermal absorption of SM as to prevent vesication. Although, WoundStat™ may reduce 
SM to a level at which cellular death is shifted toward apoptosis rather than necrosis. 
Whilst it would be desirable for WoundStat™ to completely prevent cell death, 
apoptotic cell death would reduce the inflammatory response associated with necrotic 
cell death (Festjens, et al. 2006). 
Oxidative stress is a major contributor to the cytotoxic effects of SM (Pal, et al. 
2009, Laskin, et al. 2010, Gould, et al. 2009). Several genes (manganese superoxide 
dismutase; SOD2 and carbonic anhydrase III; CAIII) which were upregulated in 
WoundStat™ decontaminated, SM-exposed skin (compared to SM-exposed skin 
without decontamination) have a role in the ROS detoxification (Chapter 6; Figure 
6.29). Increased expression of SOD2 and CAIII may be an adaptive cellular defence 
mechanism to prevent oxidative stress and associated cellular damage including DNA 
damage. Moreover, SM-induced skin lesion severity was reduced with pre-treatment 
using SOD2 (Eldad, et al. 1998). Furthermore, pre-treatment with antioxidants (e.g. 
glutathione) reduces SM cytotoxicity (Sawyer and Hamilton. 2000).  
Overall, gene expression changes suggest that treatment of SM-exposed 
damaged skin with WoundStat™ sufficiently reduces the amount of SM at the exposure 
site to allow for compensatory mechanisms to counteract SM-induced severe cell 
damage which could result in necrosis. However, a number of genes whose expression 
was significantly altered by WoundStat™ treatment do not have defined function and 
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further characterisation of porcine gene products would be beneficial as previously 
described. This study has identified that WoundStat™ treatment can significantly 
reduce SM percutaneous absorption and promote compensatory mechanisms to 
counteract SM-induced cellular damage at a gene expression level. Although, the length 
of the study (6 h) may not have been long enough to ascertain whether WoundStat™ 
treatment will prevent the macroscopic and microscopic changes normally attributed to 
SM injury and a longer term (24 – 72 h) study may be necessary.  
This Thesis formed part of a larger project investigating the suitability of 
commercial haemostats as decontaminants against three chemical warfare agents (SM, 
VX; O-ethyl-S-[2(di-isopropylamino)ethyl] methylphosphonothioate, and Soman; O-
Pinacolyl methylphosphonofluoridate). Studies investigating the efficacy of haemostats 
against VX and Soman when applied percutaneously to superficially damaged skin in 
vitro and in vivo were conducted by Helen Lydon and Christopher Dalton, respectively. 
The studies were conducted using the same in vitro methodology (see Chapter 2). 
However, the nerve agent studies used a different in vivo model (agent applied 
percutaneously to the pig’s ear) which has previously been described for nerve agent 
exposure studies (Chilcott, et al. 2005). Collectively, these studies have demonstrated 
that WoundStat™ is effective at reducing both SM and VX toxicity in vivo (Table 7.2). 
However, decontamination with WoundStat™ did not prevent death in Soman-exposed 
animals, although, there was an increase the survival time which could extend the 
window for therapeutic intervention (Table 7.2). Thus overall, the project represents a 
comprehensive evaluation of haemostatic products and all three component studies have 
converged in identifying WoundStat™ as the most effective product.  
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Agent VX Soman (GD) 
C
o
a
g
u
la
ti
o
n
 
In
 v
it
ro
 f
in
d
in
g
s 
VX by itself was pro-coagulant. 
No adverse effect on haemostat 
efficacy in vitro. 
GD by itself was pro-coagulant. 
No adverse effect on haemostat 
efficacy in vitro. 
P
er
cu
ta
n
eo
u
s 
A
b
so
rp
ti
o
n
 
In
 v
it
ro
 f
in
d
in
g
s 
WoundStat™ was the most 
effective product at reducing 
amount of 
14
C-VX percutaneously 
absorbed through undamaged or 
damaged skin 
WoundStat™ was the most 
effective product at reducing 
amount of 
14
C-GD percutaneously 
absorbed through undamaged or 
damaged skin 
In
 v
iv
o
 f
in
d
in
g
s 
WoundStat™ significantly 
increased survival rate following a 
5 x percutaneous LD50 challenge of 
14
C-VX (6/6 animals survived 6 h 
study period). 
WoundStat™ also decreased 
frequency of severe signs of 
toxicity and the amount of 
14
C-VX 
in the systemic circulation 
WoundStat™ increased survival 
time following an estimated 5 x 
percutaneous LD50 challenge of 
14
C-GD. 
However, 4 out of 6 animals still 
died and 2 surviving animals had 
severe signs of toxicity. 
Table 7-2: Summary of in vitro and in vivo decontamination efficacy data from the 
nerve agent (VX and GD) studies. 
(Summary data reproduced with kind permission from Helen Lydon and Christopher 
Dalton) 
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Future Work 
All in vitro studies were conducted with either porcine blood (Chapter 3) or skin 
(Chapter 4) therefore it would be useful to conduct in vitro experiments with human 
blood and skin to ensure SM effects (or lack thereof) on blood coagulation and SM 
penetration through damaged skin was not species specific.  
Microarray analysis conducted in Chapters 5 and 6 has identified some gene 
transcripts whose relative expression is changed in response to SM or decontamination 
of SM-exposed skin. Quantification and validation of these results by qRT-PCR would 
be required before definitive conclusions can be drawn as to the effects of SM exposure 
on gene expression in damaged skin and the efficacy of WoundStat™ decontamination.  
WoundStat™ has been shown to display cytotoxic effects against endothelial 
cells but not transformed epithelial cells (HeLa). However the lack of cytotoxicity may 
be due to the transformed nature of these cells rather than a specific cell response to 
WoundStat™. This may have an impact on gene expression in the skin. Therefore, 
changes seen may be as a result of combined SM and WoundStat™ toxicity. To 
establish what effects WoundStat™ has on gene expression in the skin microarray 
analysis could be performed on damaged (unexposed) skin and damaged (unexposed) 
skin receiving WoundStat™ treatment. Unfortunately, this analysis was beyond the 
scope of this Thesis but it would be a useful comparison to clarify what effect 
WoundStat™ has on the skin.  
This Thesis has included a study of the gene expression effects of SM on 
damaged skin. However, it would be interesting to conduct similar experiments using 
an undamaged pig model. This would allow direct comparison of the same species 
(most literature uses murine models) and thus allow the identification of gene 
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transcripts whose expression is altered in response to SM alone or whether superficial 
damage to the skin alters the gene-level response to SM. Moreover, the altered 
toxicodynamics (caused by removal of the SC) imply that the latent period associated 
with SM exposure is due to rate of absorption and not solely dependent on biochemical 
pathways. Future work should seek to further evaluate the role of the skin barrier in 
altering the toxicodynamics of SM in order to establish if the latent period associated 
with the pathology of SM lesions is due to kinetics of absorption and not metabolic 
mechanisms. 
Speciation of the 
14
C-isotopes would be useful to distinguish between SM parent 
molecule and radiolabelled degradation products. This would be of particular use in the 
in vitro screening studies to ascertain whether 
14
C detected within the receptor fluid is 
SM, particularly for reactive decontaminants. However, rapid hydrolysis of SM within 
the aqueous ethanol may prevent this. Therefore, selection or development of a receptor 
fluid that allows identification of SM but does not limit percutaneous absorption would 
be required.  
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Sample ID 
Nanodrop Bioanalyser 
RNA concentration (ng µl
-1
) A260/A280 ratio RIN value 
3 control 396.3 2.06 7.8 
4 control 278.46 2.03 8.9 
5 control 469.05 2.01 7.4 
6 control 576.14 2.08 8.1 
7 control 327.82 2.01 7.5 
8 control 163.66 2.07 7.0 
9 control 277.32 2.04 8.1 
10 control 218.16 2.04 7.7 
11 control 431.44 2.05 7.5 
12 control 535.25 2.11 7.7 
13 control 342.67 2.07 7.2 
14 control 295.84 2.04 7.7 
3 damaged 392.53 2.03 8.4 
4 damaged 199.96 2.05 9.1 
5 damaged 343.01 2.06 9.1 
6 damaged 614.73 2.11 8.2 
7 damaged 124.44 2.00 7.3 
8 damaged 231.1 2.08 7.9 
9 WS 272.84 2.07 8.2 
10 WS 181.26 2.03 8.1 
11 WS 518.7 2.07 7.6 
12 WS 204.91 2.08 8.0 
13 WS 240.32 2.09 8.1 
14 WS 228.48 2.05 8.1 
3 SM 371.82 2.07 8.7 
4 SM 299.09 2.04 7.6 
5 SM 427.92 2.03 6.6 
6 SM 458.57 2.01 7.3 
7 SM 224.37 2.02 7.4 
8 SM 144.2 2.07 6.2 
9 SM + WS 221.14 1.89 8.2 
10 SM + WS 164.58 2.03 7.1 
11 SM + WS 164.62 2.08 9.1 
12 SM + WS 266.71 2.08 8.3 
13 SM + WS 328.66 2.05 7.5 
14 SM + WS 179.36 2.08 7.2 
 
Table 1: Final RNA concentration, purity and integrity measurements for skin 
samples. Skin samples included: untreated (control) skin, unexposed damaged skin 
without (damaged) and with WoundStat™ (WS) treatment, and exposed damaged skin 
without (SM) and with WoundStat™ (SM + WS) treatment. 
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Probe ID p-value F/C Gene name 
GenBank 
accession 
number 
A_72_P39965
3 
0.006 7.6 
 (PADT) Sus scrofa cDNA 3', 
mRNA sequence 
EB416880 
A_72_P47274
2 
0.01 6.6 
S-antigen; retina and pineal gland 
(arrestin) 
NM_214079 
A_72_P48951
5 
0.01 6.6 
methionine adenosyltransferase I, 
alpha 
NM_001243
187 
A_72_P79067
5 
0.0004 6.6 
Sus scrofa kinesin-like protein 
KIF13A-like 
XM_003128
197 
A_72_P57503
9 
0.003 6.4 CLASP1 protein 
XM_001924
533 
A_72_P70606
2 
0.004 6.3 
myeloid-associated differentiation 
marker-like 
XM_003482
234 
A_72_P49042
5 
0.0007 5.7 heat shock 70kDa protein 12A 
XM_001925
611 
A_72_P47203
0 
0.0005 5.3 Uncharacterized protein 
XM_003133
566 
A_72_P47454
9 
0.04 4.8 Uncharacterized protein 
XM_003125
683 
A_72_P44450
1 
0.01 4.5 dual oxidase 2 NM_213999 
A_72_P53597
9 
0.04 4.5 
armadillo repeat gene deleted in 
velocardiofacial syndrome 
XM_001929
642 
A_72_P47226
0 
0.04 4.4 Uncharacterized protein AK351203 
A_72_P44177
3 
0.002 4.4 uroplakin 2 NM_214012 
A_72_P63482
6 
0.0003 4.4 RNA binding motif protein 19 
XM_001928
156 
A_72_P17845
6 
0.0007 4.2 Fc fragment of IgA, receptor for 
NM_001123
112 
A_72_P46605
1 
0.003 4.2 Uncharacterized protein 
XM_003135
157 
A_72_P77786
6 
0.003 4.1 
Sus scrofa mRNA, clone: 
PTG010087E10, expressed in 
pituitary gland. 
AK349501 
A_72_P59768
8 
0.006 4.0 E1A binding protein p300 
XM_001929
213 
A_72_P44199
7 
0.008 3.9 adrenergic, alpha-1D-, receptor 
NM_001123
073 
A_72_P65829
3 
0.04 3.9 chromogranin B (secretogranin 1) NM_214081 
A_72_P47700
7 
0.04 3.6 
RAB44, member RAS oncogene 
family 
XM_001927
576 
A_72_P49107
7 
0.004 3.6 
uncharacterized protein C6orf211 
homolog 
NM_001243
637 
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A_72_P15611
1 
0.002 3.5 PDZ domain containing 3 
XM_003129
933 
A_72_P37315
3 
0.01 3.5 nitric oxide synthase 2, inducible 
NM_001143
690 
A_72_P44459
2 
0.03 3.5 Uncharacterized protein 
XM_003122
137 
A_72_P44499
3 
0.006 3.5 mucin 13, cell surface associated 
NM_001105
293 
A_72_P45031
8 
0.03 3.5 transcription factor GATA-5-like 
XM_001924
182 
A_72_P56283
4 
0.03 3.4 
progesterone receptor membrane 
component 2 
NM_001097
521 
A_72_P53449
4 
0.004 3.4 
immunoglobulin superfamily, 
member 1 
AK349537 
A_72_P36680
8 
0.004 3.4 
potassium voltage-gated channel 
subfamily C member 4-like 
XM_003125
860 
A_72_P70505
2 
0.03 3.3 sorting nexin 1 
XM_001928
499 
A_72_P56445
9 
0.02 3.2 outer dense fibre protein 2-like EW159310 
A_72_P44321
8 
0.002 3.2 
prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
NM_214321 
A_72_P50587
5 
0.008 3.1 
fragile X mental retardation 
syndrome-related protein 1-like 
XM_003132
553 
A_72_P47764
1 
0.04 3.1 
myeloid-associated differentiation 
marker-like 
XM_001925
007 
A_72_P24255
2 
0.0003 3.1 
NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 8, 19kDa 
AK236557 
A_72_P45518
0 
0.009 3.1 Uncharacterized protein DB791121 
A_72_P35037
3 
0.04 3.0 
vav 2 guanine nucleotide exchange 
factor 
XM_001927
141 
A_72_P43477
9 
0.004 2.9 RIMS binding protein 3 
XM_001926
953 
A_72_P47960
3 
0.03 2.9 Uncharacterized protein 
XM_003128
783 
A_72_P56953
9 
0.009 2.9 albumin 
NM_001005
208 
A_72_P10503
6 
0.004 2.9 PR domain containing 10 AK239583 
A_72_P44387
9 
0.01 2.7 
progestin and adipoQ receptor 
family member VIII 
NM_213740 
A_72_P64989
4 
0.0003 2.7 
adenosine monophosphate 
deaminase 1 
NM_001123
076 
A_72_P70464
3 
0.01 2.7 Sus scrofa tenascin-like 
XM_001926
573 
 
324 
 
A_72_P44456
7 
0.0004 2.7 
pregnancy-associated plasma 
protein-A 
XM_001926
753 
A_72_P49368
7 
0.0004 2.6 Uncharacterized protein 
XM_003121
740 
A_72_P10554
6 
0.01 2.6 Src-like-adaptor 2 AK236978 
A_72_P44071
6 
0.0005 2.6 retrotransposon-like 1 
NM_001134
358 
A_72_P44467
4 
0.01 2.6 gastrin 
NM_001004
036 
A_72_P67976
9 
0.004 2.5 pancreatic lipase-related protein 1 
NM_001142
897 
A_72_P54718
6 
0.01 2.5 Uncharacterized protein AK232259 
A_72_P16248
6 
0.02 2.5 
steroid sulfatase (microsomal), 
isozyme S 
DN129273 
A_72_P41354
8 
<0.0001 2.5 sarcalumenin-like AF128841 
A_72_P15063
1 
0.003 2.5 CHD3-like protein EU780792 
A_72_P49955
4 
0.0003 2.4 
heterogeneous nuclear 
ribonucleoprotein F 
XM_003133
036 
A_72_P47653
1 
0.04 2.3 Uncharacterized protein 
XM_001929
101 
A_72_P03477
1 
0.02 2.3 
MARC 2PIG Sus scrofa cDNA 5', 
mRNA sequence 
BF190050 
A_72_P65377
1 
0.002 2.3 multicatalytic proteinase subunit K AY610111 
A_72_P44050
6 
0.0002 2.3 hepatocyte nuclear factor 4, alpha 
NM_001044
571 
A_72_P10734
6 
0.007 2.2 WD repeat domain 46 AK348376 
A_72_P49006
5 
0.008 2.2 cytochrome P450 2C33 NM_214414 
A_72_P25090
7 
0.0009 2.2 
Sus scrofa obscurin, cytoskeletal 
calmodulin and titin-interacting 
RhoGEF 
XM_003123
629 
A_72_P47509
7 
<0.0001 2.2 
tumour necrosis factor, alpha-
induced protein 8-like 2 
NM_001204
370 
A_72_P23389
2 
<0.0001 2.2 annexin A9 
NM_001243
348 
A_72_P47251
6 
0.002 2.2 Uncharacterized protein 
XM_001926
448 
A_72_P51519
8 
0.004 2.1 
carnitine palmitoyltransferase 1B 
(muscle) 
NM_001007
191 
A_72_P16640
1 
0.03 2.0 
MARC 2PIG Sus scrofa cDNA 5', 
mRNA sequence 
BI360438 
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A_72_P62056
4 
0.02 2.0 creatine kinase, muscle 
NM_001129
949 
A_72_P09706
6 
0.03 2.0 kinesin family member C1 AK233842 
A_72_P47723
3 
0.03 2.0 Uncharacterized protein 
XM_001929
304 
A_72_P22525
2 
0.02 1.9 
MARC 4PIG Sus scrofa cDNA 3', 
mRNA sequence 
CN166189 
A_72_P74872
2 
<0.0001 1.9 vitronectin NM_214104 
A_72_P71580
8 
0.01 1.9 
Sus scrofa mRNA, clone: 
UTR010026F01, expressed in 
uterus. 
AK352210 
A_72_P45582
7 
0.002 1.9 histidine ammonia-lyase-like 
XM_001925
061 
A_72_P41361
3 
0.04 1.9 
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 
AF123280 
A_72_P58798
6 
0.02 1.8 
receptor-binding cancer antigen 
expressed on SiSo cells-like 
XM_001925
514 
A_72_P44053
6 
0.001 1.8 
parkinson protein 2, E3 ubiquitin 
protein ligase (parkin) 
NM_001044
603 
A_72_P44004
6 
0.04 1.8 ADAM metallopeptidase domain 2 NM_213957 
A_72_P53772
0 
0.008 1.8 
killer cell immunoglobulin-like 
receptor, two domains, long 
cytoplasmic tail, 1 
NM_001113
218 
A_72_P50252
9 
0.01 1.8 
transcription elongation factor A 
(SII)-like 4 
XM_001924
869 
A_72_P41353
3 
0.04 1.8 
potassium voltage-gated channel, 
subfamily H (eag-related), member 
2 
AB030030 
A_72_P55588
5 
0.003 1.8 adenylate cyclase 4 
XM_001927
556 
A_72_P77384
6 
0.01 1.8 forkhead box protein Q1-like 
XM_001928
048 
A_72_P56781
4 
0.02 1.8 
ubiquitin carboxyl-terminal esterase 
L3 (ubiquitin thiolesterase) 
 
NM_001077
227 
A_72_P30358
9 
0.0003 1.8 Uncharacterized protein XR_131178 
A_72_P30604
4 
0.02 1.8 protocadherin 17 
XM_001927
267 
A_72_P49466
5 
0.002 1.7 transmembrane protein 8B-like 
XM_003122
009 
A_72_P21936
7 
0.02 1.6 
popeye domain containing 2 
 
NM_001144
114 
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Table 2: Differentially expressed gene transcripts which are down regulated in 
damaged skin following SM exposure compared to damaged, unexposed skin. 
Differentially expressed genes are based on a 1.5-fold change (F/C) cut-off with a FDR 
< 0.05.  
 
 
  
A_72_P47310
3 
0.003 1.6 Uncharacterized protein 
XM_003125
434 
A_72_P07025
1 
0.05 1.6 
c-X-C chemokine receptor type 2-
like 
AK237564 
A_72_P49072
9 
0.03 1.6 forkhead box protein I2-like 
XM_001928
234 
A_72_P36564
3 
0.003 1.6 Uncharacterized protein 
XM_003134
357 
A_72_P16873
6 
0.03 1.5 
MARC 4PIG Sus scrofa cDNA 5', 
mRNA sequence 
DN112477 
A_72_P02840
6 
0.03 1.5 
integrin, alpha 5 (fibronectin 
receptor, alpha polypeptide) 
XM_001925
252 
A_72_P72492
8 
0.006 1.5 transmembrane protein 70 AK231606 
A_72_P49581
0 
0.02 1.5 sarcosine dehydrogenase 
XM_001929
498 
A_72_P47726
3 
0.003 1.5 
tight junction associated protein 1 
(peripheral) 
XM_003128
424 
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Probe ID p-value F/C Gene name 
GenBank 
accession 
number 
A_72_P67317
6 
0.0002 2.2 thioredoxin interacting protein 
NM_0010446
14 
A_72_P25286
3 
0.01 2.1 
uncharacterized protein C6orf62 
homolog 
XM_0019283
89 
A_72_P70975
0 
0.001 2.0 pantothenate kinase 1 
XM_0019260
22 
A_72_P58515
6 
<0.0001 1.9 thioredoxin interacting protein 
NM_0010446
14 
A_72_P64975
4 
0.006 1.9 snurportin 1 AK350475 
A_72_P70904
0 
0.01 1.9 
chromosome 6 open reading 
frame 106 ortholog 
NM_0012430
26 
A_72_P59286
4 
0.0001 1.9 thioredoxin interacting protein 
NM_0010446
14 
A_72_P61289
7 
0.0000 1.9 thioredoxin interacting protein AK349227 
A_72_P72130
3 
0.0004 1.8 Histone H3.3 AK239851 
A_72_P51247
9 
0.0007 1.8 actin-related protein 8 
XM_0019290
49 
A_72_P72576
3 
0.002 1.8 
serine/arginine-rich splicing factor 
9 
AK347688 
A_72_P39165
3 
0.02 1.7 
eukaryotic translation initiation 
factor 4E-binding protein 2-like 
XM_0031330
58 
A_72_P56248
9 
<0.0001 1.7 thioredoxin interacting protein 
NM_0010446
14 
A_72_P57434
9 
0.0003 1.7 thioredoxin interacting protein AK349227 
A_72_P63031
9 
0.03 1.7 
scavenger receptor class B, 
member 2 
NM_0012441
55 
A_72_P54879
6 
0.003 1.6 
unactive progesterone receptor, 23 
kD 
AY610476 
A_72_P73371
8 
0.0009 1.6 
B-cell translocation gene 1, anti-
proliferative 
NM_0010999
36 
A_72_P58793
1 
0.01 1.6 
tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase 
activation protein, beta 
polypeptide 
AK231708 
A_72_P54969
6 
0.001 1.6 thioredoxin interacting protein 
NM_0010446
14 
A_72_P55762
5 
0.001 1.6 CD9 molecule NM_214006 
A_72_P29863
4 
0.005 1.6 Uncharacterized protein 
XM_0031335
19 
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Table 3: Differentially expressed gene transcripts which are up regulated in damaged 
skin following SM exposure compared to damaged, unexposed skin. Differentially 
expressed genes are based on a 1.5-fold change (F/C) cut-off with a FDR < 0.05.  
 
A_72_P54652
1 
0.01 1.6 
epithelial splicing regulatory 
protein 1-like 
XM_0031255
64 
A_72_P76037
7 
0.001 1.5 lipoprotein lipase NM_214286 
A_72_P66541
0 
0.02 1.5 nexin-1 NM_214287 
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Probe ID 
p-
value 
F/C Gene name 
GenBank 
accession 
number 
A_72_P45411
6 
0.007 7.5 homeobox protein Hox-C4-like 
XM_001925
128 
A_72_P75534
9 
0.0001 3.8 cytochrome P450 3A29 NM_214423 
A_72_P06261
1 
0.008 3.6 
MARC 3PIG Sus scrofa cDNA 5', 
mRNA sequence 
DY427469 
A_72_P53087
0 
0.02 3.2 tyrosyl-DNA phosphodiesterase 1 BI347194 
A_72_P44098
1 
0.0001 3.2 claudin 20 
NM_001159
777 
A_72_P49706
6 
0.007 3.1 nonhomologous end-joining factor 1 
XM_001925
512 
A_72_P44118
9 
0.001 3.0 
feline leukaemia virus subgroup C 
cellular receptor 1 
NM_001142
846 
A_72_P34420
8 
0.004 2.8 sphingosine-1-phosphate lyase 1 
XM_001928
140 
A_72_P49043
8 
0.03 2.5 shootin-1-like 
XM_001925
635 
A_72_P47441
9 
0.005 2.5 
poliovirus receptor-related protein 4-
like 
XM_001927
467 
A_72_P48983
6 
0.02 2.4 
solute carrier family 16, member 12 
(monocarboxylic acid transporter 12) 
XM_001928
811 
A_72_P02061
6 
0.0004 2.4 nuclear receptor coactivator 1 EU346671 
A_72_P44917
0 
0.0001 2.4 isthmin 1 homolog (zebrafish) 
XM_001925
000 
A_72_P54165
8 
0.0001 2.4 ACP6 protein 
XM_001928
346 
A_72_P44118
4 
0.0002 2.3 
DNA (cytosine-5-)-methyltransferase 
3 beta 
NM_001162
404 
A_72_P50180
5 
0.0001 2.3 
inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase 
complex-associated protein 
XM_001924
394 
A_72_P63262
1 
0.0001 2.3 glycerol-3-phosphate acyltransferase AK348444 
A_72_P53233
3 
0.0001 2.3 
Sus scrofa similar to Inositol 
polyphosphate multikinase 
XM_001926
840 
A_72_P49026
3 
0.005 2.2 
inositol 1,4,5-triphosphate receptor-
interacting protein-like 
XM_001927
312 
A_72_P39976
8 
0.001 2.2 
porcine adipose tissue cDNA library 
(PADT) Sus scrofa cDNA 3', mRNA 
sequence 
 
EB415041 
A_72_P66620
5 
0.005 2.2 carbonic anhydrase II 
XM_001927
805 
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A_72_P47369
1 
0.001 2.1 
epithelial splicing regulatory protein 
1 
XM_001925
874 
A_72_P48959
7 
0.0004 2.1 multimerin 2 
XM_001927
177 
A_72_P44514
3 
0.0006 2.1 
chromosome 6 open reading frame 15 
ortholog 
NM_001128
447 
A_72_P44033
1 
0.0005 2.0 nuclear receptor coactivator 3 
NM_001114
276 
A_72_P47553
7 
0.0001 2.0 uncharacterized protein C1orf88-like 
XM_001926
563 
A_72_P67595
6 
0.009 2.0 
SH2 domain-containing adapter 
protein F-like 
XM_001925
071 
A_72_P44061
1 
0.0008 2.0 angiopoietin-like 7 
NM_001142
828 
A_72_P44197
2 
0.0001 2.0 RNA binding motif protein 4B 
NM_001123
188 
A_72_P41068
8 
0.0003 2.0 
MARC 3PIG Sus scrofa cDNA 3', 
mRNA sequence 
DY412467 
A_72_P44313
4 
0.01 2.0 lysine (K)-specific demethylase 5C 
NM_001097
433 
A_72_P73835
8 
0.0001 2.0 
Sus scrofa mRNA, clone: 
AMP010001F07, expressed in 
alveolar macrophage 
AK230481 
A_72_P50647
0 
0.003 1.9 hypothetical protein LOC100155045 
XM_001925
366 
A_72_P44332
9 
0.0001 1.9 homeobox D13 
XM_001926
027 
A_72_P48953
0 
0.0002 1.9 tetraspanin-14-like 
XM_001926
602 
A_72_P42723
9 
0.006 1.9 cadherin-24-like AK348514 
A_72_P64442
6 
0.002 1.9 
programmed cell death 4 (neoplastic 
transformation inhibitor) 
XM_001927
049 
A_72_P55373
1 
0.001 1.9 
RALBP1 associated Eps domain 
containing 1 
XM_001925
993 
A_72_P55917
9 
0.0004 1.8 MAX interactor 1 
XM_001925
277 
A_72_P79536
4 
0.0002 1.8 ubiquitin protein ligase E3B EW061474 
A_72_P56246
4 
0.001 1.8 prolyl endopeptidase 
NM_001004
050 
A_72_P49139
0 
0.0003 1.8 
trace amine-associated receptor 8a-
like 
XM_001926
037 
A_72_P22106
7 
0.01 1.8 
v-crk sarcoma virus CT10 oncogene 
homolog (avian) 
NM_001137
636 
A_72_P70889
5 
0.0001 1.7 sortilin 1 AK236900 
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Table 4: Differentially expressed gene transcripts which are down regulated in 
damaged skin following SM exposure and decontamination with WoundStat™ 
compared to SM-exposed skin without decontamination. Differentially expressed 
genes are based on a 1.5-fold change (F/C) cut-off with a FDR < 0.05. 
A_72_P55762
5 
0.003 1.7 CD9 molecule NM_214006 
A_72_P47249
1 
0.0004 1.7 nexin-1 NM_214287 
A_72_P29922
9 
0.0009 1.7 Y55F3AM.9 
XM_001929
665 
A_72_P66599
9 
0.0003 1.7 Kruppel-like factor 10 
NM_001134
344 
A_72_P30775
8 
0.004 1.6 protein interacting with PRKCA 1 
XM_001925
023 
A_72_P27009
4 
0.0003 1.6 
protein tyrosine phosphatase, 
receptor type, G 
XM_001926
989 
A_72_P44258
4 
0.001 1.6 Uncharacterized protein C5orf4 AK233246 
A_72_P49360
2 
0.0004 1.6 alpha-kinase 2 
XM_001925
970 
A_72_P68506
0 
0.0008 1.6 
bactericidal/ permeability-increasing 
protein 
NM_001159
307 
A_72_P74618
8 
0.005 1.6 amyloid beta (A4) precursor protein NM_214372 
A_72_P16325
1 
0.003 1.6 CST complex subunit STN1-like 
XM_001929
419 
A_72_P72327
3 
0.008 1.6 MGC159817 protein 
XM_001928
319 
A_72_P26576
7 
0.0003 1.6 
Sus scrofa mRNA, clone: 
THY010202C04, expressed in 
thymus 
AK239751 
A_72_P00007
6 
0.0001 1.6 SH2B adaptor protein 3 
XM_001929
523 
A_72_P55518
6 
0.0001 1.5 sarcolipin 
NM_001044
566 
A_72_P31846
8 
0.0005 1.5 zinc finger protein 174 
XM_003124
674 
A_72_P44111
9 
0.0006 1.5 claudin 6 
NM_001161
645 
A_72_P79734
9 
0.0003 1.5 Sus scrofa similar to hCG2040023 
XM_001925
825 
 
332 
 
Probe ID p-value F/C Gene name 
GenBank 
accession 
number 
A_72_P15974
6 
0.0001 7.1 
Haemoglobin subunit alpha 
(Alpha-globin) 
AK348963 
A_72_P36556
3 
0.0001 6.6 
procollagen C-endopeptidase 
enhancer 2 
AK235631 
A_72_P68039
4 
0.02 6.6 interleukin 6 (interferon, beta 2) NM_214399 
A_72_P00842
1 
0.0004 6.3 C27H2.2a 
XM_00192860
6 
A_72_P27335
9 
0.0002 5.8 
MARC 3PIG Sus scrofa cDNA 5', 
mRNA sequence 
DY410803 
A_72_P55876
4 
0.0001 5.6 claudin 11 AY609490 
A_72_P50281
9 
<0.000
1 
4.6 collagen, type VIII, alpha 1 
XM_00192644
3 
A_72_P66942
4 
0.0001 4.3 
superoxide dismutase 2, 
mitochondrial 
XM_00192644
0 
A_72_P26940
4 
0.0001 4.1 
potassium large conductance 
calcium-activated channel, 
subfamily M, beta member 4 
XM_00192891
7 
A_72_P72322
3 
0.0001 3.7 
phosphoinositide-3-kinase, 
regulatory subunit 5 
NM_213851 
A_72_P73078
8 
0.008 3.7 amylase, alpha 2B (pancreatic) NM_214195 
A_72_P44012
1 
0.0005 3.7 amphiregulin NM_214376 
A_72_P00112
1 
0.0002 3.5 
Sus scrofa mRNA, clone:  
PBL010105F02, expressed in 
peripheral blood mononuclear cell 
AK237103 
A_72_P71580
8 
0.003 3.5 
translation initiation factor IF-3, 
mitochondrial-like 
XM_00192647
7 
A_72_P26263
7 
0.0006 3.3 Leucine rich repeat containing 23 
XM_00312652
3 
A_72_P61582
0 
0.0008 3.3 
carbonic anhydrase III, muscle 
specific 
NM_00100868
8 
A_72_P20609
7 
0.0003 3.2 
Porcine Brain Library Sus scrofa 
cDNA clone PBL 5', mRNA 
sequence 
CD572107 
A_72_P53283
4 
<0.000
1 
3.2 
transmembrane 6 superfamily 
member 1 
XM_00192914
4 
A_72_P50251
6 
0.001 3.2 SIX homeobox 1 
XM_00192893
7 
A_72_P67630
2 
0.0001 3.2 
electron-transfer-flavoprotein, 
alpha polypeptide 
XM_00192873
2 
A_72_P60255
3 
0.0002 3.1 reticulon 4 
NM_00112996
3 
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A_72_P06973
1 
0.0001 2.8 
asparagine-linked glycosylation 5, 
dolichyl-phosphate beta-
glucosyltransferase homolog (S. 
cerevisiae) 
AK238941 
A_72_P37478
8 
0.0001 2.7 crystallin, alpha B 
XM_00312986
6 
A_72_P53262
8 
0.0007 2.7 signal sequence receptor, alpha 
NM_00118516
7 
A_72_P73118
8 
0.0001 2.7 
cytochrome c oxidase subunit 5A, 
mitochondrial-like 
XM_00192722
0 
A_72_P24255
2 
0.0001 2.6 
Sus scrofa mRNA, clone:  
OVRM10202E03, expressed in 
ovary 
AK236557 
A_72_P70482
7 
0.0003 2.5 
Sus scrofa mRNA, clone: 
OVRM10218H12, expressed in 
ovary 
AK348632 
A_72_P76342
9 
0.02 2.4 actin, alpha 1, skeletal muscle 
NM_00116779
5 
A_72_P51497
4 
0.0002 2.4 glutaredoxin (thioltransferase) AK230519 
A_72_P67750
0 
0.0003 2.3 
ribosomal protein S6 modification-
like protein B-like 
XR_115935 
A_72_P62448
1 
0.0006 2.3 glutamate dehydrogenase 1 AK235921 
A_72_P35181
8 
0.0008 2.3 
Sus scrofa mRNA, 
clone:PTG010104H11, expressed 
in pituitary gland 
AK349562 
A_72_P47334
3 
0.0002 2.3 
putative deoxyribonuclease 
TATDN1-like 
AK344100 
A_72_P55283
6 
0.0001 2.2 glutamate dehydrogenase 1 AK235921 
A_72_P40423
8 
0.0009 2.2 
Sus scrofa mRNA, 
clone:OVRM10114A05, expressed 
in ovary 
AK348273 
A_72_P44200
2 
0.0001 2.2 G-protein signalling modulator 3 
NM_00112311
9 
A_72_P63384
2 
0.0004 2.1 SMAD family member 6 
XM_00192612
7 
A_72_P71013
8 
0.0001 2.1 
insulin-like growth factor binding 
protein 6 
AK240415 
A_72_P72991
3 
0.0005 2.1 matrix Gla protein NM_214116 
A_72_P44190
8 
0.0005 2.1 
proline-rich transmembrane protein 
1 
NM_00112317
0 
A_72_P40075
3 
0.0000 2.0 
MARC 4PIG Sus scrofa cDNA 5', 
mRNA sequence 
 
CK453658 
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A_72_P23078
2 
0.0001 2.0 
Sus scrofa mRNA, clone: 
THY010088C01, expressed in 
thymus 
AK239275 
A_72_P27675
4 
0.0000 2.0 
Sus scrofa mRNA, clone: 
PTG010078F03, expressed in 
pituitary gland 
AK349467 
A_72_P64026
5 
0.0001 2.0 
serine/arginine-rich splicing factor 
2 
AK235325 
A_72_P51495
9 
0.02 2.0 glycoprotein m6b 
XM_00192781
6 
A_72_P50185
4 
0.0001 1.9 
Sus scrofa similar to GDNF-
inducible zinc finger protein 1 
XM_00192699
3 
A_72_P65402
3 
0.002 1.8 cytochrome c, somatic 
NM_00112997
0 
A_72_P72742
3 
0.0002 1.8 H3 histone, family 3A AK235071 
A_72_P60977
4 
0.002 1.8 tubulin, alpha 1b 
NM_00104454
4 
A_72_P54172
8 
0.005 1.8 MTERF domain containing 1 AK347886 
A_72_P53288
2 
0.0002 1.8 
aldo-keto reductase family 1 
member C1-like 
NM_00104456
9 
A_72_P15807
1 
0.009 1.8 
UDP-N-acteylglucosamine 
pyrophosphorylase 1 
XM_00192864
3 
A_72_P01510
6 
0.004 1.8 dystonin 
XM_00192705
3 
A_72_P73513
3 
0.0005 1.7 
PRP39 pre-mRNA processing 
factor 39 homolog (S. cerevisiae) 
XM_00192712
0 
A_72_P51684
9 
0.0001 1.7 
translocase of outer mitochondrial 
membrane 20 homolog (yeast) 
XM_00192693
5 
A_72_P62958
9 
0.0002 1.7 
UDP-N-acteylglucosamine 
pyrophosphorylase 1 
XM_00192864
3 
A_72_P49049
7 
0.0007 1.7 antioxidant protein AK235228 
A_72_P58869
1 
0.002 1.7 
UDP-N-acteylglucosamine 
pyrophosphorylase 1 
XM_00192864
3 
A_72_P50244
1 
0.0040 1.6 
cyclin-dependent kinase 2 
associated protein 1 
NM_00119016
6 
A_72_P54473
7 
0.0002 1.6 
pumilio domain-containing protein 
KIAA0020-like 
XM_00192766
9 
A_72_P75540
6 
0.0003 1.6 H3 histone, family 3A BP171840 
A_72_P60335
3 
0.0002 1.5 matrilin 2 AK234298 
A_72_P58371
1 
0.007 1.5 
meningioma expressed antigen 5 
(hyaluronidase) 
 
XM_00192802
6 
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Table 5: Differentially expressed gene transcripts which are upregulated in damaged 
skin following SM exposure and decontamination with WoundStat™ compared to 
SM-exposed skin without decontamination. Differentially expressed genes are based 
on a 1.5-fold change (F/C) cut-off with a FDR < 0.05.  
 
  
A_72_P44280
6 
0.03 1.5 
membrane-bound transcription 
factor peptidase, site 1 
XM_00312683
5 
A_72_P29289
4 
0.0005 1.5 
MARC 2PIG Sus scrofa cDNA 5', 
mRNA sequence 
BI343668 
A_72_P04799
6 
0.01 1.5 
MARC 1PIG Sus scrofa cDNA 5', 
mRNA sequence 
AW360248 
A_72_P49972
6 
0.0002 1.5 Friend of PRMT1 protein-like 
XM_00192957
2 
A_72_P58129
2 
0.0005 1.5 syndecan 2 
XM_00192693
9 
A_72_P53169
2 
0.0001 1.5 
Sus scrofa mRNA, clone: 
LVR010071B05, expressed in liver 
AK232553 
A_72_P67703
0 
0.0004 1.5 
UDP-N-acteylglucosamine 
pyrophosphorylase 1 
XM_00192864
3 
A_72_P13619
6 
0.004 1.5 
Sus scrofa mRNA, clone: 
LNG010001F06, expressed in lung 
AK231609 
 
336 
 
PUBLICATIONS  AND PRESENTATIONS 
Hall, C.A., Lydon, H.L., Dalton, C.H., Chipman, J.K., Chilcott, R.P. and Graham, J.S., 
(2009) The in vitro efficacy of haemostatic products in the presence of chemical 
warfare agents—Sulphur mustard (HD) and VX. Toxicology, 262:9-10. Abstract  
 
Hall, C.A., Lydon, H.L., Dalton, C.H., Chipman, J.K., Chilcott, R.P. and Graham, J.S., 
(2010) Novel decontaminant Role for COTS Haemostats for the CW Agent Sulphur 
Mustard. DTRA CBD S&T, Orlando, Florida, Abstract and Poster  
 
Hall, C.A., Lydon, H.L., Dalton, C.H., Chipman, J.K., Chilcott, R.P. and Graham, J.S., 
(2011) Developing a Haemostatic Decontaminant for Sulphur Mustard; An in vivo 
feasibility study. Society of Toxicology Washington DC, USA, Abstract and Poster,  
 
PUBLICATIONS ARISING 
Hall, C.A., Lydon, H.L., Dalton, C.H., Chipman, J.K., Chilcott, R.P. and Graham, J.S., 
The in vitro efficacy of haemostatic products in the presence of chemical contaminants. 
 
Lydon, H.L., Hall, C.A., Dalton, C.H., Chipman, J.K., Chilcott, R.P. and Graham, J.S., 
Development of haemostatic decontaminants for treatment of wounds contaminated 
with chemical warfare agents: Evaluation of topical decontamination efficacy using 
undamaged skin.   
 
Dalton, C.H., Hall, C.A., Lydon, H.L., Chipman, J.K., Chilcott, R.P. and Graham, J.S., 
Development of haemostatic decontaminants for treatment of wounds contaminated 
with chemical warfare agents:  Evaluation of de contamination efficacy from damaged 
skin.   
 
